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Abstract 
 
Intensity modulated radiotherapy has gained attention in recent years as a high 
precision radiation technique, allowing tumour dose escalation and reductions in 
high dose to adjacent normal organs.  IMRT optimises the therapeutic ratio even 
further than conventional conformal radiation techniques, providing effective dose 
for tumour control, whilst minimising side effects.  
 
Despite these potential benefits, there is concern regarding long term effects from 
the associated low dose bath, exposing more normal tissue to lower radiation dose 
as compared to more conventional radiation techniques.  However, the effects of 
this low dose radiation have yet to be established. 
 
In this thesis, -H2AX was used to assess radiation-induced DNA damage within 
peripheral blood lymphocytes of patients undergoing fixed gantry or static field 
IMRT (SF-IMRT).  The reproducibility and sensitivity of -H2AX as a comparison of 
DNA damage following differing radiation techniques has been documented, with 
significant differences in -H2AX foci seen following SF-IMRT in comparison to 
volumetric arc-IMRT and 3D conformal radiation.  Efforts have been made to 
demonstrate a difference in whole body exposure from these techniques and 
variations in -H2AX foci distributions seen following techniques may reflect greater 
whole body exposure following SF-IMRT, which may have impact on long term 
toxicity. 
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The benefits of IMRT to treat complex shaped meningiomas, often located close to 
critical dose limiting structures, have been investigated in a clinical phase I/II study.  
The feasibility of using IMRT to deliver conformal radiation to meningiomas, whilst 
respecting normal tissue tolerance has been demonstrated here.  The preliminary 
report from this ongoing clinical study documents effective, safe treatment with 
acceptable toxicity levels and comparable local control, particularly within grade I 
meningiomas.  Prospective data collection has revealed improvements in 
neurological symptoms and no significant quality of life deterioration. 
 
The findings in this thesis provide further information to guide future work, 
examining the biological and clinical long term effects of new radiation techniques. 
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CHAPTER 1 
 
Introduction 
IMRT is a high precision technique that aims to individualise radiation therapy to 
maximize tumour dose while simultaneously protecting the surrounding normal 
tissue from high dose radiation.  Its use has been increasing and has extended to a 
wide range of tumour groups.  However, the long term effects of this delivery 
technique are still being examined. 
 
 
1.1 Intensity modulated radiotherapy 
 
1.1.1 Background 
The need to improve local tumour control, whilst minimizing treatment related 
toxicity by improving the differential dose distribution of external beam irradiation 
between tumour and normal tissues, remains a major goal in modern radiotherapy 
[1,2].  Conventional conformal radiotherapy using small numbers of simply shaped 
beams can achieve the goal of homogeneous dose delivery to the target tumour, 
but in many cases may also lead to unnecessarily large volumes of normal tissue 
being irradiated to high doses. The dose tolerance of these adjacent normal tissues 
precludes high doses of radiation being delivered to the tumour and therefore may 
have an effect on local control and perhaps even metastatic potential of tumours [1]. 
Conformal radiotherapy has evolved since the mid-20th century with the use of 
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rotational and non co-planar fields, blocks, wedges, compensators and through the 
development of radiation dosimetry; all performed with the aim of concentrating 
radiation dose in the tumour whilst attempting to spare normal tissue [3]. 
 
Progression to three dimensional conformal radiotherapy (3D-CRT) was made 
possible with the use of improved three dimensional imaging, adequate 
immobilization and computer controlled delivery systems [1,2], providing the 
capability to conform the shape of the beams to the shape of the target from each 
beam’s eye view, as well as being able to calculate three dimensional (3D) dose 
distributions [4,5].  The ability to conform the prescribed dose to the 3D target 
volume is typically achieved with a set of fixed field radiation beams of uniform 
intensity, whilst the intensity of these beams can be modified with wedges or 
compensators to accommodate missing tissue and shape dose distributions, 
allowing for a reduction of normal tissue within the high dose volume (and therefore 
a potential reduction in late toxicity) compared to more conventional techniques 
[1,6-13].  However, the ability to dose escalate within the tumour, whilst respecting 
normal tissue tolerance, is still challenging with 3D-CRT alone. 
 
By the late 1900’s, intensity modulated radiotherapy (IMRT) was being developed 
as a further enhancement on conformal radiotherapy, allowing the delivery of 
tumour doses to the target volume whilst making low doses to the critical organs 
more achievable [14] and it remains one of the major technical advances in modern 
radiotherapy.  IMRT allows the delivery of concave isodose dose distributions and 
uses computer controlled linear accelerators to produce non-uniform beam intensity 
patterns in an effort to achieve superior dose distributions.  By comparison, 3D-CRT 
allows the outlined shape of each beam to be controlled, but the intensity (or 
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fluence) generally remains uniform across the beam.  Although use of wedges and 
tissue compensators can modulate the beam intensity, this is usually only in one 
dimension per beam.    
 
IMRT enhances 3D-CRT through its capabilities in manipulating intensities of 
individual rays within each beam (by means of a combination of geometrical and 
fluence shaping) to allow greater control of the dose distribution [15], create more 
conformality and with the added benefit of generating a concave dose distribution 
[16].  This modulation of radiation fluence can be achieved by either interrupting the 
X-ray fluence through collimation and/or compensation or by temporally modulating 
the fluence and varying the temporal modulation in space [17].  In this way, and 
when combined with image guided techniques to accurately delineate target 
volumes and deliver the planned treatments, radiation can be delivered more 
precisely to the tumour with greater sparing of the surrounding normal tissues, thus 
aiming to improve tumour control and reduce normal tissue toxicity [18].   
 
The first papers on IMRT described a process, beginning with a desired dose 
distribution and producing a specification on how to create the required fluence 
modulation [19]; a process we know today as ‘inverse planning’.  In fact, most 
modern IMRT plans are often generated by means of inverse planning or 
automated optimization 3D-RTP (radiotherapy planning) systems; using computer 
optimization techniques to determine the distribution of intensities across the target 
volume and improve the shape of these dose distributions with the capability of 
producing concavities within these distributions [3].  This, in turn, can deliver steep 
dose gradients to create specific sparing of sensitive normal structures within 
complex treatment geometries [6,20-24].  Therefore, defining the optimal beam 
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fluence becomes an integral component of IMRT.  This involves determining the 
physically deliverable modulated beam fluence profile, which results in a dose 
distribution that most closely matches the desired one.  IMRT allows the delivery of 
dose distributions with complex isodose profiles so that radiosensitive normal tissue 
can be spared from radiation injury [6].  The advantages of this have been 
demonstrated in several studies, particularly in the fields of prostate and head and 
neck cancer [25-27].  
 
1.1.2 IMRT delivery techniques 
Several IMRT delivery techniques have been described in the literature, from the 
very simple method of metal compensators to much more sophisticated techniques 
described below.   
 
Metal compensators of variable thickness can simply be placed in front of the beam 
to yield a modulated beam.  However, this is often an awkward, expensive, time 
consuming arrangement and frequently difficult to position with accuracy and 
therefore limits the quality of beam modulation [6,28]. 
 
Many different IMRT delivery techniques now exist and the more modern 
techniques can be broadly categorized as follows: 
Fixed gantry 
 Step and shoot 
 Dynamic delivery 
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Rotational techniques 
 Tomotherapy helical delivery 
 Linac-based arc therapy 
 
1.1.2.1 Fixed gantry IMRT (SF-IMRT) 
1.1.2.1.1 Scanned photon and electron beam IMRT 
The use of computer-controlled beam steering magnets to direct the high energy 
electron beam onto the X-ray target was one of the first modern IMRT delivery 
techniques described [16].  Control of the angle and intensity at which the electron 
beam hits the X-ray target creates bremsstrahlung X-ray beams which can be 
placed anywhere within the radiation field using a ‘scan pattern’, giving beam 
location and intensities without the need to increase treatment times [29].  However, 
the resolution of these techniques can be limited due to the full-width half maximum; 
even with beams of 50MV photons, this can be several centimetres.  An increase in 
energy from 50 to 60MV can result in a reduction of the half width of photon beams 
down to 15mm and in the electron beams to 5 mm [29], which can be useful for 
conformal delivery of dose.  
 
Electron energies, typically those of high energy, such as 25-50MeV, can also be 
used for IMRT with this technique [29-32] and more recently there have been 
improvements on scanning photon beams with sizes down to 1.2cm using 50MeV 
[33].  
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Scanned narrow Bremsstrahlung beams in the presence of multileaf collimators 
(MLC) can produce enhanced dose delivery, which can be improved further by 
reducing the source to isocentre distance and size of the elementary photon beam.  
Decreasing the initial electron energy can reduce the width of the photon pencil 
beam further [29,33]. 
 
More recently, there has been increasing focus on implementing this concept [34] 
with the use of fast narrow high energy (50MV) scanned photon beams to deliver 
biologically optimized radiation therapy [35].  
 
1.1.2.1.2 Conventional MLC IMRT 
Conventional MLCs can be used to deliver IMRT using a linear accelerator under 
computer control.  The most efficient way to deliver fixed-field (static field) IMRT is 
by using standard MLCs in dynamic mode.  Other methods may use compensators, 
but these are very time consuming procedures.  Several MLC applications for IMRT 
are well known now (including ‘step and shoot’ IMRT or dynamic ‘sliding window’ 
IMRT).  Standard MLCs can be used to deliver the optimized fluence distribution in 
either dynamic mode (leaves move whilst radiation is on) or static mode, often 
termed ‘step and shoot’ IMRT or SMLC IMRT (segmental MLC IMRT).   
 
1.1.2.1.2.1 Step-and-shoot (SMLC) IMRT 
Step and shoot IMRT describes a technique where each treatment field is further 
subdivided and then delivered in succession.  A series of multiple segment fields, in 
which each field is composed of several small segments (or subfields) that can be 
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delivered sequentially in a ‘step and shoot’ method, provide an intensity modulated 
beam.  Each segment is made with a series of MLC shapes (segments) and can be 
used to deliver IMRT from the same gantry angle.  Each field may consist of 3-20 
segments delivered sequentially.  Multiple segment fields are set up at selected 
orientations of the gantry under computer control.  In contrast to dynamic MLC, the 
MLC leaves travel to discrete positions whilst the radiation beam is off.  The beam is 
turned on during the ‘step’ phase of treatment so that MLC movement and radiation 
delivery does not take place simultaneously, resulting in discrete intensity levels.   
 
1.1.2.1.2.2 Sliding window or Dynamic MLC (DMLC) IMRT 
The dynamic MLC technique relies on pairs of moving MLC leaves.  With a fixed 
gantry position, the opening, formed by a pair of opposing MLC leaves under 
computer control, is swept across the target volume whilst the radiation beam is on 
to produce the desired fluence profiles.  The width of the window and speed of 
leaves are continuously adjusted whilst radiation is being delivered to produce the 
required intensity patterns.  This type of IMRT was first implemented in Memorial 
Sloane-Kettering [36,37] and has the advantage of delivering any number of 
intensity levels without a significant increase in treatment time, although more 
accurate synchronization of leaf positions with ‘beam on time’ is required. 
 
Beam modulation is proportional to the delivery complexity, so that the more 
modulated a beam, the more complex its delivery.  In particular, the number of 
monitor units required with dynamic MLC techniques is directly proportional to the 
sum of rising fluence changes as the leaves move across the aperture [17] and it is 
therefore advantageous to limit beam modulation to the minimum required for 
conformality, with as little ‘noise’ as possible.  There have been reports that DMLC 
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requires 15-20% more monitor units compared to SMLC techniques, although can 
be associated with faster treatment times [38,39].   
 
The delivered dose is directly proportional to the MLC gap between opposed leaves 
as they move across a treatment field.  It is therefore imperative that any error in 
gap width is avoided as even small errors can lead to large dose errors.  The 
tolerances accepted for 3D-CRT are generally insufficient for IMRT delivery.  For 
example, if there is a 2mm error in a leaf gap of 2cm, this can produce an absorbed 
dose error of approximately 15%.  Therefore accuracy generally needs to be within 
1mm. 
 
Transmission and leakage radiation through the ends of MLC leaf pairs and 
between adjacent MLC leaves does occur and can vary between 3-6% of the total 
target dose [40].  However, the interleaf leakage can be minimised to some extent 
by the manufacture of MLC leaf edges with a tongue and groove design.  
Nevertheless, there is still some radiation leakage and this must also be taken into 
account during the dose calculation process.  In the past, rates of leakage radiation 
have varied from 1.5 to 3%.  However, the tongue and groove design may actually 
block or scatter radiation causing significant underdosage in the treatment field 
during beam delivery.  This has been estimated at 10-25% [41] due to the tongue 
and grove phenomenon, but can be reduced to as little as 3% by a process of leaf 
synchronization [42,43]. 
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1.1.2.2 Rotational IMRT 
1.1.2.2.1 Tomotherapy 
Tomotherapy or ‘slice therapy’ describes an approach to deliver IMRT using a 
narrow rotating slit beam [44-46], similar to techniques used for computed 
tomography (CT) imaging scans.  The linear accelerator rotates during delivery and 
the beam is modulated during rotation.  A temporally modulated slit MLC is used to 
rapidly move the leaves in or out of the slit and, in the same method used in a CT 
unit, the radiation source and the collimator continuously revolve around the patient.  
Either the patient is moved between successive rotations (serial tomotherapy) or 
during rotation (helical tomotherapy). 
 
1.1.2.2.1.1 Serial Tomotherapy 
  
A temporally modulated binary mini MLC was developed commercially by Peacock 
MIMiC, Nomos Corporation and became available in 1996.  Serial tomotherapy uses 
this Peacock system MIMiC, mounted to a medical linear accelerator, and can 
deliver treatment to a narrow slice of the patient using arc rotation.  The beam is 
collimated to a narrow slit (usually 2cm x 20cm) and beamlets of varying intensity 
are created by driving the MIMiC’s leaves in and out of the radiation beam’s path as 
the gantry rotates around the patient.  The modulation of the beam is created by 
computer controlled opening and closing of the leaves and the leaf opening pattern 
is predetermined by the treatment planning system.  The relative intensities of each 
beam are determined by the fraction of arc travel that each leaf is open.   
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As a result of the narrow spacing between the independently modulated segments, 
there is greater flexibility in modulating the fluence, allowing for highly conformal 
dose distributions [47,48].  A full treatment is accomplished by serial delivery to 
adjoining axial slices.  As such, accuracy in the couch motion is imperative 
(especially with irradiation of large areas), as the treatments are delivered in a 
series of adjacent arc strips.  Even errors of 1mm can result in dose errors of 10-
20% in these adjacent (or abutment) areas [49-51], depending on the isocentre and 
arc length used.  Reports have suggested that shorter arc lengths are associated 
with higher dose errors [51], whereas arcs of 300 degrees are able to maintain an 
abutment homogeneity of approximately 10% [52].   
 
The first clinical use of  IMRT was undertaken in Houston, Texas using the Peacock 
NOMOS MIMiC delivery technique in 1994, where a variety of patients were treated 
with tumours of the CNS, head and neck and prostate and also in those who had 
been previously irradiated [53].  They demonstrated the feasibility of dose 
escalation as a way of attempting to improve tumour control, in addition to 
introducing the concept of SMART (simultaneous modulated accelerated radiation 
therapy) boost to shorten the overall treatment time. 
 
1.1.2.2.1.2 Helical Tomotherapy 
Helical tomotherapy was first defined by Mackie et al in 1993 [44], whereby 
radiation could be delivered in a continuous spiral.  They described a system of 
delivering IMRT while the patient on the treatment couch is moved through a 
moving ring gantry, in a similar way to a helical CT scanner.   
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Helical tomotherapy may address the abutment heterogeneity problem posed by 
serial tomotherapy since it delivers IMRT in a continuous manner as the patient is 
moved through a ring-gantry during treatment, rather than delivering a series of 
adjoining strips of radiation.  The intensity of the beam is modulated throughout 
delivery by dynamic MLC movement, whilst the dose rate and gantry speed are kept 
constant.  The beamlets are created using temporally modulated binary mini-MLC 
similar to the Peacock’s system and also uses a low energy linear accelerator 
mounted in a modified CT scanner gantry. 
 
Helical tomotherapy can generally achieve similar dose distributions to static field 
MLC based IMRT with variable results on treatment times. 
 
1.1.2.2.2 Intensity modulated arc therapy 
The basic theory behind arc therapy is to deliver radiation treatment from a 
continuous rotation of the gantry.  Intensity-modulated arc therapy (IMAT), first 
proposed by Yu et al in 1995 [54,55] as an alternative to tomotherapy, delivers 
radiation using superimposing arcs and can be implemented on existing linear 
accelerators equipped with MLCs to combine the spatial and temporal intensity 
modulation with movement of the gantry.  MLC-shaped fields, with the ability to 
change during gantry rotation, are used to deliver dose to the target.  However, in 
order that the gantry can move continuously throughout treatment delivery, the 
changes in MLC leaf positions between the consecutive gantry positions often need 
to be limited.  Initial studies have tried to overcome this issue with the use of 
multiple superimposed treatment arcs, although this has frequently resulted in an 
increase in radiotherapy treatment times [54,56,57].   
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The optimization of this dynamic gantry motion is usually carried out by taking a 
‘sample’ or snapshot of the gantry and MLC positions at a particular time point 
during the delivery.  The continuous gantry and MLC motion is then approximated 
by individual beams that are optimized at 5-10 degree gantry angle intervals and 
causes changes in MLC leaf positions of 2- 4cm between the gantry angle samples 
[56-58].  However, poor sampling may lead to a reduction in quality and the 
potential for dosimetric error [57], whereas increasing the sampling at smaller gantry 
intervals may restrict the ability of optimization and leaf sequencing algorithms to 
provide an efficient and acceptable plan. 
 
RapidArc® (Varian Medical Systems, Palo Alto, CA) or volumetric modulated arc 
therapy (a solution to IMAT) was first approved for clinical use in 2008 by Otto [59].  
He described a system where treatment could be delivered efficiently and 
accurately using a single dynamically modulated arc.  This has the capability of 
delivering IMRT with different monitor units at varying dose rates while MLCs are 
continuously moving as the gantry is simultaneously rotating with variable speed 
and, therefore, has the potential to deliver intensity modulated radiation more 
efficiently than static field IMRT. 
 
An aperture-based algorithm has been utilized for treatment plan optimization, 
where dose can be delivered during a single gantry arc of 260 degrees.  Although 
this is a similar technique to tomotherapy, it is different in that the entire dose 
volume is delivered in a single source rotation, rather than with several slices.  IMAT 
uses multiple irregular fields shaped with a conventional MLC during gantry rotation 
and is planned as a series of static fields, every 5-10 degrees apart, but delivered 
with multiple superimposing arcs; the MLC shape continuously changing as a 
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function of gantry angle on the basis of the results of optimization, such that the 
cumulative intensity distribution leads to the desired dose distribution.  In this 
technique, dose is delivered using single or multiple radiation beams which sweep 
in an uninterrupted arc or arcs around the patient.  The intensity of the radiation 
beam is modulated throughout delivery by varying the dose rate and speed of the 
gantry rotation as well as dynamic MLC movement.  
 
Other IMRT techniques, such as static field IMRT, can increase treatment times by 
requiring a larger number of beam directions, monitor units and, in the case of 
tomotherapy, with slice by slice delivery.  With these techniques and through the 
development of image guided positioning and plan adaptation, treatment times may 
be increased.  In contrast to static field IMRT, the MLC leaf motion and number of 
monitor units per degree of gantry rotation with arc therapy is restricted during 
optimization so that the speed of gantry movement, speed of leaf translation and the 
dose rate maxima do not limit the delivery efficiency.  Otto presented work that 
demonstrated efficient treatment with a single arc producing high dose conformality 
and high-resolution sampling of beam directions during planning (starting with a 
smaller number of samples and gradually introducing new samples).  He also 
documented that delivery times using VMAT can be reduced to approximately 1.5-3 
minutes for a 2Gy fraction [59].  In fact, others have proceeded to examine the 
potential advantage that VMAT offers over static field IMRT when treating various 
sites of disease [25,60-63].  A direct comparison of static field IMRT and RapidArc 
(RA) using either 1 or 2 arcs for treating prostate cancer found that treatment times 
were reduced by 2-7 minutes using RA compared to static field IMRT with a monitor 
unit reduction of between 37-66% [60].  A further study demonstrated a reduction of 
63% in average treatment times (165 seconds with RapidArc and 447 seconds with 
static field IMRT) and a 60% reduction in monitor units with RapidArc (550 MU 
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compared to 1379MU with static field IMRT) when treating nasopharyngeal cases 
[25].  A review in 2013 documented that VMAT treatment typically took 2.08minutes 
(with SRS/SBRT taking 4.06 minutes) and required an average of 285 monitor units 
(compared to 317MU for the radiosurgical group), providing a monitor unit reduction 
of 45% in prostate cancer patients, 58% in head and neck cancer patients and 39% 
in lung cancer patients, although this was seen in a retrospective review involving 
small patient numbers [61]. 
 
In this way, VMAT works by simultaneously varying the gantry rotation speed, 
treatment aperture shape with MLCs and delivery dose rate [64].  Arc based 
therapies have the ability to achieve highly conformal dose distributions. The added 
advantages of RapidArc over static field IMRT appear to be a reduction in treatment 
times and monitor units required, which may in turn have benefits of a reduction in 
leakage radiation and therefore a reduction of integral radiation dose to the rest of 
the body [58,65,66], with less interfraction movement, more accurate treatment 
delivery and a potential reduction in second cancer risk.  This, theoretically, can 
produce further benefits, including greater patient tolerability, cost effectiveness with 
quicker and efficient use of machine time. 
 
1.1.2.2.3 Robotic linear accelerator IMRT 
The use of a small linear accelerator mounted on an industrial robot is now being 
used in the clinical setting.  The initial idea of highly focused radiation using many 
beams centred on one point was developed for radiosurgery using the Gammaknife 
system [67,68].  This consists of cobalt-60 sources distributed through a dome 
shaped shell so that beams can be focused on a common point.  To ensure highly 
focused treatment, a stereotactic frame is anchored to the patient’s skull.  However, 
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this technique is limited to use for central nervous system tumours, although the 
idea has subsequently been proposed for other clinical settings [69-71]. 
 
Stereotactic body radiation therapy (SBRT), delivered using systems such as 
CyberKnife (Accuray, Inc., Sunnyvale,CA) utilises a 3D co-ordinate system with 
advanced imaging technology to allow precise tumour localisation.  In this way, a 
stereotactic frame is not required and treatments can be delivered to anywhere in 
the body, with the added advantage of delivering fractionated treatments if required.  
This technique uses high levels of accuracy in patient immobilisation and target 
localization with methods to limit or compensate for tumour movement.  Through 
minimal margins for set up uncertainties and increased normal tissue sparing, 
delivery of hypofractionated regimes becomes possible.  The CyberKnife system, 
uses a compact linear accelerator mounted on a robotic arm, which can then be 
moved along predetermined, non-concentric paths around the patient to allow for 
very conformal therapy [65,71].  This technology can deliver concentrated beams of 
radiation to the target from multiple positions and angles.  Using image guidance, 
CyberKnife can track the target co-ordinates in real time, allowing the head of the 
linear accelerator to re-align itself and accommodate any changes in the target 
position.  As a result, high doses can be administered in 1-5 fractions to smaller, 
harder to treat areas, while also reducing organs at risk.  This technique can be 
useful in patients who have small curable tumours who are not suitable for surgery 
or in those that have received previous radiation. 
 
In order to deliver dose to a target, stereotactic radiotherapy does require a larger 
number of monitor units compared to conventional treatments and there have been 
reports of radiation leakage in older systems, with more recent systems needing 
additional shielding to reduce this issue. 
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Unless otherwise specified, MLC based IMRT will be discussed for the rest of this 
thesis. 
 
1.1.3  Features of IMRT 
Several features of IMRT make its use an advantage to the clinical setting. 
1.1.3.1 Concave dose distributions  
Traditional conformal radiotherapy can produce convex dose distributions.  As each 
of the beams with uniform fluence (as in 3D-CRT) is brought together around an 
isocentre, a convex volume will be created.  This can be suitable for some tumour 
volumes, however at least 30% of tumours show a concavity in the planning tumour 
volume [6] and for others, which are close to critical structures, such as in the case 
of tumours of the central nervous system or where concaved shaped tumours wrap 
around the spinal canal (as with tumours of the head and neck area), 3D-CRT often 
fails to produce an acceptable plan [5].    
 
Conversely, with IMRT techniques, the volume at the intersection of fluence 
modulated beams will have invaginations and therefore will be concave in nature.  
Treatments can be constructed so that the high dose volume conforms tightly to the 
shapes and boundaries of the planning target volume, whilst the organs at risk lie in 
the concavities of the dose distribution.  The advantages of this technique are 
improved target volume conformality, particularly with complex concave shaped 
volumes.  This, in turn, can provide sparing of normal tissues and organs at risk with 
reduced acute and late toxicities and morbidities [21,22,72]. 
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1.1.3.2 Normal organ sparing 
The ability to create shaped dose distributions with IMRT can be exploited to create 
sharp dose fall offs near the boundaries of the target and critical structures, thus 
producing a significant reduction in radiosensitive normal tissue areas receiving 
high dose radiation.  If areas close to the PTV are defined (usually as shaped 
concavities), IMRT can produce dose distributions that imitate these concavities and 
therefore allow for sparing of normal tissue within these areas.  This may, in turn, 
allow dose escalation in addition to a reduction of normal tissue dose [73,74]. 
 
1.1.3.3 Dose homogeneity 
Intensity modulated beams from varying directions can be designed to produce 
dose homogeneity within the target site in comparison to more conventional 
techniques, allowing sparing of normal structures and superior dose conformity [3].  
However, in addition, IMRT can produce intentional dose inhomogeneity or non-
uniform absorbed-dose distributions of a certain volume within another deﬁned 
volume (also known as simultaneous integrated boost techniques) [44].   
 
1.1.3.4 Multiple simultaneous treatments 
The features of IMRT allow multiple targets and boost fields to be integrated into a 
single treatment plan during the whole course of a treatment.  This can be more 
efficient and also optimises the overall doses by considering the interactions of 
different dose prescriptions.  Previous studies, in particular for head and neck 
cancers, have demonstrated improved tumour control and survival rates with 
accelerated treatment schedules, some of which have used altered fractionation 
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and modest dose escalation [75-77].  However, the associated increased toxicity 
seen with 3D-CRT techniques can limit its use.  
 
IMRT can produce inhomogeneous dose distributions which can be exploited to 
allow the simultaneous delivery of different doses per fraction to separate areas 
within a target volume.  In particular, during the treatment of head and neck cancer, 
it is possible to treat more than one volume simultaneously without the need for 
matching fields, which in turn comes with risk of reduced dose coverage in the area 
of matching beams. Therefore multiple targets and boost fields can be integrated 
into a single treatment plan during the entire course of a treatment without actually 
increasing the overall treatment time.  A simultaneous modulated accelerated 
radiation therapy (SMART) boost technique was developed in 1994 to increase 
tumour control and allows a larger dose per fraction to the primary tumour, while 
simultaneously delivering conventional fraction sizes to areas of microscopic 
disease and whilst delivering this in 5 fractions per week [53,78].   
 
The approach of ‘simultaneous integrated boost’, a term coined by Wu et al in 2003 
[79-81], through its accelerated fractionation, can also manipulate the 
radiobiological benefits by reducing the effects of accelerated repopulation in 
tumourogenesis [82-85].  The high dose conformality with IMRT provides the 
opportunity to do this with the added benefits of reducing normal tissue toxicity by 
avoiding normal tissue and organs at risk.  A phase I study looked at using this 
regime when treating patients with head and neck cancers [79].  They were able to 
escalate doses to the gross tumour volume using accelerated fractionation 
simultaneous integrated boost IMRT with doses up to 73.8Gy, whilst delivering 
lower doses to the margins around the GTV and uninvolved nodal areas as well as 
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sparing at least one parotid gland.  More recently, similar techniques have been 
employed to use varying dose per fraction to different target volumes [27].  
 
In a similar way, simple IMRT methods have been used to increase the dose to 
specific areas of a tumour.  A group in the 1990s used MR spectroscopy to identify 
the dominant intraprostatic lesion corresponding to the area of gross tumour and 
utilized 18-20 fields and subfields to minimize dose to the rectum, treat the whole 
prostate to 73.8Gy, whilst simultaneously boosting the area of gross tumour to a 
higher dose (>90Gy) [86]. 
 
The use of larger dose per fraction theoretically may be associated with an increase 
in late normal tissue radiation effects in structures with a low alpha:beta ratio, such 
as nerves within the high dose PTV.  However, long term follow-up is essential to 
determine whether this will be clinically significant. 
 
1.1.4 IMRT planning process 
1.1.4.1 Immobilization and reproducibility 
One of the benefits of IMRT is the ability to produce high dose gradients adjacent to 
critical normal tissue structures.  As a result, reducing patient movement and 
internal organ motion has become critical for IMRT as dose distributions mould 
closer to the tumour volume or organ at risk with rapid fall off outside the volume.  
Thus even a small movement may result in a dramatic difference in dose delivered 
to a specific volume.  With the reduction of areas irradiated to high dose levels with 
IMRT comes the possibility of geographical miss, as well as longer treatment times 
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[87].  This may, to some extent, be overcome with four dimensional adaptive image 
guided radiotherapy. 
 
Adequate immobilization techniques are required to ensure that treatment can take 
place with accurate and reproducible positioning of the patient.  Typically, for 
tumours of the head and neck or brain, customized thermoplastic shells are used to 
immobilize the patient during treatment and have been shown to allow a movement 
error of less than 3mm [88]. 
 
In the past stereotactic frames have been used for cranial irradiation and, in 
particular, skull base tumours [89,90], although less invasive devices such as ankle 
stocks can also be used for IMRT treatments, for example, when treating tumours of 
the prostate [91].  However, in general, the necessary degree of accuracy depends 
on the proximity of the high dose region to organs at risk and the fall off dose 
around the tumour volume. 
 
Another important consideration is the issue with intra-fraction movement and in 
particular the uncertainties with internal organ motion.  The effects of internal organ 
motion can be reduced by tumour immobilization or tumour tracking. 
 
The motion of the prostate has been shown to reduce by maintaining a constant 
bladder and rectal volume [92,93].  Whereas, the motion of the lung by respiration 
means that accuracy of patient set up has become more challenging.  Intra-fraction 
motion, if not recognized adequately, may lead to a reduction in coverage of the 
 
 
38 
 
tumour volume, geographical miss and even an increased dose to organs at risk.  
Four dimensional 4D CT scanning can allow visualization of the tumour position 
within the respiratory cycle, so that this can be incorporated into radiotherapy 
delivery [94] using various techniques, such as the inclusion of tumour movement 
within the PTV, reducing tumour motion by employing breath hold techniques [95-
98], gating of radiation or even marker tracking [99], though these methods do 
require patient and operator training to ensure adequacy of reproducibility. 
 
There has been intensive investigation into tumour tracking using image guided 
radiotherapy, offering the possibility of ‘real time’ tumour tracking.  Some methods 
have used implantable markers, such as fiducial markers for prostate cancer [100] 
and, more recently, wire clips for breast cancer [101,102].  This involves the 
incorporation of imaging before and/or during treatment to enable precise 
verification of treatment delivery and allow for adaptive strategies to improve 
accuracy of treatment [103,104].  With this comes a requirement for more time on 
the treatment couch and possibly an increase in the total amount of radiation to 
patients, especially in those with daily IGRT schedules. 
 
1.1.4.2 Delineation of target volume and critical structures 
The success of modern radiotherapy techniques is dependent on the delivery of 
adequate doses to the tumour, while minimizing dose to organs at risk (OAR).  The 
International Commission on Radiotherapy Units and Measurements (ICRU) has 
issued several reports to standardise the prescribing, recording and reporting of 
radiation treatments [105-110].  ICRU 50 introduced the concept of the gross 
tumour volume (GTV), clinical target volume (CTV) and planning target volume 
(PTV) [106].  These were refined in the supplement ICRU 62, which allows the 
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definition of more than one CTV and also introduced the concept of the planning 
organ at risk volume (PRV) [107].  ICRU 83 further extended these concepts to the 
prescribing, recording and reporting of IMRT [110]. 
 
IMRT planning involves delineation of the target volumes and OARs.  The benefits 
of IMRT depend heavily on the accuracy of the outlined target and critical organs, 
which should be identified and outlined precisely using one or more imaging 
techniques.  The existence of intra- and inter-observer variation in GTV delineation 
is well-documented and varies with the tumour site and imaging modality [111,112].  
However, variation due to operator inexperience is also recognized and can be 
improved with training [113].  Multimodality imaging can enhance our knowledge on 
the extent of disease to be treated and plays an important role in the IMRT process.  
Such imaging includes CT scans, magnetic resonance imaging (MRI) and, more 
recently, Positron Emission Tomography (PET) imaging and it is now quite common 
to fuse these imaging modalities with the CT planning scan to improve target 
definition [114]. 
 
The degree of conformality is a direct function of the resolution power of the 
diagnostic tools used to define the true anatomical dimensions of the tumour and its 
relationship to surrounding organs.  The improvements in conformality have been 
enhanced by computerized imaging techniques with the ability to visualise the 
tumour in three and, now even, four dimensions. 
 
As with conventional planning, the PTV margin is composed of the internal margin 
(accounting for organ motion) and set-up margin (allowing for set up inaccuracies) 
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[107].  A further report discussed the systematic error margin and random error 
margin during planning and treatment delivery, which can contribute to set-up errors 
and therefore guide the PTV [115].  Systematic errors are those related to treatment 
preparation, including errors related to delineation, phantom transfer errors and 
systematic set-up errors, whilst the random error margin represent those related to 
treatment execution and include set-up errors and target motion. 
 
Precise delineation or contouring the OAR is an important step in RT planning to 
guide the algorithm on how to form the desired 3D dose distributions.  However, 
with the use of IMRT, it is imperative to contour the entire sensitive organ within the 
irradiated volume, rather than only that seen within the PTV.  If this is not done, the 
planning optimizer may ‘dump’ inappropriate dose in areas that have not been 
contoured.  Therefore, it is important to identify and define organs or tissues to 
avoid unwanted dose dumping in these areas.   
 
In fact, due to the number of beams used in IMRT delivery, one needs to be wary of 
all potential organs at risk.  A recent parotid sparing technique, whilst identifying 
benefits of IMRT in the preservation of salivary function, also incidentally detected a 
proportion of patients with acute fatigue, in comparison to those treated with 3D-
CRT.  Further exploration of this has detected significantly higher mean doses to 
the posterior fossa, brainstem and cerebellum, possibly due to the differing beam 
portals used [116]. 
 
Sensitive normal structures can be considered to be functionally ‘serial’, ‘parallel’ or 
‘serial-parallel’.  OAR, such as spinal cord, brain stem, optic nerves and chiasm, 
 
 
41 
 
have a high relative seriality so that doses above tolerance limits to even a small 
volume or subunit of these organs may have severe clinical consequences.  
However, in organs with a lower relative seriality, the relative risk of damage is often 
related to the size of volume that is irradiated above a tolerance level.  
Nevertheless, a PRV margin, analogous to the PTV, is added to further protect the 
OAR from over-dosage as a result of uncertainties in radiotherapy planning and 
delivery and may be helpful to allow dose escalation in the vicinity of critical 
structures.          
 
3D-CRT can offer a partial reduction in the volume of serial organs that are 
irradiated but, due to their organisational nature, this may not always result in a 
reduction of toxicity.  In these situations, it is common to compromise dose to PTV.  
IMRT offers a more conformal dose distribution, aiming to avoid these critical 
structures with the use of concave dose distributions and therefore improving dose 
to PTV.   
 
1.1.4.3 Treatment planning, objectives, optimization and evaluation 
1.1.4.3.1 Treatment planning and optimization  
Treatment planning and computer optimization make up the core of IMRT.  These 
processes translate clinical requirements into machine deliverable commands.  
IMRT plans can be created by using either the ‘forward planning’ or ‘inverse 
planning’ method [3]. 
 
 
 
 
42 
 
1.1.4.3.1.1  Forward planning 
Many aspects of radiotherapy planning require a manual iterative process, often 
starting with pre-defined beams resulting in desired dose distributions.  However, 
simple IMRT methods have been used for quite some time [5,117,118], utilizing 
existing 3D treatment planning systems and iterative optimization, with a trial of 
beam configurations, wedges and weighting.  Forward planning IMRT uses similar 
methods to those used in conventional 3D-CRT, where planners initially define 
beam directions, shapes and intensities on the basis of planning experience and 
intuition.  Optimising beam orientation with fewer optimally placed beams could be 
better than using a larger number of sub-optimally or uniformly placed beams and, 
therefore, leads to more efficient IMRT treatments. 
 
This is followed by a calculation of the 3D dose distribution and subsequent 
qualitative review of this dose distribution, with plan improvements made by further 
modification of the beam geometry (beam orientation, shape, modifier, weighting) to 
improve target coverage or reduce organ at risk dose if necessary.  It can often be 
described as a trial and error process, in which treatment fields and beam weights 
are modified manually to achieve clinical solutions.  It works well for simple shapes 
that are not surrounded by numerous critical structures.  For more complex tumour 
geometries (such as concave tumours and those surrounded by sensitive 
structures), forward planning may be limited by the restricted variation in beam 
intensity within the beam.  
 
A step beyond forward planning, known as ‘aperture-based optimization’, involves 
the design of several beam shapes for each beam angle and computer optimization 
to determine intensities or weightings of these beam shapes in all angles [119].  
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This has the advantage that the planner can control the complexity of a treatment, 
and is less dependent on the expertise of the planner.  Another variation on forward 
planning, is to select a number of segments or subfields allowed for each beam and 
for computer optimization to determine the shape of each segment and its 
associated weighting [120]. These plans often consist of multiple subfields with MLC 
shaping and are designed to reduce dose to normal structures; commonly termed 
‘field in field’ planning. This progressive form of forward planning may produce 
comparable plans, in term of quality, to those produced using inverse planning, 
although with much simpler treatment delivery.  Forward planning is possible for 
some forms of IMRT using segmented field optimisation and initial attempts were 
made to spare salivary function using this technique when treating head and neck 
tumours [121].  However, these isodose plans often have large areas of dose 
inhomogeneity.  This method may well be ideal in tumour sites that are surrounded 
by less sensitive structures, such as breast tumours [122].  However, manual 
forward planning can be too time consuming for more complex planning problems.   
 
1.1.4.3.1.2  Inverse Planning   
IMRT is now capable of generating complex 3D dose distributions to conform 
closely to the target volume and uses the concept of ‘inverse planning’ with 
significant reductions in dose to normal tissue [5].  In contrast to forward planned 
IMRT, inverse planning begins with a desired dose distribution and planning 
constraints decided at the outset. With inverse treatment planning, the focus is on 
the desired outcome, rather than how it will be achieved.   
 
A computer optimisation system is used to adjust beam parameters (usually beam 
intensities), in an attempt to create fluence distributions that approximate the 
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desired dose distributions, with the quality of the resultant plan evaluated by a 
score. The process of inverse planning includes three components, including 
formulation of the score function (also known as objective function or planning 
objective), input of dose constraints to tumour targets and normal tissues and 
methods of computer optimisation that search for optimal plans.  An optimisation 
algorithm is utilised to optimise the dose intensity delivered from each beam to 
create optimal target volume coverage, whilst avoiding the organs at risk.  The 
iterative inverse planning methods allow many treatment plans to be generated and 
evaluated prior to arriving at the best solution.   This method is capable of 
generating significant dose gradients between target volumes and adjacent normal 
structures to provide the required dose-volume prescription [48].  In order for this to 
be achieved, dose-volume constraints or limits need to be set.  These specifications 
act to drive the computer aided optimisation, so that the constraints are met and the 
best plan achieved.   
 
The ideal plan should comprise high uniform dose to the tumour and minimal dose 
to the organs at risk.  This is often performed through an optimisation process that 
translates mathematical formalism of clinical requirements into deliverable intensity 
patterns.  In reality, however, the best plan is a compromise on what is clinically 
required and what is achievable.  This often comes with experience to select 
appropriate planning parameters and, as experience is gained, ‘class solutions’ are 
created in order to minimize planning time.  Planning studies offer opportunities to 
assess the advantages of new techniques within each tumour site.  Rival 
techniques can be compared and the best technique used as a basis of a ‘class 
solution’: a technique that will produce the best results when applied to a group of 
patients with a particular tumour type [6]. 
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Plan objectives are the mathematical translation of clinical objectives which aim to 
quantify the underlying clinical goal.  Objectives are set for the tumour as well as the 
organs at risk.  The response of tumour and normal tissues is a function of radiation 
doses, and also of the volumes subjected to each dose level (depending on the type 
of tissue).  Dose-based prescriptions define the dose that the tumour or organ 
should receive, for example, 60Gy to the PTV.  Dose-volume-based objective 
functions are expressed in terms of limits on the volumes of each structure that may 
be allowed to receive a certain dose or higher; for example, no more than 5% of the 
PTV should get less than 60Gy.  There is also consideration to be made in areas 
where the PTV and organ at risk overlap.  These overlap areas are considered 
separately to the rest of the PTV and may be designated a slightly lower dose.   
 
Objectives and constraints are often used interchangeably.  However, there is an 
important distinction between the two terms: objectives are doses that are desired 
to be met, whereas a constraint is something that must be met.  Specifications of 
these objectives and dose constraints are the only direct input required to steer the 
inverse planning system towards the desired plan.  Unrealistic constraints can lead 
the computer optimized system to produce an inferior plan.  Planning objectives can 
also be considered as planning tools to achieve the real clinical goals.  The key is to 
prioritise each planning objective and constraint so that the optimiser produces the 
most desirable plan in terms of tumour dose coverage and normal tissue sparing.  
These planning objectives and constraints often require modification and weighting 
to drive the plan to a better clinical solution; often a process of trial and error and 
frequently the most time consuming part of the planning process.  This may involve 
a certain amount of compromise to the tumour volume to allow adequate sparing of 
the organs at risk.  The inverse planning problem can be specified as a best cost 
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score; maximizing the tumour control probability (TCP) and allowing for a maximum 
normal tissue complication probability (NTCP). 
 
1.1.4.3.1.3  Treatment generation (Leaf sequencing)  
An IMRT optimised dose distribution needs to be transferred into machine 
deliverable parameters.  Linac-based IMRT requires the formation of leaf position 
sequences as a function of monitor units (MUs) and beam on time.  Conventional 
MLCs under computer control can be used to deliver IMRT in 3 distinct ways: 
 
1. Sliding window or Dynamic MLC (DMLC). 
In fixed gantry positions, this method allows the opening formed by each pair of 
opposing MLC leaves to be swept across the target volume under computer control 
whilst the radiation beam is on to produce desired fluence, during which time the 
gap opening and speed can be optimally adjusted.  As the gap slides across a 
point, the radiation received by the point is proportional to the number of monitor 
units (MUs) delivered during the time the tip of the leading leaf goes past the point 
and exposes it, until the tip of the trailing leaf moves in to block it again [123]. 
 
2. Step-and-shoot or segmental MLC (SMLC).   
This method uses a series of multiple segment fields, where each field is composed 
of multiple MLC shapes (segments or subfields) delivered from the same gantry 
angle.  The multiple segment fields are set up at selected orientations of the gantry 
under computer control.  However, radiation is only turned on when the MLC leaves 
are stopped at each prescribed segment position, so that the MLC leaves only 
move to discrete positions when the beam is off. 
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3. Intensity modulated arc therapy (IMAT).   
This MLC method is similar to that seen in dynamic MLC, although the radiation 
remains on, not only with movement of the MLCs, but also during rotation of the 
gantry. 
 
1.1.4.3.2 Plan evaluation 
Plan evaluation plays a critical role in defining the original objectives and evaluating 
the final optimisation results.  It involves the assessment of dose, dose–volume and 
dose-response models to adequately and quantitatively assess the merits of 
different IMRT plans.  This necessitates slice by slice review of the individual 
isodose distributions, with particular attention to hot and cold spots, which can 
cause damage to target or normal tissues.  If the criteria are not met, it is essential 
to assess the key limiting factors and whether there are dose constraints that may 
be impossible to achieve, perhaps due to proximity of the tumour volume to the 
organ at risk.  It is also important to consider areas that are not truly organs at risk, 
but where planning systems will ‘dump’ dose in order to allow for better compliance 
with specified objectives.  In such cases, ‘dummy volumes’ are created to reduce 
dose to otherwise unassigned normal tissue. 
 
Acceptable dose to the PTV is usually set at +7% and -5% of the prescribed dose.  
However, for each organ at risk, there is a maximum acceptable dose and goal 
dose that needs to be adhered to.  In these situations, it is important to have an 
indication of whether the tissue is in-parallel or in-series.  There are now dose-
volume complication correlations derived from large groups of patients [124,125]. 
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1.1.4.4 IMRT reporting and prescribing 
ICRU 83 recommends that the median absorbed dose specified as D50% should be 
reported [110].  The D50% is likely to be a good measure of a typical absorbed dose 
in a relatively homogeneously irradiated tumour.  Therefore it is appropriate to use 
the median dose for both reporting and prescribing.  The near-minimum (D98%) and 
near-maximum (D2%) values are preferred, as the actual minimum and maximum 
doses may occur only in a few voxels due to noise or rounding errors in the 
calculation and may not be representative of dose in the PTV. 
 
Typically plans are also assessed on ability to produce homogeneous and 
conformal plans.  The homogeneity index (HI), 
 𝐻𝐼 =
(𝐷2%−𝐷98%)
𝐷50%
, 
can be useful to give an indication on the homogeneity of a plan, with HI levels 
nearer to 0 suggesting a higher level of homogeneity. 
 
The Conformity index (CI), 
 𝐶𝐼 =
𝑇𝑉95%
𝑃𝑇𝑉
 , where TV95% = treated volume covered by 95% isodose,  
originates from ICRU 62 documentation.  However, ICRU has made no formal 
recommendations on how best to calculate the CI for use in cases of IMRT and its 
applicability may be limited.  However, alternative measures of CI also exist [126], 
 𝐶𝐼 = (
𝑇𝑉 𝑃𝐼2
𝑇𝑉 𝑥 𝑃𝐼𝑉
)  𝑥 100%,  
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where TVPI = volume of target covered by the prescription isodose and PIV=volume 
of prescription isodose. 
The conformity gives a reasonable indication of how conformal a plan is, with CI of 
0 indicating a complete miss, and CI values of 100 suggesting perfect conformity. 
 
1.1.4.5 Quality Assurance (QA) 
In view of the use of mathematical optimization and beam intensity modulation, 
IMRT treatment planning and delivery are more complex and less intuitive than 
conventional 3DCRT techniques.  Quality Assurance (QA) becomes a vital step in 
the IMRT process, to guarantee that “what you plan is what you get”.  It is feasible 
that the potential for dose error can be greater for IMRT treatments, because a 
much steeper dose gradient is, invariably, used near to tumour and critical structure 
boundaries.  Reports have suggested that a 7-10% difference in dose delivery could 
produce significant change in tumour control probability [18]. 
 
Verification is undertaken both before and regularly during treatment to ensure that 
any underdosage to the tumour and overdosage to the organs at risk is prevented 
by minimising the systematic and random errors.  Accurate verification of treatment 
delivery entails both quality assurance of the planning and delivery techniques, as 
well as verification of the treatment for the individual patient.  Therefore, quality 
assurance comprises 2 broad areas: patient QA and equipment QA, although these 
are not entirely specific for IMRT.   
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Patient QA encompasses patient set up, absolute dosimetry, relative dosimetry and 
fluence verification.  Patient set-up is key to ensuring accurate treatment.  A variety 
of image guided localization techniques have been used with IMRT treatments, from 
simple orthogonal films to beams-eye view portal films with IMRT intensity pattern 
overlay, daily electronic portal imaging (EPI) of implanted fiducial markers, daily 
ultrasound guided localization and integrated tomotherapy solutions.   
 
Orthogonal images have been used in abundance for verification of the isocentre 
position.  Reference images can be simulator images or digitally reconstructed 
radiographs.  Field sizes were chosen to include the necessary anatomy in order to 
perform accurate field matching.  However, the use of modern devices can also 
enable 3D volume verification using kilovoltage (kV) cone beam CT and in vivo 
dosimetry has proved popular with improvements in IMRT techniques and IGRT. 
 
The gamma index is the preferred IMRT quality assurance tool for assessing 
agreement between phantom measurements and the treatment plan.  The gamma 
index scrutinizes how well the distributions agree within specified acceptance 
criteria in terms of dose difference and distance-to-agreement distributions and are 
measured in a phantom [127].  A good QA phantom should have the following 
features: tissue equivalent density, multiple measurement points/planes, the ability 
to enable measurement from different gantry angles, easy and quick set-up as 
machine time is being used.  The ionization chamber should measure point doses 
(i.e. have a small measurement volume, rather than measuring the average dose 
over a large volume), give accurate and reproducible measurements and measure 
accurately at low doses for organs at risk (i.e. have a low leakage rate).  A daily 
output correction factor is needed to normalise the measured reading to remove any 
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daily variation in the linear accelerator’s output dose (which has a daily tolerance of 
+/- 1.5%).  The phantom is subsequently set up to deliver the IMRT plan with the 
chamber positioned at the chosen dose point.  Readings are taken for each beam 
angle individually and can be summed for a total reading, following which a dose 
can be calculated. 
 
To verify treatment set up accurately and efficiently, EPI is essential.  It can be used 
to verify the individual intensity maps and dose delivered. 
 
Films can also be used for QA.  They give a measurement of optical density, 
performed by creating a calibration curve (plotting optical density against dose in 
the film).  The calibration film is often exposed at the same time as the QA 
measurements.  Small areas of the film are exposed to known doses and the 
resulting optical density is then plotted against the dose given.  The ideal film is one 
with a linear response between optical density and dose across the dose range of 
interest.  The film is scanned into an appropriate software application; the optical 
density is converted into dose and then compared to the dose plan predicted by the 
treatment planning system. 
 
Arrays of detectors can be used to combat the time consuming problem of checking 
absolute dose at a range of positions.  However, arrays must be large enough to 
cover the region of interest and to provide discrete measurement points.  They must 
be easily manoeuvrable, provide instantaneous read-out and have the facility for 
quantitative analysis of distribution.  The dose at each detector can be compared 
and the dose mapped onto the dose distribution.  The quantitative measure used to 
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assess the dose distribution is the gamma analysis.  Arrays are often preferable to 
film as they provide instantaneous results without the need for film processing. 
 
Most linear accelerators have a portal imager which can be deployed during 
treatment.  They allow fluence maps to be checked during a patient’s treatment as 
well as in patient-specific QA.  Check programmes, used to independently check 
the monitor units before any radiotherapy is given, are more complex than with non-
IMRT plans due to the large number of fields, size and angle of beam delivery.  
There is also additional dose from transmission through, or leakage between, the 
MLC leaves. 
 
Equipment QA involves assessment of the MLC leaf positioning and gap testing.  
This should include testing of the motion, movement and repositioning of the leaves.  
MLC position errors may present potentially significant dose delivery errors, for 
example, an error as small as 1mm in leaf opening can produce a 10% error in 
fluence delivery [40,128].  
 
 
1.2 Clinical Use of IMRT 
 
Since its conception, IMRT techniques have been described in many clinical 
retrospective case series.  There have also been many comparative studies with 
conventional radiotherapy, although very few data from randomised controlled trials 
[23,72] to substantiate that IMRT has an advantage over conventional radiotherapy.  
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However, IMRT is now becoming part of the standard treatment of patients in many 
tumour groups. 
 
1.2.1 Indications for IMRT 
IMRT may be considered in cases with irregularly shaped targets and tumours close 
to critical structures.  It can cover a volume with narrow margins to protect adjacent 
structures and can also be considered in a nearby previously irradiated area. 
 
Ideal tumour sites for IMRT should have a positive response to radiation dose with 
the potential to dose escalate and, therefore, improve local control.  Most benefit is 
seen in tumours that are in close proximity to critical structures or close to a 
previously treated area (to take advantage of the sharp gradient) and in those 
where treatment margins and set up inaccuracies are minimal. 
 
Previous radiotherapy studies have looked at various aspects of IMRT.  Some have 
investigated the benefits of IMRT planning in comparison to other methods.  Verhey 
et al. compared conformal and different IMRT plans on 3 patients (with prostate, 
nasopharynx and paraspinal tumours), demonstrating that the IMRT plans can 
produce significantly better dose results at the expense of planning time and 
resources [5].  Others have demonstrated the use and tolerability of IMRT to treat 
prostatic lesions, up to a dose of 90Gy without exceeding normal tissue tolerances 
[86,129].  Cardinale et al. found improved conformity and reduction in normal tissue 
dose with IMRT compared to radiosurgery or standard conformal treatments for 
brain tumours [130].  Other groups have examined the dosimetric aspects of clinical 
IMRT treatment techniques and some have reported the outcomes of patients 
 
 
54 
 
treated with such techniques.  Several groups have demonstrated that IMRT 
provides an answer for complex planning problems, with surrounding normal tissues 
limiting prescription dose, for example, in the delivery of high doses to the prostate, 
whilst limiting rectal toxicity, or similarly for the treatment of head and neck cancers 
[36,131-133]. 
 
IMRT is now being utilised in a variety of tumour sites, most notable in the fields of 
prostate cancer and head and neck malignancies.  Prostate cancer has been one of 
the initial targets for IMRT worldwide, with the aim of allowing dose escalation to the 
prostate and pelvic nodes to improve clinical outcomes, whilst simultaneously trying 
to limit dose to adjacent organs at risk and thereby improving long term toxicity 
[134-138].  IMRT has also been used to deliver hypofractionated schedules (using 
70Gy in 2.5Gy), with rectal late toxicity rates of 5%, in comparison to 12% with 
3DCRT [139].   
 
Head and neck cancer radiotherapy can be challenging due to the complex 
anatomy with bony structures, soft tissues and air cavities in close proximity.  Due 
to the aggressive nature of these tumours, dose escalation is often preferred to gain 
local control, but can be difficult to achieve due to the proximity of critical structures.  
In fact, it is difficult to deliver high doses using conventional 3D conformal 
radiotherapy to some head and neck tumours without significant toxicity to organs, 
such as parotid glands.  IMRT, on the other hand, has been shown to reduce late 
toxicity such as xerostomia from 74% to 40% in the first year after radiotherapy, 
through sparing of parotid glands, and without affecting treatment outcomes 
[24,27,121,140].  There is now increasing interest in trying to prevent other 
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debilitating long term toxicities, such as dysphagia and sensorineural hearing loss 
from irradiation of the cochlea [24,141]. 
 
One can also exploit the ability to create various dose distributions with IMRT to 
deliver different doses and potentially dose escalation to head and neck volumes 
without the need to extend overall treatment times.  This can be achieved with the 
simultaneous integrated boost or simultaneous modulated accelerated radiotherapy 
techniques highlighted earlier [79], to allow a form of dose painting within a target 
volume. 
 
Similarly to head and neck tumours, radiotherapy can be challenging for the 
treatment of central nervous system tumours and especially intracranial tumours 
due to the proximity to dose limiting critical structures.  IMRT has been used to 
achieve superior dosimetry for glioma treatments compared to conventional 3D-
CRT [142], with improvements in progression free survival [143].  Similarly, IMRT 
has been used to spare the spinal cord during treatment of primary and metastatic 
disease of the spine, including cases of re-irradiation without spinal cord 
complications [144,145], whilst also enabling moderate dose escalation [146].   
 
The use of IMRT in the paediatric setting remains controversial due to the potential 
long term risks of second malignancy highlighted in the literature [147,148].  
However, there have been a number of studies demonstrating improvements in 
normal tissue toxicity, such as reductions in ototoxicity from 64% to 13% with IMRT 
for paediatric tumours [149].  
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There is now also interest in the use of IMRT for the treatment of other cranial 
tumours, including meningioma.   
 
1.2.2 Meningioma 
Meningiomas describe a group of tumours originating from the meningeal coverings 
of the brain and spinal cord, and are by far the most common intracranial tumour 
[150-152].  In fact, it is estimated that 2-3% of the general population have an 
asymptomatic meningioma.  Most have an unknown aetiology, but there are 
recognised associated risk factors, including genetic disorders (such as 
neurofibromatosis), effects from hormones and also as a long term effect of cranial 
irradiation, with the risk of developing meningioma linked to increasing time from 
exposure and dose [153,154].  
 
Approximately 80% of meningiomas are considered to be benign, whilst the 
remainder are classified as more aggressive high grade tumours and associated 
with increased morbidity and mortality [155].  The WHO histopathological 
classification has formally separated the meningiomas into grade I (benign); grade II 
(atypical), making up approximately 15% of cases; grade III (malignant or 
anaplastic), which account for up to 5% of cases [156,157].  However, there have 
been new developments in the classification system which have caused some 
previously designated grade I tumours to be upgraded to grade II tumours [156], 
making direct study comparisons difficult.   
 
Despite the benign label, grade I meningiomas can spread through the dura and 
may recur, regardless of surgical resection.  Grade II tumours are often associated 
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with an 8 fold increase in recurrence (up to 52%) and malignant meningiomas, 
although rare, are associated with much higher rates of recurrence (up to 94%) 
[152,158-162].  However, grade II meningiomas appear to have a poorer outcome if 
associated with bony involvement [163] and malignant or anaplastic meningiomas 
have been shown to have a worse prognosis with a median survival of under 2 
years [156].  Attempts have been made to determine those that have a propensity 
to higher rates of recurrence and the expression of proliferation markers (such as 
MIB-1 and Ki67) have been shown to correlate with meningioma grade and 
subsequent recurrence rate [155,164,165]. 
 
The management of meningioma largely depends on the grade, age of patient and 
symptoms produced.  Due to the increasing use of CT and MRI, meningiomas are 
being discovered as an incidental finding and, as such, are often asymptomatic.  
These patients may be followed with active surveillance using magnetic resonance 
imaging (MRI), rather than initial surgical resection [166,167].  However, depending 
on their location and histological grade, meningiomas can become symptomatic 
with the development of seizure disorders, focal neurological deficits or even 
neuropsychological and cognitive decline. 
 
The mainstay of treatment is surgical resection, aiming for safe tumour resection, 
relieving mass effect and associated symptoms, but with the added ability to obtain 
a diagnosis and histological grade.  Nevertheless, due to the high recurrence rates 
with grade II and III tumours, surgery alone is often inadequate.  Simpson described 
recurrence rates following surgery according to the extent of surgical resection 
(table 1.1), ranging from a 9% recurrence rate with grade 1 excision, to 29% with a 
grade 3 resection at 10 years [168], though these rates have been noted to increase 
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with longer follow up [169].  Often the anatomical locations of the meningiomas 
mean that significant debulking surgery is difficult and may be associated with 
considerable morbidity [170]. 
 
1.2.2.1  Radiotherapy for Meningiomas 
Radiotherapy use in the management of meningiomas is now well established and 
can be used in the primary setting or as an adjunct to surgery [171-177], with post-
operative radiotherapy generating rates of progression free survival over 90% in 10 
years follow-up [177].  However, clinical practice has often favoured surgery due to 
the apparent associated radiation induced long term toxicities and morbidity in a 
disease which is perceived to be slow growing.  
 
Definitive radiotherapy can achieve high rates of long term tumour control, but is 
often reserved for situations where surgery is not possible due to tumour location 
(most notably optic nerve sheath and base of skull lesions [170]), or patient 
contraindications to a surgical procedure.  Large retrospective studies have 
demonstrated comparable progression free survival outcomes using stereotactic 
radiosurgery as an alternative to a surgical procedure achieving a Simpson’s grade 
1 resection, and, in fact, can achieve superior outcomes to surgical resection with 
Simpson’s grade 2 and over [178].  These findings have been replicated in other 
large series and confirm its use as an alternative to surgery [179-184].  More 
fractionated regimes with external beam radiotherapy and stereotactic fractionated 
radiotherapy (SFRT) have also been utilised in this setting, in particular, with 
meningiomas that are not resectable due their location [174,184-189].  Mendenhall 
and colleagues found no overall difference in cause specific survival in patients who 
were treated with radiotherapy alone and in those treated with a combination of 
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surgery and radiotherapy [174].  SFRT has the additional ability to spare critical 
adjacent normal structures that are sensitive to the hypofractionated regimes of 
radiosurgery, in particular in cases of optic nerve sheath meningiomas [190,191]. 
 
Due to the progressive nature of grade II and III tumours, radiotherapy may often be 
employed in addition to surgery or at the time of recurrence and has been shown to 
reduce recurrence rates and improve overall survival [192,193].  Much of the data 
comes from observational and retrospective studies [152,194], with very little data 
from prospective randomised controlled trials.  However, there does appear to be a 
trend towards improved outcomes with adjuvant radiotherapy and one study has 
concluded a benefit with immediate adjuvant radiotherapy compared to salvage 
[193].  A single centre series examined outcomes over an 11 year period of 108 
patients with atypical meningioma, who had undergone gross total resection 
(Simpson’s grade 1).  Of these, only 8 had immediate radiotherapy (stereotactic 
fractionated) to 1cm around resection cavity.  None of these patients recurred, 
whereas 30 patients recurred in the group receiving surgery alone, although this did 
not reach statistical significance [195].  They found that actuarial recurrence rates 
were 7%, 41% and 48% at 1, 5 and 10 years in the entire cohort.  In patients who 
developed a recurrence, disease specific survival was 86% and 69% at 5 and 10 
years after the first recurrence.   
 
Despite their dismal prognosis, patients with grade III tumours are not routinely 
treated with adjuvant radiotherapy [194].  A case series of 13 patients with surgical 
resection for a grade III meningioma observed that only 3 patients had adjuvant 
radiotherapy.  They reported a recurrence rate of 92% over a period of 0.4-2.8 
years, with an associated 47% and 12% actuarial 5 and 8 year survival rates [196], 
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although other reports have suggested slightly higher 5 and 10 year survival rates of 
64.3% and 34.5-40% [197-199].  Several studies have reported on the outcomes of 
grade III meningiomas (although often combined in the same group as grade II 
tumours) and have shown benefits in post-surgical radiotherapy with doses over 
50Gy [193,200] and some have even recommended higher doses [192,201].  In 
fact, this is the subject of two current ongoing studies (RTOG 0539 and European 
Organisation for Research and Treatment of Cancer EORTC 22042-26042), 
evaluating the role of radiotherapy and dose escalation in non-benign meningiomas.  
Others have suggested a greater benefit from immediate adjuvant radiotherapy with 
an increase in disease free survival rates from 15% to 80%, whereas a smaller 
increase in 2 year disease free survival (50% to 89%) and no significant difference 
in 5 year disease free survival was seen when radiotherapy was administered at the 
time of relapse [200]. 
 
Despite this, there is dispute over recommendations for radiotherapy further to 
surgery [202].  Radiotherapy seems to be effective in difficult to resect tumours or in 
the presence of residual tumour and at skull base locations.  Therefore, some would 
argue that, incompletely resected tumours should be irradiated at some point during 
the course of the disease, and when the risks of surgery outweigh complications 
from radiotherapy [152].  However, without any randomised trials, there is much 
controversy over the clinical value and optimal timing of radiotherapy, either after 
surgery or as salvage at time of recurrence. 
 
Adjuvant radiotherapy for grade I (benign) tumours is much more controversial, as 
there is little data to demonstrate long term survival outcome and this needs to be 
weighed against the potential long term radiation toxicity in, what is essentially, a 
 
 
61 
 
slow growing, benign disease.  Meningiomas in this group have been observed 
following surgery, rather than treated with radiotherapy [169,203].  Yet, despite the 
lack of enhanced overall survival, there is evidence to suggest that the addition of 
radiotherapy (with doses above 50Gy [204]) provides an improvement in local 
control following subtotal resections [203-207], with the risk of progression after 
subtotal resection alone amounting to 35% and 50% at 5 years and 10-15 years 
respectively, but improving to over 90% 10 year progression free survival with the 
addition of radiotherapy [177].  In this case, the timing of radiotherapy is critical – 
should it be offered just after surgery or for salvage?  A previous phase III EORTC 
26021-22021 study sought to answer this question, but closed early due to poor 
recruitment.  However, there is currently an ongoing RTOG 0539 study, aiming to 
assess the role radiotherapy (using 3D-CRT or IMRT) and dose escalation for non-
benign meningiomas, although it also encompasses an observation only arm for 
grade I tumours, following either gross total resection or subtotal resection and will 
attempt to answer the question of radiotherapy timing. 
 
1.2.2.2  IMRT for Meningiomas 
 
Whilst SFRT can achieve good results for meningiomas close to critical structures 
[181,189], it is often restricted in its use for larger lesions, where non stereotactic 
treatments may be more appropriate.  3D-CRT has been used in the past with 
improvements in local control and long term organ preservation [188,192,208-211], 
with overall actuarial 5 year local control rates of over 90% in patients with grade I 
tumours [174,210,212], although this technique can also be limited in areas close to 
critical organs, where dose to these structures can be unavoidably high [210].  
IMRT can be useful to ensure improved target volume conformation to the complex-
shaped tumours, especially in the skull-base, whilst adjacent organs at risk can be 
spared and therefore allowing safer delivery of standard meningioma doses of 50-
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60Gy, whilst also providing the potential of dose escalation [201,213-216].  With the 
use of IGRT, IMRT can offer high treatment accuracy, especially when high dose 
gradients are close to critical structures. 
 
There have only been a few (largely retrospective) reports of using IMRT in patients 
with meningiomas, many of which have involved tumours of the skull base 
[201,215,217-221].  Initial studies involved case reports or planning studies, 
charting the feasibility of IMRT in brain tumours.  In the late 1990s, a group 
compared different shaped targets planned with 5 arc linac stereotactic 
radiotherapy, 6-fixed non-coplanar 3D custom blocked fields and IMRT using 6 non-
coplanar beams and MLCs.  They found that arc therapy spared more normal brain 
tissue for ellipsoid lesions, although IMRT appeared favourable for hemisphere and 
more irregularly shaped lesions, in terms of dose conformity and low dose normal 
brain tissue volumes [130].  Another group compared stereotactic radiotherapy with 
IMRT, using 5 tomotherapy arcs for various small intracranial tumours.  They found 
similar outcomes with the two techniques when treating a petroclival meningioma, 
but better dose homogeneity with IMRT, although resulting in higher dose to the 
brain stem.  Nevertheless, they concluded that IMRT was valuable for large 
irregular shaped tumours in close proximity to critical structures [222].  In the same 
year, Grant et al., reported on one optic sheath meningioma treated to 50Gy in 25 
fractions and a craniopharyngioma treated to 50.4Gy in 28 fractions, whilst 
successfully limiting dose to the optic chiasm to 45Gy using the IMRT Peacocok 
MIMiC system [219].  An early planning study from the Royal Marsden Hospital, 
demonstrated a small improvement in PTV coverage of 5 convex-shaped tumours 
(including a sphenoidal sinus meningioma) using IMRT-tomotherapy method and a 
transaxial method of arc delivery.  However, there were higher doses to optic 
nerves and optic lenses in comparison to the stereotactic conformal radiotherapy 
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method, although these doses were still within tolerance [47].  Similar findings came 
from a group in India, with superior dose distributions and better sparing of critical 
structures observed with IMRT in comparison to stereotactic radiosurgery [223]. 
 
In the early 2000s, Pirzkall and colleagues compared different IMRT techniques to 
3D-CRT for complex skull base tumours, including meningiomas and demonstrated 
improvements in target conformality and coverage, with a 7 coplanar beam method 
producing the most conformal dose distribution, at the same time as maintaining 
organ at risk dose constraints [224].  The same group proceeded to look at 20 
patients with meningiomas of the skull base and demonstrated better target 
conformity and homogeneous coverage with IMRT, compared to conformal plans by 
10% and 36% respectively, using 5-7 equally spaced coplanar beams.  They 
reported mild and tolerable acute side effects, with 6 patients recording no side 
effects at all.  With a median follow up of 36 months, 60% of patients noted 
functional improvement of pre-existing neurological symptoms with 2 patients 
developing late toxicity (pituitary dysfunction and visual impairment), although the 
authors were uncertain as to whether this was a direct result of IMRT as opposed to 
natural progression of the meningioma, given its location [201].  They concluded 
that IMRT could achieve good rates of control, while minimising dose to normal 
structures and was useful in unresected or subtotally resected tumours. 
 
In 2002, Uy and colleagues published a report of 40 patients (32 with skull base 
lesions) treated by IMRT using the NOMOS system, delivering a median dose of 
50.4Gy to the target volume.  They were able to demonstrate good target dose 
conformity, as well as acceptable levels of toxicity.  The dose limiting organs such 
as optic nerve and chiasm received a mean dose of 47Gy with maximum doses up 
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to 55Gy.  Their cumulative 5 year local control rate was 93% with just 2 patients 
developing progressive disease (one local and one distal recurrence).  Over a 
median of 30 months follow up, most patients appeared to tolerate their treatment 
well and only 2 patients experienced late grade 3 CNS toxicity [220].   
 
Following on from this, Milker-Zabel examined the long term experience with IMRT 
using a median 7 coplanar beams treating to a dose of 50.4Gy in a group of 94 
patients with meningiomas of the skull base. Their local control rate was 93.6% over 
a median follow up of 4.4 years, with 19 patients displaying a radiological reduction 
in the size of their tumour.  They documented a recurrence free survival of 97.5% 
and 96.3% (grade I tumours) and 89% and 77.8% (grade II) at 3 and 5 years 
respectively.  Almost 40% had improvements in symptoms, 4 patients experienced 
worsening symptoms and 2 developed new symptoms due to tumour recurrence 
[215].  They concluded that IMRT was able to improve tumour dose coverage, 
although recognised a wider spread of low dose into other areas, such as normal 
brain (which others have also made note of [201,215,223]).  This was comparable 
to previous reports using IMRT, with local control reported as 97% at 3 years, 
relapses in only 3 patients and no long term complications noted [225]. 
 
There have been further attempts to use different IMRT solutions for meningioma, 
with initial reports suggesting some benefit for tomotherapy over arc and static field 
IMRT for tumour coverage [221].  However, Fogliata et al. in 2009 reported on the 
use of RapidArc and static field IMRT for a group of 12 patients with benign 
intracranial tumours including 5 meningiomas.  They found similar levels of dose 
conformity and organ sparing [213] and this has been replicated in other studies 
examining different IMRT techniques to allow safe dose escalation in skull base 
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lesions [226], although there have been reports of an increase in monitor units with 
static field IMRT compared to arc based solutions [227]. 
 
One of the few prospective studies using IMRT (or SFRT) has demonstrated local 
control rates of 95% and 88% at 5 and 10years following treatment in a group of 
507 patients with a median follow up of 10 years.  Control rates of 91% at 10 years 
have been observed in benign tumours and rates 81% and 53% at 5 and 10 years 
for higher grade tumours [217].   
 
Long term toxicity, including neurocognitive outcomes and quality of life measures 
have been a concern and important consideration when using radiotherapy for 
slowly progressing disease.  It is unclear to what extent deficits are caused following 
radiotherapy.  The risk, to some extent, may depend on the dose and volume of 
irradiated normal tissue and may increase over time.  However, Combs’ group 
found treatment to be well tolerated, with quality of life in most patients unchanged, 
or even, improved [217].  It is, therefore, imperative that studies are conducted to 
examine prospective data, with quality of life and long term follow up, to accurately 
describe treatment related outcomes and toxicities. 
 
Many groups have considered the use of proton therapy or carbon ions in the 
management of meningiomas, in an attempt to limit normal tissue toxicity in a group 
of patients who have prolonged life expectancies, whilst also maintaining or 
improving local control rates [192,218,228-230].  Some have even shown superior 
outcomes with reductions in irradiation to normal healthy tissues [229].  Kosaki and 
colleagues in 2012 reported marginal improvements with protons and carbon ions in 
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comparison to photon therapy, although acknowledged that this difference may be 
greater when higher doses are required.  However, there was a clear indication that 
photon therapy produced a larger normal tissue low dose area in comparison to 
particle therapy plans [218].  Groups have also looked at the combinations of 
photon and proton therapy and demonstrated impressive long term control rates 
(especially with doses over 60Gy) for atypical and malignant meningiomas within 
the post-operative setting [192,231].  Recently Slater and colleagues reported on a 
series of 72 patients treated with fractionated proton therapy as primary or adjuvant 
treatment for benign cavernous sinus meningioma, resulting in an overall 5 year 
actuarial control rate of 96% (with rates of 99% in those with grade 1 histology) 
[230]. 
 
Whilst there are no randomised control trials, proton therapy does offer a potential 
advantage of further reducing dose to normal tissues and possible dose escalation 
over the use of current photon therapy.  However, the long term toxicity is yet to be 
fully assessed.  With the limited access to proton therapy, it is imperative that highly 
conformal photon therapies, such as IMRT are exploited. 
 
For maximum value, radiotherapy trials need primary endpoints to define the rates 
of tumour control, late toxicity and therapeutic ratio [232].  For trials using 
radiotherapy in potentially curable tumours, it is usual to need 10 years of follow-up 
to ensure accurate estimates of tumour control and late toxicity.  Benign tumours 
carry long life expectancy and, therefore, any long term effects from radiation 
become of paramount importance.   
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1.3 Limitations of IMRT 
Despite the obvious benefits of IMRT, there are some possible disadvantages; 
some of which may improve with experience and others which require more 
investigation to determine their long term impact to the patient. 
 
1.3.1 Treatment planning and delivery 
With the reduction of areas irradiated to high dose levels using IMRT, comes the 
possibility of geographical miss.  As a result there is a requirement for clear and 
quantitative definition of both target volume and critical organs.  This is an important 
aspect of treatment planning, as IMRT is less forgiving of uncertainties in defining 
the CTV and critical structures. 
 
Various uncertainties exist in the definition of the planning target volume (PTV) 
which may limit the efficacy of IMRT, such as those related to the inter-fraction 
positioning, displacement and distortions of internal anatomy and intra-fraction 
motion.  In fact, the high degree of conformity associated with IMRT may lead to 
underdosage to a portion of the target (or even high doses to nearby critical 
structures) and could, therefore, be a cause of subsequent recurrence, especially 
for disease sites where positioning and motion uncertainties play a large role. 
 
To take full advantage of the sharp gradients and tight dose conformations, IMRT 
treatments should be accompanied by better immobilization and target localization 
techniques.  
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Careful assessment of the balance between the plan quality and the efficiency and 
accuracy of treatment delivery is required.  Certain dose distributions designed by 
the IMRT planning system may not be physically achievable or may not be 
delivered with accuracy.  In addition, mathematical formulas can create unexpected 
dose distributions, such as the ‘dose dumping’ effect in unspecified tissues.  
Complex plans that use many beams and highest levels of intensity modulations 
increase ‘indirect radiation’ to the patient because of scatter and leakage doses and 
it is important to note that these indirect radiation doses may not be predicted 
accurately [233]. 
 
Standard IMRT plans often require multiple fixed angle radiation beams which can 
increase treatment times.  This can impact on patient comfort, reproducibility of 
treatment positions and intra-fraction motion, as well as the impact of patient 
throughput within a radiotherapy department. 
 
Planning and quality assurance (QA) for IMRT are often more complex and time 
consuming compared with conventional conformal radiotherapy.  However, as 
experience is gained in centres, this can become a less time restraining process, 
although there still may be a significant bearing on departmental resources 
[113,234].  QA can often have an impact on linear accelerator time, although many 
departments are now beginning to perform QA checks in batches in order to 
streamline the process somewhat. 
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1.3.2 Uncertainties in dose response data 
In contrast to typical IMRT treatments, large and uniform treatment fields are 
commonly used in 3D-CRT.  Previous experience with dose tolerance is based 
largely on uniformly irradiated organs [124].  However, attempts have been made to 
determine dose tolerances in the new era of radiotherapy [125].  IMRT dose 
distributions can have sharp dose gradients, a factor that challenges our clinical 
knowledge about the dose-volume relationship, especially for critical organs in 
which the dose gradients usually occur.  The risk of a small volume receiving a high 
dose versus a large volume receiving a low dose is still unknown in many cases.  In 
addition, the effects of fraction sizes used in simultaneous integral boost IMRT for 
tissues embedded within the CTV is relatively undefined and may present an 
increased risk of injury or reduction in local control if used inappropriately.  
Adequate understanding of the radiobiological characteristics, dose, dose-volume 
and functional characteristics of normal tissue is critical in prescribing IMRT 
treatments. 
 
1.3.3 Low dose bath 
The advantages of high dose conformality with IMRT need to be weighed against 
the higher volumes of low dose radiation received by non-target areas compared to 
conventional radiotherapy techniques.  Goitein posed the question of ‘bath or 
shower effect’: “is it better to dispose of the integral dose by delivering a relatively 
lower dose over a larger volume or a relatively higher dose over a smaller volume?” 
[235]. 
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This low dose observation has been noted early in the implementation of IMRT.  
Verhey et al., in the late 1990s, compared IMRT plans with that of CRT for 
treatment of a prostate tumour and observed that IMRT plans showed slightly 
increased low dose distributions to the rectum than CRT plans [5].  In fact, recent 
studies have also highlighted that, while IMRT can be useful in sparing some 
organs at risk, inadvertently, due to the increased number of beam portals, it can 
produce other unexpected adverse effects, such as fatigue, thought to be related to 
increased outside target dose to the CNS with IMRT techniques for head and neck 
tumours [116]. 
 
Dose outside the treatment volume (also referred to in the literature as peripheral 
dose or whole body dose) can be a result of many factors (including collimator 
scatter and transmission, head leakage and internal scatter), which depend on the 
collimator design and beam delivery technique [236].  The inefficient leakage of 
photons from the treatment head and collimators is a significant source of this extra 
dose, although there have been recommendations limiting the maximum dose due 
to leakage radiation to less than 0.1% of the dose at the isocentre [237].   
 
Scattered radiation originates from two components.  The first is generated inside 
the patient due to the scattered photons of the Compton interaction and is 
dependent on the dose delivered to the target volume.  The second source of 
scattered radiation comes from the target, collimators and any physical inserts 
used, and is largely dependent on the number of monitor units.  Neutrons, 
originating in the treatment head and leaking through the head shielding, are also a 
consideration, although neutron production is likely to be negligible below energy 
levels of 10MeV [238].  In addition to the factors mentioned above, the increasing 
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use of IGRT may cause supplementary dose to patients undergoing RT and needs 
to be considered when treatment is planned. 
 
The inefficient use of a photon beam that is produced by a linear accelerator means 
that techniques, such as intensity modulation, require a considerable increase in 
beam-on-time and number of monitor units in comparison to more conventional 
radiotherapy methods [236,239].  As a consequence of more treatment fields used 
with IMRT, there is a larger volume of normal tissue exposed to lower doses.  
Unavoidably, the ratio between integral dose to the tumour and that to the whole 
body decreases [239].   
 
The increase in monitor unit requirements is a function of many factors, including 
the complexity of the modulated field [240] and features of the modulating device, 
such as wedges or multileaf collimators (MLCs).  Monitor unit requirements are 
largely dependent on technique and energy used.  The number of monitor units 
required to deliver a 6MV photon unwedged beam has been found to be 20% more 
than that required for a comparable 18MV beam and, similarly, requirements are 
60% more for a 6MV wedged beam compared to that for an 18MV wedged beam.  
Comparable findings are seen with a 6MV and 18MV MLC modulated field and 
tomotherapy field [241].  Nevertheless, there is a definite increase in monitor units 
required to deliver an MLC modulated field or tomotherapy field compared to 
conventional techniques and a greater use of monitor units raises the chances of 
higher whole body dose to the patient by leakage and scattering of X-rays [242].  
The exact effects of this are unknown, but may have consequences on the long 
term effects of radiotherapy, which is a significant issue, especially as newer 
treatments may lead to improvements in outcome. 
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The increase in monitor units (MU) to cover the PTV using IMRT is an important 
factor in treatment consideration.  Followill et al. found the number of  MU required 
for SMLC IMRT to be up to 1.4 and 2.8 times that required with conventional 
radiotherapy (with and without the use of wedges respectively) using 6MV, 18MV 
and 25MV X-rays [241], with an even greater number of monitor units needed for 
the use of tomotherapy techniques [241].  Similarly, others have estimated a 2-3 
fold increase in monitor unit requirement for IMRT techniques [147,242], whilst 
some groups have reported an almost 10 fold increase in the mean number of 
monitor units required for IMRT tomotherapy in comparison to 3D-CRT and an 
almost doubling of estimates for the effective absorbed dose at various positions 
outside the target [239].  
 
The link between whole body dose and number of monitor units has been 
demonstrated by Verellen and Venhavere in 1999.  They estimated an 8 times 
increase in the whole body equivalent dose per MU for IMRT techniques, directly 
related to the increase in MU with this technique [239].  Similar results have been 
seen from other studies [241,243,244], although Mutic and colleagues 
demonstrated somewhat lower whole body dose risk estimates than the predictions 
of Verellen’s group [244].  
 
The increase in MU with IMRT results in an increased amount of leakage radiation 
in the treatment field, as well as scattered radiation [241] and contributes to an 
increase in the whole body dose outside the treated area [236].  There have been 
several predictions in the literature suggesting measured whole body dose to be 
300mSv [244] or 543mSv [241] at a distance of 40cm from field edge using a field 
size of 10x10cm or 20x20cm (respectively) with 6MV serial tomotherapy, whilst 
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others report 520mSv with 10MV photons [245].  However, the exact values do 
seem to be less with MLC modulation rather than with tomotherapy techniques: 
190mSv for MLC modulation and 543mSv for tomotherapy, when compared to 
67mSv and 134mSv with conventional unwedged and wedged plans [241,243].  Out 
of field dose from tomotherapy has been shown to be much higher than from 
conventional radiotherapy, with leakage radiation contributing to both out of field 
dose close to and at distant locations from the treatment field [244,246].  However, 
Ramsey and colleagues, in 2006, contradicted these results and demonstrated that 
helical tomotherapy results in an equal or lower leakage dose to non-target volumes 
compared to MLC IMRT [247].  They postulated that, whilst helical tomotherapy 
treatment delivery requires 5-15 times longer beam on times, treatment machines 
were being designed with appropriate shielding to minimise radiation leakage.  This 
was reinforced by Bennett and colleagues, who reported that at 20cm from target 
edge, a dose of 1% was recorded with MLC based IMRT and 0.4% with helical 
tomotherapy [248].  However, a recent study has attempted to measure peripheral 
dose and demonstrated that 0.1% of the dose is recorded at distances over 30cm 
from the target area, with 0.28% of the dose measured at 17.5 cm from the target 
volume.[249] 
 
Nevertheless, MLC based IMRT plans use a larger number of monitor units 
compared with conventional conformal radiotherapy plans.  This may cause an 
increased amount of low dose radiation to the rest of the body.  There have been 
suggestions that, in part, the number of monitor units required depend on the form 
of static field IMRT technique used; with reports of more monitor units when using 
the dynamic leaf MLC technique [250-252]. 
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Following on from this, Sharma and colleagues found that peripheral dose was 
higher with dynamic fields in comparison to open static fields, and larger dose was 
associated with smaller strip field width (MLC gap) sizes by a factor of 8 and 2 for 
width sizes of 0.5cm and 2cm respectively [252].  Highly modulated beams often 
use narrow MLC openings and result in sharp increases in monitor units and thus 
peripheral dose.  However, a slight reduction in peripheral dose can be seen near 
the edge of a DMLC field, where there is often a wider gap, possibly as a function of 
a reduction in collimator scatter and transmission of the DMLC fields at these areas.  
The increase in monitor units for smaller gap widths for the same field and dose, 
further elevates both scatter and leakage dose, leading to an increase in peripheral 
dose by a factor of 2-15 with DMLC IMRT (which is similar to the increase in 
monitor units when compared to open static fields).  They also noted that, within 
30cm of field edge, peripheral dose estimations appear to vary and seem to be a 
complex interaction of leaf scatter, leaf end design, MLC placement in the treatment 
head, MLC motion and beam on time [252], whilst some groups have demonstrated 
that scattered radiation appears to be the dominant source of radiation up to 14 cm 
from the beam edge [253] and becomes negligible relative to leakage radiation 
beyond 20cm [244].  Nevertheless, peripheral dose beyond 30cm from field edge 
appears to fall exponentially [252].  Some groups have observed higher peripheral 
doses for low energy and large field sizes (and therefore internal scatter) within 10 
cm, whilst head leakage is more dominant at more distant sites [254].  However, 
other reports have demonstrated a large variation in dose at different anatomical 
sites, dependent mainly on the distance from the field edge [255,256]. 
 
In fact, comparisons of data from treatments using SMLC and DMLCs demonstrate 
that DMLC produces more out of field dose per monitor unit, although the amount of 
monitor units rely heavily on the treatment site.  Groups have demonstrated that the 
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use of non-coplanar beams in IMRT can increase the peripheral dose in organs by 
a factor of 1.8-2.5, due to the associated increase in internal scatter [257].  As 
expected, tomotherapy seems to produce higher out of field dose compared to most 
MLC IMRT techniques [258]. 
 
As cancer mortality decreases, any increase in low dose radiation to healthy tissues 
is particularly important.  Many patients are surviving for many years after diagnosis 
and treatment; therefore any treatment related effects need to be minimized. 
 
 
1.3.4 Second malignancies 
A major concern with any radiotherapy technique is the potential risk of radiation-
induced second malignancies [258] and in the past estimates have produced a 
relative risk of up to 4.5 for second malignancy following irradiation of carcinoma of 
cervix [259] and as much as 6% in those treated for prostate cancer [260], with 
areas affected either adjacent to or at some distance from the irradiated area and 
can be present even 40 years after treatment [261].  This potential risk has been 
debated widely, but accurately assessing these risks is often difficult; due, in part, to 
confounding lifestyle and genetic factors.  Nonetheless, the risks of second 
malignancy are especially pertinent in young patients and in those with good 
prognosis tumours, but are also relevant in other groups as treatment regimens 
improve and the number of long term cancer survivors increase.  
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Much of our knowledge regarding the potential carcinogenic effects of radiation 
comes from atomic bomb survivors exposed to low doses, as well as from medical 
exposures to radiation [262,263].  As such, increasing attention has turned to the 
low dose effects from IMRT techniques as a cause for long term toxicity 
[147,239,264].  A more recent study demonstrated an increase in second primary 
cancer following radiotherapy treatment for prostate cancer, as compared to those 
receiving surgical treatment alone [265], though they could not detect a difference in 
second malignancies according to radiotherapy technique when a subset of patients 
treated with 3D-CRT or IMRT were analysed.  The authors acknowledge that this 
may have been due to the small group of patients treated using these techniques 
and the relatively short follow up of this cohort. 
 
However, estimates have been made for the risk of radiation induced malignancies 
following IMRT techniques in comparison to conventional treatments, with as much 
as a doubling of the risk [147,148] and higher risk estimated with 6MV as opposed 
to 10MV plans, although highest risks were with energies where neutron 
contribution was significant [148].  As such, steps to reduce a source of leakage 
radiation can be made, including increasing shielding from treatment head, 
secondary beam blocking to reduce leakage radiation through MLCs and reduction 
of scattered radiation by removal of the unused flattening filter with IMRT treatments 
[266]. 
 
Modelling studies on carcinogenesis have supported a non-linear dose response, 
meaning that tissue receiving low doses of radiation (for example 3-5Gy) may be at 
increased risk of second malignancies [267-269].  Some hypothesize that higher 
radiation doses may actually lead to cell death in potentially oncogenic cells within 
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the bone marrow and therefore lower the leukaemic potential [260].  Others also 
seem to suggest that second cancers appear to develop in volumes exposed to low-
intermediate doses, rather than within high dose volumes [235,270] and 
consideration has also been given to the bystander effect, where relatively small 
doses can have significant radiosensitising effects on nearby tissues [271-273].  
There is some evidence to suggest that doses of 10-50mGy are associated with 
increased cancer risk [274], with some risk estimates below these levels 
extrapolated from high dose data [250,275-277]. 
 
Hall postulated that the smaller volume receiving high dose may lead to a reduction 
in the number of induced sarcomas and carcinomas within the high dose region in 
comparison to more conventional techniques.  However, due to the increase in low 
dose volume (and higher whole body dose), they also proposed an increase in 
radiation induced second malignancies from 1% to 1.75% for patients who survive 
10 years or more [147], estimating that an additional 0.5% of patients will develop a 
second cancer as a result of the low dose bath effect, and an additional 0.25% will 
develop second cancers due to the effects of increased monitor units.  These 
conclusions are similar to those of Followill et al., who made estimates, based on 
extrapolation of scatter dose.  They estimated at least a doubling of second cancer 
increased risk from 0.4% to 1% with 6MV, and higher values with 18MV and 
tomotherapy [241,243]. 
 
In a review of 31000 patients treated with radiotherapy, Dorr et al. suggested that 
most second cancers occurred at a margin around the PTV (within 2.5cm inside to 
5cm outside the boundary margin on the PTV), with the majority of tumours 
observed in the volume of tissue receiving less than 6Gy [269]. 
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Verellen and colleagues aimed to assess the increase risk of second cancers using 
thermoluminescent badges and neutron bubbles detectors to quantify in vivo 
measurements of whole-body equivalent dose of conventional and arc IMRT 
techniques for head and neck tumours.  They demonstrated 1.2x10(-2)mSv/MU for 
conventional and 1.6x10(-2)mSv/MU with IMRT respectively, which, when using 
70Gy to a target dose, provides an estimated whole-body equivalent dose of 
242mSv and 1969mSv respectively.  Using the nominal probability coefficient for a 
lifetime risk of second cancers recommended by the ICRP 60, they suggest that this 
results in an 8 fold risk for second malignancies [239].  More recently, Ruben and 
colleagues demonstrated a small increase in relative risk in second cancers with 
IMRT in comparison to 3D-CRT due to the increased low dose effect and in 
particular monitor units used [268].  
 
In principle, the lower integral dose (absorbed dose to normal tissues in irradiated 
area outside the PTV) and smaller radiation volume, the better.  More recent IMRT 
techniques, such as RapidArc, have been shown to have improved integral dose 
compared to static field IMRT [25].  However, long term follow up of patients 
currently treated with IMRT is imperative to accurately and fully evaluate the risk of 
second cancers. 
 
 
1.4 Biodosimetry 
The effect of low dose radiation exposure associated with IMRT is often difficult to 
quantify.  Total body dose, postulated to rise as a result of increased beam-on-time 
and scatter, is difficult to measure using conventional techniques and often results 
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in varying observations as detailed in the last section.  Some authors have 
suggested this is increased by as much as a factor of 1.8 when IMRT is compared 
to conventional techniques [278].  Up to now, these estimates have been based on 
indirect measures of total body dose, making realistic assessment of risk difficult, 
but new biological markers of radiation induced damage may provide completely 
new approaches to this problem. 
 
Data published has shown that phosphorylation of histone H2AX, which occurs at 
sites of radiation induced DNA double strand breaks, could be used as a marker of 
damage even at very low dose levels [279]. 
 
1.4.1 DNA damage and its measurement 
Ionising radiation produces a wide variety of DNA lesions including double strand 
breaks (DSB), which, if unrepaired, result in cell cycle arrest, apoptosis and cell 
death [280,281].  However, if repaired incorrectly, carcinogenesis can result 
[280,282-284].  These DSBs can be produced by ionising radiation, UV light, 
hypoxia and some chemicals, but can also arise endogenously [285]. 
 
Once a DSB occurs, a complex local cellular damage response ensues to allow for 
subsequent repair [282,286,287].  The MRN (Mre11/RAD50/NSB1) complex binds 
to DSBs and activates ATM (ataxia telangiectasia Mutated), a P13K related kinase 
in the DNA damage response.  ATM autophosphorylates at the site of DSB, 
allowing the consequent phosphorylation of substrates including phosphorylation on 
residue serine 139 of the histone H2AX, an early marker of DSBs [288-290].  The 
phosphorylated form of this histone, known as -H2AX, leads to the accumulation of 
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DNA damage response proteins at break sites and the subsequent formation of 
ionizing radiation induced foci (IRIF), whilst also retaining the broken chromosomal 
ends in close proximity [291,292].  These nuclear foci can be visible after staining 
under a microscope and are likely to represent a single DSB [279,293,294].  
Recruitment of further DNA damage response proteins occurs, including MDC1 
(mediator of DNA damage checkpoint protein 1), MRN (MRE11/RAD50/NBS1) 
complex, 53BP1 (tumour suppressor p53 binding protein 1), NSB1 (Nijmegen 
breakage syndrome protein), RAP80, KAP-1 and BRCA1 (breast cancer 1 protein) 
[292,295].  This in turn causes downstream phosphorylation of CHK2, p53 and 
CDC25, leading ultimately to cell cycle arrest and therefore allows time for DNA 
repair.  In fact, many components of the DNA damage response such as ATM, 
RAD51, RAD50, 53BP1 and BRCA1, co-localise with the -H2AX foci [292,296-
298]. 
 
Repair takes place in the form of two separate pathways, known as non-
homologous end joining repair (NHEJ) and homologous recombination (HR) 
[299,300].  NHEJ repair can occur at any point in the cell cycle and has no 
requirement for sequence homology.  The two ends of DNA are processed and 
ligated by the repair complex Mre11/RAD50/NSB1 and Ku70/80/DNS-PK ligase IV 
and involves the DNA dependent protein kinase catalytic subunits (DNA-PKCs) 
repair protein [282,283,296].   By contrast, HR has a role in the late S and G2 
phases of the cell cycle where sister chromatids are used to allow recombination, 
utilizing homology to restore any sequence break error-free [283,296].  Once DNA 
repair has occurred, dephosphorylation of -H2AX takes place. 
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The formation of DNA DSBs following irradiation can be quantified by various 
methods [287], including those that utilise the physical estimation of DNA size or 
those that measure chromosomal breaks, such as immunostaining, flow cytometry, 
immunoblotting and enzyme linked immunoabsorbent assay (ELISA).  Total DSBs 
can also be measured in cell lysates using techniques, such as immunoblotting or 
pulsed field gel electrophoresis (PFGE), or alternatively directly within the cell using 
procedures involving microscopy or fluorescence activated cell sorting (FACS).  
Conventional methods to measure DSBs in cell culture include the Comet assay or 
PFGE, although these methods tend to be more sensitive following doses of 
radiation over 5Gy [301,302].   
 
Physical techniques, such as pulsed field gel electrophoresis (PFGE) have been 
employed extensively [303,304].  This can directly quantify DSB repair by assessing 
the molecular weights of DNA molecules, although detection is limited to ionising 
radiation from doses in the region of 10-80Gy[305], rather than with much lower 
doses. 
 
DSBs can also be measured by cell imaging through the comet assay by 
suspending cells in an agarose gel using a weak electric field.  This forces cellular 
DNA containing strand breaks to migrate from the nucleus, thus generating a comet 
tail which is proportional to the level of strand breaks in the cell and can allow the 
detection of DSBs by fluorescence following doses as low as 0.5Gy [306,307].  
Comet assays allow DNA damage detection in single cells, although is less 
sensitive at determining low damage levels [307,308] and can be subject to poor 
specificity. 
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Although these techniques are useful in some contexts, most result in a relatively 
low rate of DSB detection (with the lower limit of DSB detection approximately 100 
DSBs per nucleus) and are unable to determine the localisation of the DSBs within 
the nucleus [285].   
 
Direct measurement in the cell is often the preferred method due to the formation of 
bright foci produced by large numbers of -H2AX at individual DSB, therefore 
allowing the quantification of foci as a sensitive assay to detect DNA damage. 
 
1.4.2 Detection of -H2AX as a marker of radiation induced 
DNA damage (and repair) 
The knowledge of the cellular response to DNA damage can be used in the 
detection of DSB and -H2AX has been shown to be a rapid, sensitive cellular 
response to the presence of DNA DSB and, therefore, a surrogate marker for the 
identification of DSBs [288,289].  Other repair proteins, such as 53BP1, RAD50, 
MRE11, NSB1, have also been studied as a marker for DNA damage.  However, 
the advantages of using -H2AX include its property as a molecule that is directly 
induced by DNA damage alone, unlike others, such as 53BP1 which use 
translocation to form foci.  In addition, its formation takes place throughout the cell 
cycle, whilst others can be dissociated from DNA damage during the mitotic 
stage.[309-311] 
 
Obtaining cells from patients for analysis of DSB can be achieved by using 
minimally invasive techniques, such as through blood samples and skin punch 
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biopsies.  Peripheral blood lymphocytes (PBLs) are the most common and easiest 
cells to obtain in order to analyse -H2AX formation in vivo.  Approximately 2% of 
lymphocytes reside in the peripheral blood with the remainder in organs such as 
lymph glands, thymus and other lymphoid tissue.  The majority of lymphocytes 
migrate between the peripheral blood and these organs with a recirculation time of 
12 hours [312]. 
 
Easily accessible and proliferating skin cells are also useful for the identification of 
-H2AX foci. Several groups have utilised skin cells to assess -H2AX foci formation 
and repair, showing increased residual -H2AX foci in DNA repair deficient cells 
[298,313-315].  Others have looked to animal studies in order to examine -H2AX 
formation and repair in other organs such as heart, small intestine, brain, kidney 
and spermatozoa with -H2AX foci seen in most normal tissue organs [316-319]. 
 
Buccal cells have also been used to examine -H2AX in a simple and non-invasive 
manner following low dose irradiation [320].  These cells can be collected by 
scraping the inner cheek, but this can often lead to a mixture of a limited numbers of 
cells, including dead and dying squamous cells [311].  Although these cells often 
have high levels of background DNA damage [312,321,322], they can still be used 
to measure low dose radiation exposure [320].  In a similar manner, hairs plucked 
from the scalp or eyebrow have also been used to assess -H2AX in follicle cells 
[311,323].   
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1.4.2.1  Immunofluorescent staining 
In order to study tissue response following radiation, techniques are available that 
allow quantitative measurements of DNA repair foci in situ.  Immunostaining is one 
of the most accurate measures of recruitment proteins to areas of DSB, such as -
H2AX, and subsequent analysis using microscopy has been used in the past to 
detect DNA damage in cell nuclei [279,324-328].  Although high throughput flow 
cytometry methods have also been utilised, this is associated with less sensitivity 
[329]. 
 
Recent immunofluorescent assays have been developed that are sensitive and 
specific to identifying -H2AX and therefore DNA DSBs [296,313], with the added 
advantage that one DSB is generally presumed to correlate to one -H2AX focus, 
and likewise, one -H2AX focus corresponds to one DSB [279,288], although some 
have questioned this [287,330]. 
 
Using immunohistochemistry, antibodies can be raised against -H2AX and when 
labelled with secondary fluorescence antibodies, allows the sensitive and specific 
visualisation of -H2AX foci [288].  However, antibodies need to be titrated so as to 
maximise detection of the area of interest, whilst minimising background signal thus 
avoiding identification of non-specific targets.  The secondary antibody is also an 
important consideration to reduce the impact of autofluorescence.  This is seen 
better with fluorescent dyes that tend to emit in the far red range, such as Alexa 
647, compared to those that emit in the orange to red range [331].  The radiation 
induced foci can then be visualised within cells using high resolution fluorescence 
optical microscopy [331]. 
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Widefield microscopy utilises an illumination source, such as a lamp or laser, to 
excite the field of view.  Whilst widely available, foci that are out of focus produce a 
haze or blur, making quantification very difficult.  However, microscopes are often 
enabled with moving platforms that can acquire images at various levels through the 
cell providing z stack images. 
 
In a similar manner, confocal laser scanning microscopy uses a laser beam to scan 
across a sample.  Foci are not restricted to single plane of view, but are located 
throughout the nuclear volume and, as such, imaging needs to take account of this.  
Fluorescence is produced throughout the whole depth of the sample, but a pin hole 
aperture excludes any fluorescence produced outside the focal point of the lens, 
allowing improved resolution. 
 
Once appropriate images are obtained through microscopy, the most common 
method to quantify foci is to manually count -H2AX foci by eye.  This can be done 
directly by visualising the number of foci through a microscope or on a captured 
image.  Since the number of foci can appear as different sizes or intensities and, 
because of the time consuming methods of manual quantification, high throughput 
foci counting systems are also being developed [311]. 
 
1.4.2.2  Other techniques 
Flow cytometry allows rapid measurement of -H2AX levels in a large number of 
cells and within different phases of the cell cycle.  The fluorescent signal produced 
allows for the size and number of -H2AX in the nuclei [332] and several studies 
have demonstrated that -H2AX levels detected using flow cytometry correlate well 
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with DSB numbers [329,333,334], while other groups have demonstrated that this 
approach can be used to detect DSBs in cells exposed to 1-2Gy of radiation [335].  
Flow cytometry enables detection of fluorescence intensity within each cell, as 
opposed to the scoring of each individual focus using microscopy.  It is a much 
quicker method of assessing -H2AX when compared to the laborious method of 
foci counting.  However, foci counting has been found to identify -H2AX foci 
following up to 10 times lower doses of radiation [279]. 
 
Enzyme Linked Immunosorbent Assay (ELISA) is based on 
electrochemiluminescent detection to measure -H2AX following irradiation and 
allows objective quantification of -H2AX [336].  However, poor sensitivity means 
that this method is not suitable for clinical samples [311].  Similarly, western blotting 
is difficult to use in the clinical setting and requires isolation of a large number of 
cells to obtain a sufficient amount of nuclear protein. 
 
1.4.3 -H2AX kinetics 
Kinetic studies, using immunofluorescent foci detection, demonstrate that half 
maximal foci numbers are achieved by 1-3 minutes following radiation exposure 
(although detection at this point is often difficult due to small foci size [305]), with 
maximal numbers reached by 10 minutes [289].  At its maximum, approximately 1% 
of all H2AX becomes phosphorylated per Gy of radiation, corresponding to 
approximately 2x106bp of DNA DSB [289]. 
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Following this, there is reduction of -H2AX foci after 30 minutes over a period of 
hours [288], although a significant level remains even several hours after irradiation 
[337].  By 24 hours, the -H2AX signal returns to background levels and this is 
thought to reflect repair of DNA DSB rather than the complete elimination of 
damaged cells [279,329,338].  However, it has been noticed that some repair does 
occur within the 30 minute period and, as such, foci numbers may actually 
underestimate the amount of DSBs (as opposed to PFGE which may conversely 
overestimate the number) [305,326].  Initial reports have demonstrated a close 
correlation between the numbers of radiation induced DSBs and numbers of -
H2AX foci, suggesting that each focus represents a DSB and vice versa 
[279,288,293]. 
 
Radiation doses as low as 1mGy have been shown to lead to the formation of foci 
and appear to have a linear relationship with dose in the dose range 1mGy to 2Gy 
[279,313,326,333,334,339-341].  These features mean that -H2AX foci can be 
used as a useful biological assay to measure induction and repair of radiotherapy 
induced DSBs at varying doses [279,283,285,289,292,342]. 
 
1.4.4 -H2AX and DNA damage from diagnostic and 
therapeutic radiation  
-H2AX is a well-established marker of DNA DSBs and a sensitive measure of 
radiation damage.  It has, therefore, been validated as a measure of whole body 
exposure in patients exposed to diagnostic and therapeutic ionising radiation 
[327,340,343,344].  The -H2AX assay has been shown to be very sensitive to 
radiation exposure and has been used to estimate radiation dose ex vivo 
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[325,345,346], while estimates can also be made on total and partial body 
irradiation [325], in vivo irradiation in non-human primates [323] and in diagnostic 
[327], as well as therapeutic radiotherapy [340]. 
 
The production and loss of -H2AX has been evaluated following doses of radiation 
as low as 1mGy [279] and evidence supports a linear increase in -H2AX foci 
number per cell with radiation dose [279,313,325,329,338,340,347] in the range 0 to 
10Gy within various cell lines [279,288,289,297,312,323,333,348]. In addition, it has 
also been found to be a useful maker for radiation exposure following radionuclide 
therapy for doses as low as 20mGy [284]. 
 
Correlation of -H2AX with DNA damage in PBLs, skin and other human tissue has 
been observed [337].  Easily accessible PBLs are convenient for determination of -
H2AX foci by venous blood sampling from patients and, as such, have been widely 
used in the past [325,327,335,349].  PBLs need to be isolated from blood collection 
and then purified by density gradient.  Although there are many subsets of 
lymphocytes, any difference in the level of -H2AX expression appears to be 
minimal [329,335].  They have low background levels of -H2AX foci [338,350,351] 
and this makes them ideal for assessing changes in foci following treatment.  
 
Using samples irradiated in vivo and ex-vivo [327,335,338,340,350], various studies 
have examined -H2AX induction 5-30 minutes following radiation exposure by 
quantifying foci in peripheral blood mononuclear cells (PBMCs) in patients who 
have undergone diagnostic CT scans and have demonstrated a very good 
correlation with Monte Carlo estimates of whole body exposure [327,338].  The -
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H2AX assay has been shown to detect very low radiation doses with an average 
0.2-0.4 -H2AX foci induced per 10mGy per cell [279,327,338].  Increase in levels 
by a factor of 10 was seen at 5 minutes and a reduction in foci levels seen 5-30 
minutes after irradiation, indicating repair.  It has also been noted that foci levels 
appear to be lower in patients undergoing CT scans of the chest in comparison to 
patients undergoing whole body CT scans [327].  Similarly, Lobrich and colleagues 
found that the number of DSB induced by CT scans was dependent on the dose 
delivered and length of body exposed to radiation [338].  In both studies, -H2AX 
foci levels appear to fall after 30 minutes, with background levels of foci reached in 
the majority of cases by 24 hours, although it was noted that this was subject to 
interindividual variability.  Others have utilised the -H2AX assay to assess DNA 
damage in patients undergoing cardiac CT and conventional coronary angiography 
[350,352-354], with suggestions of increased DNA DSBs as a result of conventional 
coronary angiography as compared to CT angiography [354]. 
 
Some groups have demonstrated the feasibility of assessing -H2AX foci in 
lymphocytes following a fraction of therapeutic radiotherapy at various time points 
after irradiation [349], with maximal levels at 30 minutes and a gradual reduction in 
levels over 2.5, 5 and 24 hours [349].  Further studies have shown that the assay 
can also be used to measure radiotherapy related doses and allow an estimation of 
the applied integral body dose following partial body irradiation due to the 
redistribution of lymphocytes in blood flow [340,355], but also taking account of the 
site of irradiation and time taken.  This approach has the advantage that DNA 
damage is visualised directly using easily accessible peripheral blood samples and 
is very sensitive to very low damage levels.   
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Studies have examined the use of -H2AX following ex vivo irradiation and have 
shown that this can result in the induction of 10-15 foci per Gy within sampled 
lymphocytes [279,325,336,337,345].  However, various groups have also attempted 
to evaluate -H2AX following in-vivo irradiation [313,315,327,340,347,356] and have 
shown that the -H2AX levels following in vivo irradiation are often lower and appear 
to depend on the dose, area of the body exposed to radiation, as well as the 
duration and fractionation of radiation.  Nonetheless, in vivo measurements of foci 
numbers in PBLs have produced a linear correlation with integrated total body 
radiation dose [327,338,340,350] and allows accurate assessment of radiation 
induced DSBs in normal tissues at clinically relevant doses [318,357].   
 
Skin cells have also been used to confirm the ability to determine -H2AX following 
EBRT for prostate cancer [313] 30 minutes following radiation and have 
demonstrated a linear dose response beyond 0.05Gy [313,315] and additionally 
shown that repair appears to be complete between radiotherapy fractions [315].   
Others have demonstrated a negative correlation following radiotherapy between -
H2AX foci and TCD50 (dose at which 50% of tumours are controlled) in head and 
neck squamous cell carcinoma xenograft models, such that the number of residual 
foci following radiotherapy appears to be a good indicator of radiosensitivity, and is 
a potential biomarker for local tumour control [358]. 
 
The -H2AX assay is sensitive enough to detect inter-individual differences in DNA 
response following irradiation [335,338] and the extent of DNA damage and repair 
has been considered to be a significant indicator of radiation induced normal tissue 
toxicity [326].  The ability to use DNA damage markers, as a way of predicting those 
at higher risk of radiation induced toxicities, has been investigated by a number of 
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studies.  Quantification of -H2AX foci and also persistence of -H2AX foci (and 
therefore rate of DNA DSB repair), seen at time points after ex-vivo irradiation, has 
been shown to identify those at high risk of acute and late toxicity [324,347,359-
361], with accumulation of DNA DSBs similarly seen in both acute and late 
responding tissues during fractionated radiotherapy [362].  Yet, other groups have 
failed to demonstrate any correlation between -H2AX foci levels and intensities 
with radiation induced toxicities [349,363-365].   
 
Whilst DNA damage following radiation is now established, there have been very 
few studies examining the differences in DNA damage following various 
radiotherapy techniques.  Zwicker and colleagues, in 2011, investigated DNA 
damage through -H2AX foci levels following 3D-CRT and step and shoot IMRT in 
patients undergoing prostate radiotherapy [356].  However, their results did not 
demonstrate any statistically significant difference between the two techniques.  A 
more recent study has demonstrated increased -H2AX foci in blood cells taken 30 
minutes following prostate IMRT, with some persistence of DNA damage 18-24 
hours after irradiation [366].  The authors also found that cell cycle arrest was not 
activated (and shown not to be activated under a threshold of 200mGy) and they 
have, therefore, postulated that this, taken together with the persistence of -H2AX 
foci, may lead to continuing unrepaired or mismatched repair breaks, which may, in 
turn, proceed to cancer induction as a result of low dose irradiation, particularly with 
IMRT [366]. 
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1.5 Aims of study 
This work aims to examine specific biological and clinical implications of IMRT:  
1. Investigation of -H2AX in peripheral blood lymphocytes (PBL)  as a 
potential surrogate marker for whole body dose after IMRT 
2. Investigation of utility of -H2AX to compare whole body dose when different 
radiation delivery techniques are used. 
3. Examination of the feasibility of using IMRT for patients with meningioma. 
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Table 1.1: Simpson’s grading for meningioma resection and the associated 
rate of symptomatic recurrences observed at 10 years. 
Grade  Description 
Rate of symptomatic 
recurrence at 10years 
(%) 
I Macroscopically complete removal of tumour, with 
excision of dural attachment, and any abnormal 
bone. Includes resection of venous sinus if involved 
9 
II Macroscopically complete removal of tumour and its 
visible extensions with coagulation of its dural 
attachment 
19 
III Macroscopically complete removal of the intradural 
tumour, without resection or coagulation of its dural 
attachment or its extradural extensions 
29 
IV Partial removal, leaving intradural tumour in situ 44 
V Simple decompression, with or without biopsy 100 
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Chapter 2 
 
The feasibility of using -H2AX assay during  
static field IMRT (SF-IMRT)  
 
 
2.1 Aims 
 
 To determine the feasibility of using the -H2AX assay in peripheral blood 
lymphocytes of patients undergoing radiotherapy as a surrogate for DNA 
damage caused by ionizing radiation. 
 To quantify -H2AX foci induction at various time points following SF-IMRT. 
 To ascertain whether -H2AX foci in lymphocytes can be used as a sensitive 
and reproducible measure of radiation exposure in patients undergoing SF-
IMRT. 
 To confirm a linear dose response in -H2AX foci formation in lymphocytes 
following radiation exposure. 
 
 
2.2 Introduction 
 
IMRT has become the standard approach for the treatment of a wide variety of 
tumours, aiming to increase tumour control, whilst minimising normal tissue toxicity.  
Despite a smaller volume of normal tissue receiving a high radiation dose with static 
field intensity modulated radiotherapy (SF-IMRT) compared to conventional 
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techniques, there is inevitably a larger volume of normal tissue (outside the target 
area) which receives a low radiation dose. 
 
In an attempt to document the low radiation dose, this chapter describes the use of 
the -H2AX assay in patients undergoing radiotherapy for brain tumours using SF-
IMRT.  -H2AX has been shown to detect very low radiation doses with reports 
suggesting 0.2-0.4 -H2AX foci per cell for 10mGy [279,327,338]. This assay has 
been previously used to demonstrate -H2AX foci levels following diagnostic CT 
scans, with levels found to increase linearly with the dose delivered and length of 
body exposed [327,338]. Others have observed that the assay can also be used to 
measure radiotherapy-related doses, thereby allowing an estimation of the integral 
body dose [340,355] and -H2AX foci numbers measured, within peripheral blood 
lymphocytes following in vivo radiation, have been found to show a linear correlation 
with integral dose [327,338,340,350]. 
 
This study was carried out to ascertain whether -H2AX foci induction in peripheral 
blood lymphocytes can be used as a sensitive and reproducible measure of 
radiation exposure in vivo for patients undergoing SF-IMRT to the brain. Patients 
with tumour volumes in the brain were chosen as the direct irradiation of circulating 
blood is minimal, making up approximately 15% of total blood volume [367].  
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2.3 Methods and Materials 
 
2.3.1 In-vivo lymphocyte irradiation 
2.3.1.1 Patient selection 
Patients at University College London Hospital (UCLH), due to undergo radical 
radiotherapy for a tumour of the brain using SF-IMRT, were recruited prospectively.  
All enrolled patients were recruited as part of the study entitled, “Evaluation of DNA 
damage and radiation exposure in patients receiving intensity modulated 
radiotherapy”.  Inclusion criteria encompassed all patients with a histological 
diagnosis of a tumour undergoing radiotherapy treatment with SF-IMRT and also 
those patients who were suitable to attend regular follow up. Exclusion criteria 
comprised patients undergoing neoadjuvant, adjuvant or concurrent chemotherapy 
and those who had a previous or concurrent illness which may have interfered with 
either completion of therapy or follow up.  The study design described in this 
chapter was conceived and set up was set up by Professor Short and Dr Guerrero 
Urbano and the protocol was approved by the local ethics committee (ref: 
06/Q0512/98).  I was involved from the time of patient recruitment and written 
informed consent was obtained from all patients. All patients were treated with 
radiotherapy according to the indications set out by the treating clinician. 
 
2.3.1.2 Sample Collection and Beam Parameters 
4ml peripheral blood samples were collected for analysis from the anterior cubital 
vein in each patient at the following time points:  
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i. Baseline (prior to any ionising radiation exposure, including the radiotherapy 
planning CT scan, to measure background damage), 
ii. Prior to and 30 minutes after the first fraction and then before and after each daily 
fraction of radiotherapy for the first week (for the first 4 patients only), 
iii. Before and after every further 5 fractions (9Gy) of radiotherapy (i.e. weekly 
measurements)  
iv. 2 and 6 weeks following completion of treatment.   
 
Detailed beam and dosimetric data were collected for each patient, including target 
volume size irradiated, prescribed dose and fractionation, total dose, number of 
incident fields, beam-on time, number of monitor units and dose rate used (see 
appendix A).  Beam parameters have been identified as contributing to scattered 
radiation [236], with internal scatter felt to be a reflection of the dose delivered and 
target size.  Additionally, factors such as beam delivery technique, multileaf 
collimators and the number and orientation of beams also contribute to scatter dose 
and is thought to be largely dependent on the number of monitor units used and 
beam-on-time.    
 
2.3.1.3 Sample Processing  
Following collection, blood samples were transferred to BD vacutainer® CPT™ (cell 
preparation tube with sodium citrate) to allow separation of lymphocytes from whole 
blood by centrifugation (20 min, 1600g).  Lymphocytes were washed with 4ml of 
phosphate buffer solution (PBS) followed by further centrifugation (10 min, 250g). 
The supernatant was decanted and the remaining cell pellet was resuspended in 
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100µl PBS.  20µl of this was placed onto a slide, allowed to dry, and then fixed with 
100µl of 3.7% paraformaldehyde.  Slides were suspended in methanol solution for 
10 minutes at -20oC, then in acetone for 1 minute at room temperature to allow 
better preservation of nucleic acid.  The slides were washed with 2% PBS/BSA 
(bovine serum albumin) to prevent the non-specific binding of the primary antibody.  
40µl of mouse anti--H2AX monoclonal antibody (Millipore, CA) with antibody 
diluent (Dako) at a concentration of 1:300 was added and left at 4oC overnight.  
Slides were washed in 2% PBS/BSA for 2mins and 80µl (1:500 dilution) of 
AlexaFluor green 488 Goat anti-mouse secondary antibody (Invitrogen, USA) was 
added and left for one hour in the dark.  Slides were washed again in 2% PBS/BSA 
and mounted using DAPI/DABCO mounting medium (Vector lab inc., Burlingamo, 
CA). 
   
2.3.1.4 -H2AX Foci Analysis 
Foci were visualized with an inverted confocal microscope (SPE inverted 
microscope, Leica Microsystems CMS), equipped with acquisition software using 
x63 oil objective and pin hole size of 1 AU (Airy unit).  Foci were identified as well-
defined green spots within the blue nuclei of lymphocytic cells.  Optical sections 
through the nucleus were obtained at 0.5μm intervals to compose z stack images 
and combined in a maximum projection so that all the visible foci were recorded. 
Two sample slides were produced for each time point and at least 150 cells were 
examined per slide.  Images were saved as a TIF (tagged image format) file and 
transferred to ImageJ64 (National Institute of Health, USA) software.  The numbers 
of foci within each visualized nucleus were counted manually by the same person to 
reduce inter-observer variability. However, to exclude a significant observer bias, 
two independent investigators also counted a subset of the samples.   
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2.3.1.5 Statistical Analysis 
Data evaluation and statistical analysis was performed by me using PASW® 18.0 
statistical package (SPSS Inc., Chicago).  Some support was obtained from the 
UCL Research Support Centre to ensure that appropriate statistical analysis was 
being performed. Paired t-tests were used to test for statistical difference between 
pre and post-radiotherapy samples and repeated measures anova (Greenhouse-
Geisser) was used to test for statistical difference between the samples taken at 
different times of treatment.  Statistical significance was set at 5%.   
 
2.3.2 Ex-vivo lymphocyte irradiation 
To illustrate and confirm the -H2AX foci dose response within lymphocytes, 4ml of 
peripheral blood was collected from the anterior cubital fossa of 2 healthy 
volunteers and irradiated ex-vivo using 137Cs source (15.06TBq) at doses of 0.05Gy, 
0.1Gy, 0.3Gy, 0.5Gy, 1Gy and 2Gy at a dose rate of 250 +/- 0.59% Gy/hr.  Cells 
were fixed after 30 minutes and analysed for foci formation.  Samples were 
processed and foci analysis was performed in a similar manner to the in vivo 
samples using inverted confocal microscopy. 10 random images were taken per 
sample and the mean number of foci calculated.  Three experimental repeats were 
performed.  This ex-vivo work was facilitated by the Head and Neck Oncology 
Group, Department of Oral pathology, King’s College London. 
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2.4 Results 
 
2.4.1 Patient Characteristics  
15 patients consented to study entry and all received radiotherapy using SF-IMRT 
technique. 14 patients received SF-IMRT for a cranial meningioma and 1 patient 
received radiotherapy for a pituitary adenoma.  The median tumour volume 
(planning target volume [PTV]) irradiated for these patients was 88 cm3 (range 23.1 
to 254.9 cm3).   All radiotherapy was delivered using a linear accelerator with 6MV 
photons at a median dose of 50.4Gy in 28 fractions over 5 and a half weeks and 
using a median of 5 intensity modulated fields (range 4 to 7 fields).  A median of 
518 monitor units (MU) (range 393 to 1014 MU) was needed to deliver this 
treatment with a median ‘beam on time’ of 124 seconds (range 98 to 254 seconds).  
Detailed patient characteristics and beam parameters are summarized in tables 
2.1a and 2.1b.   
 
One patient had a large PTV measuring 245.9cm3 and required 7 modulated fields 
for adequate treatment.  This necessitated a total number of 1014 MU and the 
longest treatment delivery with beam on time of 245 seconds.  In contrast, the 
patient treated for a pituitary adenoma had a PTV of 23.1 cm3 and required 5 
modulated fields, which needed treatment with 431 MU and a beam on time 0f 109 
seconds.  However, the patient who had the lowest number of monitor units (393 
MU) and shortest treatment time (98 seconds), had a PTV volume of 48.8cm3 , but 
required only 4 modulated beams, indicating that monitor units and beam-on-time 
are directly related, which in turn are likely to be dependent on the number and 
complexity of modulated beams.  
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2.4.2 Quantification of -H2AX foci per cell during SF-IMRT 
Mean baseline level of -H2AX foci per nucleus for this group of patients was 0.186 
± 0.05 (standard deviation).  An increase in radiation-induced -H2AX foci were 
clearly visualised in patient samples taken 30 minutes after each 1.8Gy fraction of 
SF-IMRT with green fluorescent foci seen within dark blue stained cell nuclei (fig. 
2.1).  The initial phase of the study demonstrated that there was an increase in -
H2AX foci levels following daily treatment in the first week of radiotherapy for the 
first cohort of 4 patients (fig 2.2).  However, there was no statistically significant 
difference in the increased foci levels following each fraction of radiotherapy during 
the first week of treatment (0.438 v 0.334 v 0.209 v 0.444 v 0.412, p=0.0983), (fig 
2.3 and table 2.2).  In view of this finding, we proceeded to omit daily blood 
sampling during the first week of treatment and continue with weekly blood samples 
as planned for the remainder of the cohort of patients. 
 
There was a statistically significant increase in foci levels seen in post-treatment 
samples compared to pre-treatment levels and this appeared consistently between 
samples taken at the same time during each week of radiotherapy (fig. 2.4 and table 
2.3). Throughout the entire course of radiotherapy, -H2AX focus yields were 2-3 
fold higher in blood samples taken following SF-IMRT compared to pre-treatment 
samples.  Throughout a six week course of SF-IMRT the mean -H2AX focus per 
nucleus was 0.170 ± 0.025 pre-treatment and 0.493 ± 0.042 post SF-IMRT, with a 
mean increase in foci numbers per cell nuclei of 0.323 ± 0.030 (p<0.0001), (fig.2.5).  
 
The post radiation increase in mean -H2AX levels varied slightly from one week to 
another (fig. 2.6).  However, there was no statistically significant difference in the 
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observed increase in -H2AX foci levels following SF-IMRT between samples taken 
during different weeks of treatment (0.317 v 0.307 v 0.323 v 0.364 v 0.311 v 0.334, 
p=0.718), suggesting that there is no accumulation of foci in lymphocytes.  In 
addition, there was no statistically significant difference between baseline foci levels 
compared to foci levels taken at 2 weeks (0.186 v 0.252, p=0.199) and also at 6 
weeks (0.186 v 0.159, p=0.424) post-radiotherapy, indicating no long-term 
accumulation of damage after completion of treatment. 
 
2.4.3 Ex-vivo lymphocyte irradiation  
As expected, there are low numbers of -H2AX foci in unirradiated cells (0.05 
foci per nucleus), which increase following irradiation. The data in figure 2.7 
demonstrate a clear dose response in -H2AX foci formation at 30 minutes 
following ex-vivo irradiation of lymphocytes from healthy volunteers.  From this 
graph we can see that these data support a dose response that is linear at early 
time points over this dose range, and indicate an estimated 3.092 foci are 
induced per Gy above background levels of 0.47 foci.  
 
 
2.5 Discussion 
 
This in-vivo study was undertaken to evaluate the use of -H2AX as a marker for 
radiation damage in patients undergoing SF-IMRT.  A cohort of patients with brain 
tumours was chosen, as the proportion of blood volume in the brain lying within the 
directly irradiated target area is relatively low (approximately 15%) [367] and this 
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may imply that a significant proportion of damage expressed as foci formation in 
lymphocytes results from radiation deposited outside the target volume, allowing for 
a more accurate measurement of non-target, low-dose radiation exposure from SF-
IMRT.  
 
The use of peripheral blood lymphocytes to demonstrate DNA DSBs following in 
vivo SF-IMRT has the advantage of acquiring material for analysis through a 
minimally invasive procedure and has been shown to have relatively low 
background levels of -H2AX foci [338,350,351,368].  Background levels in this in-
vivo study have shown to be 0.186 ± 0.05 foci per cell and is broadly in line with 
other studies, allowing for inter-individual variability 
[325,338,340,343,345,349,356,364].  
 
The results confirm that -H2AX foci can be visualised in lymphocytes of patients 
undergoing standard therapeutic dose radiotherapy, and in particular following SF-
IMRT.  It clearly demonstrates that there is a reproducible and statistically 
significant increase in foci numbers following a single fraction of radiotherapy, which 
appears to be constant between daily fractions of radiotherapy within the first week 
of treatment.  In view of this finding, daily blood tests for change in -H2AX foci 
levels were discontinued for the remainder of the patients.  This meant less invasive 
sampling procedures for the study patients, whilst still facilitating the measurements 
of -H2AX foci levels over the course of radiotherapy.  
 
The results demonstrate that there is an increase in -H2AX foci levels between 
successive doses during a 6 week course of treatment and appears to be consistent 
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each week throughout the course of treatment.  However, despite the slight 
difference in radiation induced foci from one week to another during treatment, this 
variation was not found to be statistically significant.  -H2AX foci levels returned to 
baseline by two weeks following a six-week course of radiotherapy, suggesting that 
there was no accumulation of DNA-damage in this lymphocyte population, likely to 
be a reflection of the short half-life of these cells in the blood and efficient repair of 
damage. 
 
Ex vivo irradiation was performed on peripheral blood lymphocytes from healthy 
volunteers to confirm a linear dose response with foci induction using the same -
H2AX assay utilised for the in vivo work.  The close correlation of DNA DSBs and -
H2AX foci induction with radiation dose has been well documented in the past 
[279,288,289,313,325,329,337,338,340,347], even to doses as low as 0.02Gy using 
in vitro irradiation of peripheral blood lymphocytes [337]. The data from this ex vivo 
experiment demonstrate 3.092 foci per cell per Gy, whilst others, evaluating foci 
induction within lymphocytes, have reported slightly higher figures of 9 foci per cell 
per Gy (with 220kVp x-rays) [369], 12.6 foci per cell per Gy (with 137Cs source) 
[337] and 14.7 foci per cell per Gy (with 150kV) [327].  In addition, we have 
demonstrated 0.47 foci per cell with 0.1Gy, whereas others have measured 1-1.4 
foci [337,338], although the background -H2AX foci levels in this cohort appear to 
be similar to other groups at approximately 0.05 foci per cell [369].  The differences 
seen may reflect inter-individual variability and it must be noted that samples were 
analysed in only 2 healthy volunteers in this experiment.  However, it can also be 
accounted for by differences in assay technique and variability in foci counting 
between researchers when this is carried out manually. 
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Previous reports have exploited -H2AX focus formation as a sensitive tool for in 
vivo detection of DSB following radiation exposure with diagnostic computed 
tomography (CT) scans [327,338]. One study utilized this assay to demonstrate -
H2AX foci levels following diagnostic CT scans of the thorax and abdomen, with 
levels found to increase linearly with the dose delivered and length of body exposed 
[338].  Similarly, it has been used to examine DNA damage following radiotherapy 
to different sites of the body and tumour types, demonstrating a linear relationship 
to the integrated total body radiation dose [340].  Comparable to our results, both 
studies demonstrated that background levels of foci were achieved by 24 hours 
following exposure to radiation.  However, other groups have suggested that a 
proportion of radiation induced DSBs remain unrepaired after 24 hours [349] and 
may be a reflection of an inter-individual’s variability and radiation sensitivity [347].  
Furthermore, this study has demonstrated that any variation in radiation induced 
foci seen from one week to another during treatment is not statistically significant 
and, therefore, one could justify sampling blood and analysing for foci induction at 
just one time point during treatment, rather than on a weekly basis, to give an 
indication of the level of radiation damage induced.  
 
There have been relatively few studies looking at -H2AX induction within peripheral 
blood lymphocytes following in vivo therapeutic radiation [340,347,349] and even 
fewer data exploring and quantifying -H2AX foci induction following SF-IMRT 
[356,366].  The data from this study demonstrates an increase of 0.323 foci per cell 
following SF-IMRT and is comparable to that found from a similar study by Zwicker 
and colleagues[356], assessing -H2AX foci levels in patients undergoing IMRT to 
the prostate .  They found a mean 0.47 foci per nucleus following step and shoot 
IMRT (with a mean difference of 0.42 foci per nucleus after subtracting baseline 
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levels).  Similarly, El-Saghire and colleagues have demonstrated an increase in -
H2AX foci levels within blood samples taken 30 minutes following the first fraction of 
step and shoot IMRT, with induced foci level reported in the range 0.194 – 0.622 
foci per cell among 8 patients (giving a mean increase of 0.47 foci per cell) [366]. 
 
The data also confirm that -H2AX foci levels returned to baseline by two weeks 
after completing a six-week course of radiotherapy.  Other studies have 
documented detailed kinetics of -H2AX foci and demonstrated a persistence of 
over 20% of original foci numbers at 8 hours after exposure to in vitro radiation.  
With low doses, such as 0.02Gy, foci numbers return to near baseline levels by 48 
hours post exposure, although with doses greater than 1Gy, foci numbers were still 
persistent and measured at 6.6% of original levels compared to levels identified 
30minutes after in vitro radiation [337].  Some groups have proposed that, even 
following radiation doses in the region of 1.2mGy (0.0012Gy), there is a persistence 
of foci numbers in cell cultures for up to 14 days, indicating that some cells are 
unable to repair DSB efficiently [279].  A study examining -H2AX foci levels in 
patients with prostate cancer undergoing IMRT, also demonstrated some 
persistence of foci levels 18-24 hours following IMRT, associated with inactivation of 
cell cycle arrest under doses of 200mGy [366].  Suggestions have been made that 
this could be compatible with continuing unrepaired DNA DSBs, which may in turn 
be a cause of cancer induction as a result of these low radiation doses.  However, 
the findings from the study presented in this chapter suggest that there was no 
accumulation of DNA damage in this lymphocyte population, likely a reflection of 
short half-life of these cells in the blood and efficient repair of damage within this 
particular sample population. 
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The method of foci counting can be labour and time intensive and may pose issues 
with quantification.  This is particularly relevant in samples with numerous foci and 
where there is evidence of foci coalescence, often resulting in difficult quantification 
and subsequent underscoring of foci.  Manual foci counting may also be subject to 
inter-observer variability; although we have attempted to address this issue by 
utilizing a single scorer.  In order to exclude significant observer bias, a proportion 
of samples were independently counted by two people.  It was, however, not 
feasible to utilize two independent scorers to manually count the whole dataset, due 
to the time taken to count each slide manually (which, on average, took over 60 
minutes per slide).  
 
One method that has been increasingly employed is that of automated foci counting 
systems, as a way of decreasing observer variation, as well as reducing time and 
labour to analyse foci distribution [345].  Validation is essential to enable the 
extension of these methods to analyse foci size and intensity [311] and there are 
now developments in image analysis algorithms incorporated into image acquisition 
software programs to enable this.  Flow cytometry methods have also been used to 
identify -H2AX foci as a fast and relatively effective tool due to their high 
throughput, although they may be associated with loss of sensitivity in comparison 
to evaluating foci counts and size [311,329,370] and there have been reports that 
manual foci counting can identify -H2AX foci following up to 10 times lower doses 
of radiation than other methods [279]. 
 
The dose from scattered radiation as a result of radiotherapy measured within 
circulating lymphocytes is not easy to establish.  Groups have acknowledged that 
there may be an effect of partial irradiation with attempts to distinguish cells that 
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have been directly irradiated from those that have not within the blood pool 
[325,347].  However, further work with mathematical modelling would be required to 
explore and accurately associate our findings to scatter dose.    
 
 
2.6 Conclusion 
 
This chapter confirms that ex-vivo irradiated lymphocytes demonstrate a linear dose 
response in -H2AX foci formation 30 minutes after radiation exposure.  
Furthermore, the in vivo experiment demonstrates that -H2AX foci induction is a 
sensitive and reproducible measure of DNA damage in lymphocytes of patients 
undergoing radiotherapy, in particular SF-IMRT, to the brain and may be useful as a 
marker of DNA damage. 
 
IMRT is a potential source of increased radiation exposure.  Higher -H2AX foci 
numbers following SF-IMRT may be used as a surrogate measure for DNA DSB, 
the repair of which can be a source of stochastic change, in particular at low doses 
of radiation, where cellular systems to eradicate DNA DSBs may not be active. This, 
therefore, may have implications for long-term radiation risk, including the potential 
risk of second malignancies.  Quantification of -H2AX foci induction following 
differing radiation delivery techniques may provide useful information for the 
comparison of DNA damage and, therefore, the long term effects produced by these 
techniques. 
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Table 2.1a: Individual patient characteristics and beam parameters for SF-IMRT 
Abbreviations: SF-IMRT = Static field intensity modulated radiotherapy; M=male, F=female; PTV = planning target volume 
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 SF-IMRT 
 Median Range 
Number of patients 15  
Age 52 38-65 
Dose (Gy) 50.4  
Dose/# (Gy) 1.8  
   
Monitor Units (MU) 518 393-1014 
Dose rate 400  
Beam on time (seconds) 124 98-254 
Number of fields 5 4-7 
PTV (cm3) 88 23.1-254.9 
 
Table: 2.1b:  Median patient characteristics and beam parameters 
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Fig. 2.1: -H2AX foci prior to (fig. 1a) and 30 minutes following (fig. 1b) SF-
IMRT.   
There is a greater increase in -H2AX foci (shown as green spots) within 
lymphocyte nuclei (seen as blue) following exposure to SF-IMRT. 
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Fig. 2.2: Mean -H2AX foci per nucleus measurements at daily time points 
(after each 1.8Gy) in 4 patients during the first week of SF-IMRT 
Error bars represent standard deviation.   
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Fig 2.3:  Observed difference in pre and post SF-IMRT mean -H2AX foci levels 
taken daily in 4 patients during the first week of treatment. 
There is no statistically significant difference in the change in mean -H2AX levels 
from one day to another during the first week of SF-IMRT (p=0.0983). 
Error bars represent standard deviation.  
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 Mean -H2AX foci per nucleus (SD)  
Day during first 
week 
Cumulative dose at 
point of sampling 
1 
 
1.8Gy 
2 
 
3.6Gy 
3 
 
5.4Gy 
4 
 
7.2Gy 
5 
 
9.0Gy 
 
Pre SF-IMRT(SD) 
 
0.2178 
(0.0252) 
 
0.410 
(0.089) 
 
0.219 
(0.0699) 
 
0.270 
(0.0278) 
 
0.423 
(0.0737) 
Post SF-IMRT (SD) 
0.656 
(0.0916) 
0.744 
(0.0413) 
0.428 
(0.0515) 
0.713 
(0.061) 
0.836 
(0.082) 
Difference (SD) 
0.438 
(0.066) 
0.334 
(0.059) 
0.209 
(0.018) 
0.444 
(0.033) 
0.412 
(0.155) 
P values <0.0001 0.0628 0.05 0.05 0.05 
 
Table 2.2: Mean -H2AX foci per nucleus levels in 4 patients pre and post SF-
IMRT for each fraction of radiotherapy during the first week of treatment.   
Abbreviations: SD=standard deviation 
 
The observed difference in -H2AX foci numbers between the daily fractions is not 
statistically significant (p= 0.0983). 
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Fig.2.4: Mean -H2AX foci per nucleus measurements in 15 patients at weekly 
time points during and after a six week course of SF-IMRT. 
 
Error bars represent standard deviation; *=p<0.05. 
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Table 2.3: Mean -H2AX foci per nucleus levels pre and post SF-IMRT for each 
week during treatment. 
 
There is a statistically significant difference in foci numbers in samples taken weekly 
pre and post-treatment and calculated at the same time during each week of 
treatment.  The difference observed is independent of treatment week. 
 Mean -H2AX foci per nucleus (SD) 
Week during 
treatment 
Cumulative dose 
at point of 
sampling 
1 
 
1.8Gy 
2 
 
10.8Gy 
3 
 
19.8Gy 
4 
 
28.8Gy 
5 
 
37.8Gy 
6 
 
46.8Gy 
Pre SF-IMRT        
(SD)  
0.175 
(0.161) 
0.193 
(0.139) 
0.140 
(0.067) 
0.183 
(0.112) 
0.149 
(0.089) 
0.180 
(0.185) 
Post SF-IMRT      
(SD) 
0.492 
(0.235) 
0.501 
(0.287) 
0.463 
(0.146) 
0.548 
(0.279) 
0.460 
(0.132) 
0.514 
(0.182) 
Difference (SD) 
0.317 
(0.158) 
0.307 
(0.199) 
0.323 
(0.114) 
0.364 
(0.223) 
0.311 
(0.169) 
0.334 
(0.077) 
P values <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
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Fig. 2.5: Mean -H2AX foci per nucleus measurements over a six week course 
of SF-IMRT. 
 
There is an increase of 0.323 ± 0.030 (p<0.0001) mean -H2AX foci seen within 
lymphocyte nuclei following SF-IMRT over a whole course of treatment. 
Error bars represent standard deviation. 
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 Mean -H2AX foci per nucleus (SD) 
Week during 
treatment 
Cumulative dose at 
point of sampling 
1 
1.8Gy 
2 
10.8Gy 
3 
19.8Gy 
4 
28.8Gy 
5 
37.8Gy 
6 
46.8Gy 
       
Difference in mean 
-H2AX foci (SD) 
0.317 
(0.158) 
0.307 
(0.199) 
0.323 
(0.114) 
0.364 
(0.223) 
0.311 
(0.169) 
0.334 
(0.773) 
 
Fig.2.6:  Observed difference in pre and post SF-IMRT mean -H2AX levels 
taken weekly during treatment. 
 
There is no statistically significant difference in the change in mean -H2AX levels 
from one week to another during a course of SF-IMRT. 
Error bars represent standard deviation. 
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Fig. 2.7: Mean -H2AX foci numbers lymphocytes of healthy volunteers 
counted 30 minutes following ex-vivo irradiation at varying dose levels.  
 
A linear fit to the data gives an estimated 3.092 foci induced per Gy above 
background levels of 0.47 foci. 
Error bars represent standard deviation. 
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Chapter 3  
 
-H2AX as a reproducible and sensitive marker 
for the comparison of DNA damage from static-
field intensity modulated radiotherapy (SF-
IMRT), volumetric modulated arc therapy 
(RapidArc
TM
) and 3D-conformal radiotherapy 
(CRT). 
 
 
3.1 Aims 
 
 To confirm that -H2AX is a sensitive and reproducible measure of DNA 
damage in patients undergoing volumetric modulated arc therapy 
(RapidArcTM [RA]) and 3D-conformal radiotherapy (CRT) to the brain where 
direct irradiation of circulating blood is minimal. 
 To quantify -H2AX foci induction at various time points following RA and 
CRT. 
 To investigate whether foci induction following RA and CRT remains 
constant between successive doses during a 6 week course of treatment. 
 To determine the feasibility of using the -H2AX assay for comparison of -
H2AX foci induction for differing radiation techniques (SF-IMRT, RA, CRT).  
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 To explore whether the differences seen between techniques may be due to 
low dose whole body exposure. 
 To document dose (using various radiotherapy techniques) to regions 
outside the target volume using a phantom and correlating this with in-vivo 
data from -H2AX foci analysis. 
 
 
3.2 Introduction 
 
There are now various ways to deliver external beam radiation and attempts have 
been made to provide increasing target volume conformality.  Intensity modulated 
arc therapy (IMAT) or Volumetric modulated arc therapy (RapidArcTM [RA]), a 
solution to IMAT, is a novel IMRT delivery technique.  It has been shown to achieve 
radiotherapy plans comparable to static-field IMRT (SF-IMRT), in terms of 
conformality, with the advantage of shorter treatment times [59,62,213,371,372].  
RapidArcTM (RA), in contrast to SF-IMRT, requires a lower number of monitor units 
and beam-on time to deliver an equivalent tumour dose [25,60,61,373] and may 
therefore produce a lower whole body exposure [66,373,374].  3D-conformal 
radiotherapy has been used for many years and, although also uses a lower 
number of monitor units and beam on time, it is often inferior to both SF-IMRT and 
RA in terms of tumour conformality. 
 
The study described in chapter 2 was extended to assess -H2AX foci induction in 
peripheral blood lymphocytes as a marker for DNA damage in patients undergoing 
radiotherapy using various techniques and confirm its sensitivity and reproducibility 
as a measure of radiation exposure.  Comparison of DNA damage levels is made in 
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patients treated with static-field IMRT [SF-IMRT], volumetric modulated arc therapy 
(RapidArcTM [RA]) or 3D-conformal radiotherapy [CRT] techniques delivered to 
equivalent target volumes and doses within the central nervous system.  Attempts 
have been made to establish whether this DNA damage, measured as -H2AX foci 
levels, is due to low dose radiation as a result of the radiation technique employed.  
 
 
3.3 Methods and Materials 
 
3.3.1 In-vivo lymphocyte irradiation 
3.3.1.1 Patient selection 
Following confirmation of the feasibility of using the -H2AX assay in patients 
undergoing SF-IMRT (Chapter 2), further patients at UCLH undergoing radical brain 
radiotherapy using RA and CRT were also recruited prospectively as part of the 
study entitled “Evaluation of DNA damage and radiation exposure in patients 
receiving intensity modulated radiotherapy”.  Inclusion criteria encompassed all 
patients with a histological diagnosis of a central nervous system tumour 
undergoing radiotherapy treatment and who were suitable to attend regular follow 
up.  Exclusion criteria comprised patients undergoing neoadjuvant, adjuvant or 
concurrent chemotherapy and those who had a previous or concurrent illness which 
may have interfered with either completion of therapy or follow up.  The study 
protocol was approved by the local ethics committee (ref: 06/Q0512/98) and written 
informed consent was obtained from all patients.  The radiotherapy technique used 
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for these patients was chosen according to the indications set out by the treating 
clinician. 
 
3.3.1.2 Sample Collection, Processing and -H2AX Foci Analysis 
4ml peripheral blood samples were collected as outlined in chapter 2 (see section 
2.3.12).  Detailed beam data were collected for each patient (see section 2.3.1.2 
and appendix A).  Blood samples were processed and analysed as in chapter 2 
(see sections 2.3.1.3 and 2.3.1.4) 
  
3.3.2 TLD Measurements 
A Rando-phantom was used to further demonstrate dose to body regions outside 
the target volume with typical SF-IMRT, RA and CRT plans.  Thermoluminescent 
dosimeter (TLD-100H (LiF)) chips (Bicon-Harshow), all 3x3x1mm3 in size, were 
used for this purpose and dose recorded using a Harshaw TLD Reader Model 5500.   
 
Initially, four TLD-100H chips were irradiated with 100MU at 5cm depth in solid 
water (local reference conditions ensuring 1Gy equivalent to 100MU) to provide a 
TLD reading to dose in Gy conversion factor.   
 
Subsequently, 2 TLD-100H chips were placed in each of the three following 
positions: right and left shoulder regions (25cm from the central axis of the beam 
and 10cm laterally from the centre) and the mid pelvic region (60cm from the 
isocentre, placed approximately at the centre), at a depth of 10cm from the phantom 
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surface (fig. 3.9).  A typical plan from each of the radiotherapy techniques being 
investigated and with equivalent irradiated tumour volumes was transferred to the 
Rando-phantom and radiation dose delivered.  Dose delivered to the prescription 
point was 4 fractions of 1.8Gy each (a total of 7.2Gy) for all plans. This was 
because the dose read out for just a single fraction of 1.8Gy was felt to be too small 
to be recorded accurately by the TLD chips.  Therefore the estimated dose read out 
after one 1.8Gy fraction of radiotherapy was calculated by dividing the actual dose 
equivalent read out obtained following 4 fractions by 4.  It should be noted that 
these estimates are taken in regions for which no data are available from the 
treatment planning system since they are beyond the region that is scanned for 
planning purposes in individual patients. 
 
The mean of 2 TLD measurements at each site represented the outcomes variable 
at that point and the mean of all TLD chips placed at various positions was 
calculated to give the mean dose to areas outside the target volume.   
 
3.3.3 Statistical Analysis 
Data evaluation and statistical analysis was performed using PASW 18.0 statistical 
package.  Paired t-tests were used to test for statistical difference between pre and 
post-radiotherapy samples and repeated measures anova (Greenhouse-Geisser) 
was used to test for statistical difference between the samples taken at different 
weeks of treatment.  One-way anova and post hoc tests (Bonferonni) were used to 
test for statistical difference between the radiotherapy delivery techniques and 
univariate analysis of regression was used to assess for confounding factors, such 
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as planning target volume, monitor units and beam on time.  Statistical significance 
was set at 5%.  
 
Mean dispersion index (MDI) was used to determine whether the distribution of foci 
numbers per cell deviated from the Poisson distribution.  The MDI can quantify 
whether the observed occurrences are clustered or dispersed compared to a 
standard statistical model.  The MDI was used to measure deviation away from the 
expected Poisson distribution and, in particular, to determine whether different 
techniques would produce different effects on foci distribution within cell nuclei.  The 
MDI was calculated as the variance:mean ratio with MDI values above 1 implying 
overdispersion away from the Poisson distribution.   
 
 
3.4 Results 
 
3.4.1 Patient Characteristics  
25 patients were recruited in total, with the radiotherapy technique used based on 
clinical indication.  One patient, due to receive CRT, withdrew from the study after a 
baseline blood sample was taken, leaving 24 fully evaluable patients.  All 
radiotherapy was delivered using a linear accelerator, 6MV photons at a median 
dose of 50.4Gy in 28 fractions.  15 patients received SF-IMRT for meningiomas (14) 
and pituitary adenoma (1) (the details of which have been recorded in chapter 2).  5 
patients received RA for meningiomas (1), pituitary adenoma (1), 
craniopharyngiomas (2) or astrocytoma (1).  4 patients received CRT for pituitary 
adenomas (3) and meningioma (1).  Patient characteristics and beam parameters 
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are summarized in table 3.1.  The lower numbers of patients recruited to the RA and 
CRT groups were determined based on the variance in the initial data. 
 
3.4.2 Beam characteristics and quantification of γ-H2AX foci 
per cell during RapidArcTM (RA) 
Radiotherapy using RapidArcTM (RA) was delivered to a median planning target 
volume (PTV) of 94 cm3 (range 16.9 to 506.9 cm3).  A median of 1 arc (range 1 to 2 
arcs) was used with a median of 323 MU (range 284 to 470 MU) and at a dose rate 
of 600 MU/min.  The median ‘beam on time’ was 98 seconds (range 96 to 188 
seconds).  One patient with a target volume of 506.9 cm3, treated to a dose of 
54.9Gy in 1.8Gy per fraction for an astrocytoma, required 2 arcs for adequate dose 
conformality.  This necessitated 470 monitor units and a beam-on-time of 188 
seconds.  The patient with the smallest target volume (16.9 cm3), treated to a dose 
of 50.4Gy in 1.8Gy per fraction, needed 343 monitor units and a beam on time of 98 
seconds.  However, the patient with the shortest beam on time (96 seconds) and 
lowest number of monitor units (284 MU) had a target volume of 79 cm3.   
 
Baseline -H2AX foci levels in the RA cohort of patients were 0.166 ± 0.05.  An 
increase in radiation-induced -H2AX foci was clearly visualised in patient samples 
taken 30 minutes after each 1.8Gy fraction of RA (fig.3.1).  Similarly to SF-IMRT, 
there is a statistically significant increase in -H2AX foci levels following RA 
treatment and this was consistent between samples taken at the same time during 
each week of radiotherapy (fig. 3.1 and table 3.2). Throughout the entire course of 
radiotherapy, there is a statistically significant increase in -H2AX foci following RA 
compared to pre-treatment samples (fig. 3.3).  The mean -H2AX foci per nucleus 
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was 0.175 ± 0.067 pre-treatment and 0.360 ± 0.101 post RA, with a mean increase 
of 0.185 ± 0.081 (p<0.0001) over a 6 week course of RA radiation therapy.  
 
Furthermore, in a similar way to SF-IMRT, the post RA increase in mean -H2AX 
levels varied slightly from one week to another.  However, there was no statistically 
significant difference in the observed increase in -H2AX foci levels following RA 
between samples taken during different weeks of treatment (0.135 v 0.241 v 0.203 v 
0.201 v 0.173 v 0.156, p=0.333).  In addition, there was no statistically significant 
difference between baseline foci levels compared to foci levels taken at 2 weeks 
(0.166 v 0.197, p=0.585) and also at 6 weeks (0.166 v 0.198, p=0.706) post-
radiotherapy, indicating no long-term accumulation of damage after completion of 
treatment. 
 
3.4.3 Beam characteristics and quantification of γ-H2AX foci 
per cell during CRT 
CRT was delivered using 3 fields to treat a median planning target volume (PTV) of 
39 cm3 (range 29.5 to 160 cm3).  This was performed using a median of 256 MU 
(range 240 to 339 MU), at a dose rate of 600 MU/min and with a median ‘beam on 
time’ of 57.7 seconds (range 51.5 to 72 seconds).  The patient with the largest 
tumour volume (160 cm3) required 261 monitor units and a beam-on-time of 72 
seconds.  However, the largest monitor units (339 MU) were required for a target 
volume of 30.4 cm3 and radiation was delivered in 51.5 seconds.  The patient with 
the smallest tumour volume of 29.5 cm3 required 251 monitor units and a beam-on-
time of 58 seconds.   
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Baseline -H2AX foci levels in this cohort of patients were 0.108 ± 0.60.  An 
increase in radiation-induced -H2AX foci could be visualised in patient samples 
taken 30 minutes after each 1.8Gy fraction of CRT.  Similarly to the other radiation 
techniques, there is a statistically significant increase in -H2AX foci levels following 
CRT treatment and this was consistent between samples taken at the same time 
during each week of radiotherapy (fig. 3.4 and table 3.3).  Throughout the entire six 
week course of radiotherapy, there is a statistically significant increase in -H2AX 
foci following CRT compared to pre-treatment samples (fig. 3.5).  The mean -H2AX 
foci per nucleus over a whole course of CRT was 0.104 ± 0.090 pre-treatment and 
0.247 ± 0.125 post CRT, with a mean difference of 0.142 ± 0.041 (p<0.0001).  
 
In a similar way to SF-IMRT and RA, the post CRT increase in mean -H2AX levels 
varied slightly from one week to another (fig. 3.6).  However, there was no 
statistically significant difference in the observed increase in -H2AX foci levels 
following CRT between samples taken during different weeks of treatment (0.148 v 
0.140 v 0.121 v 0.148 v 0.161 v 0.137, p=0.817).  In addition, there was no 
statistically significant difference between baseline foci levels compared to foci 
levels taken at 2 weeks (0.108 v 0.053, p=0.271) and also at 6 weeks (0.108 v 
0.045, p=0.335) after completion of radiotherapy, indicating no long-term 
accumulation of damage after completion of treatment. 
 
3.4.4 Comparison of radiotherapy treatment groups 
3.4.4.1 -H2AX Measurements  
There is a reproducible increase in the number of -H2AX foci per nucleus following 
radiotherapy associated with all delivery techniques described (fig.3.7a-c).  
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However, the overall increase in mean -H2AX foci levels per nucleus following 
irradiation varies significantly between the techniques (SF-IMRT v RA v CRT: 0.322 
v 0.185 v 0.142, p=0.005), (table 3.4).  There is a statistically significant greater 
increase in mean -H2AX foci levels per nucleus over the whole course of treatment 
with SF-IMRT compared to both RA and CRT (SF-IMRT v RA: 0.322 v 0.185, 
p=0.044; SF-IMRT v CRT: 0.322 v 0.142, p=0.013) (fig. 3.8).  However, the small 
increase in mean -H2AX foci levels following radiotherapy seen with RA compared 
to CRT is not statistically significant (0.185 v 0.142, p=1.00).  
 
Any difference observed in the pre radiotherapy mean -H2AX foci values between 
the various treatment groups is not statistically significant (SF-IMRT v RA v CRT: 
0.170 v 0.175 v 0.104, p=0.378).  Likewise, the difference seen in baseline values is 
also not statistically significant; SF-IMRT v RA v CRT: 0.186 v 0.166 v 0.108, 
p=0.667. 
 
3.4.4.2 Planning target volume  
The univariate analysis for regression demonstrates that the planning target volume 
is not directly related to the differences seen in -H2AX foci numbers after 
radiotherapy, F(1,20)=0.851, p=0.367.  There continues to be a statistically 
significant effect of radiotherapy technique on change in foci numbers following 
irradiation after controlling for the effect of target volume, F(2,20)=6.991, p=0.005, 
suggesting that any difference in planning target volumes between the groups does 
not have an effect on the difference in foci numbers seen between the groups. 
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3.4.4.3 Beam Parameters  
The covariates, monitor units and beam on time, were also not directly related to the 
change in foci numbers after radiotherapy: F(1,20)=0.375, p=0.547, F(1,14)=0.008, 
p=0.928 respectively.  There continued to be an effect from radiation technique on 
change in foci numbers when controlling for the effect of ‘monitor units’ and ‘beam 
on time’, F(2:12)=7.814, p=0.007.   
 
3.4.4.4 TLD measurements      
Table 3.5 demonstrates the reference reading obtained from 4 TLD chips 
irradiated with 100 monitor units at 5cm depth in solid water, so that 1Gy is 
equivalent to 100 MU and therefore provided a TLD reading : Gy factor.  The 
mean of these reference readings provides a value of 1296.57 (with a standard 
deviation of 114.77 and coefficient of variation (standard deviation/mean) of 9%) 
read out equivalent for each Gy.  For the purposes of likely low doses to areas 
at some distance from the target volume, we used a conversion factor of 12.97 
per cGy. 
 
The TLD measurements from chips placed in regions outside the target area 
similarly suggest that there is a greater mean dose to all areas measured 
outside the primary target volume following SF-IMRT compared to both RA and 
CRT.  Table 3.6 details the TLD measurements and equivalent dose from each 
TLD chip placed at the right and left shoulders and the mid pelvis regions 
following four fractions of 1.8Gy per fraction (and also after one 1.8Gy fraction) 
using one radiotherapy plan from each of the three different radiation 
techniques.  As expected, the greatest dose is demonstrated in TLDs located 
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closest to the target volume (those placed at the level of the shoulders), with the 
lowest dose seen within TLDs placed furthest away from the target volume (mid 
pelvis).  Table 3.7 documents the mean and the standard deviation (SD) of 
scattered dose according to radiation technique. The mean dose to areas 
outside the target volume, taking into account all TLDs placed, is higher with SF-
IMRT (SF-IMRT v RA v CRT: 0.196cGy v 0.144cGy v 0.116cGy).  These 
measurements illustrate an increased dose to non-target areas with SF-IMRT by 
a factor of 1.4 and 1.7 in comparison to RA and CRT respectively. 
 
Assuming the same dose response as seen in our ex-vivo data from lymphocytes of 
healthy volunteers (from section 2.4.3), we can also estimate the whole body 
exposure per fraction associated with the different radiotherapy techniques using 
this data.  The ex-vivo data suggests 3.092 foci induced per Gy, above background 
levels of 0.47 foci. Therefore the 0.322 increase in mean -H2AX foci with SF-IMRT 
would suggest an estimated mean whole body exposure of 0.104Gy.  Similarly, the 
estimated mean whole body exposure with RA and CRT is 0.060Gy and 0.046Gy 
respectively (table 3.8).   
 
3.4.4.5 -H2AX Foci distribution 
Since we hypothesized that SF-IMRT may specifically increase low dose whole 
body exposure, foci distributions were also analysed in these samples to ascertain 
whether there was a greater change in cells with low foci numbers (fig. 3.10), 
suggesting exposure to low radiation doses. Following SF-IMRT, the percentage of 
cells without any foci was lower than after both RA and CRT (IMRT 11% reduction 
in cells with no foci post treatment, RA 6.6% reduction, CRT 5.9% reduction, 
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p<0.0001).  Conversely, there is a greater percentage increase in cells with 1-2 foci 
and 3-5 foci following SF-IMRT compared to RA and CRT (1-2 foci: SF-IMRT 7.1 %, 
RA 3.7%, CRT 4% more cells, p=0.002; 3-5 foci: SF-IMRT 2.8%, RA 1.7% and CRT 
1.6% more cells, p=0.002).  Interestingly there is a greater percentage increase in 
cells with 6-10 foci following SF-IMRT compared to CRT (SF-IMRT 1.5%, CRT 
0.2%, p=0.008), but no statistically significant difference between SF-IMRT and RA 
(1.5% and 1.1% respectively, p=0.857) (fig 3.10). There is no statistically significant 
difference in the percentage increase of cells with over 10 foci following the three 
radiotherapy techniques.   
 
We used the mean dispersion index (MDI) to measure deviation away from the 
expected Poisson distribution to further investigate whether different techniques 
produced different effects on foci distribution. MDI levels above 1 indicate 
overdispersion. There was evidence of some overdispersion in baseline samples 
associated with all radiotherapy techniques. Following irradiation there was a clear 
change, with evidence of more deviation away from Poisson distributions, 
associated with MDIs above 2.  However, the MDI with SF-IMRT was greater than 
with RA and CRT (4.11 v 3.13 v 2.60 respectively; an increase in MDI of 1.61, 1.10, 
and 0.81 from baseline respectively) (table 3.9).  This data demonstrates that the 
distribution of foci does not follow a simple Poisson distribution and may, in fact, 
represent a combination of cells that are directly irradiated as well as those cells 
that are indirectly irradiated.   
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3.5 Discussion 
 
The results from this comparative study have attempted to quantify the DNA 
damage produced following different radiation techniques.  Similarly to SF-IMRT, 
there is a statistically significant increase in -H2AX foci per nucleus in post-
radiotherapy samples compared to pre-treatment samples for both the RA and CRT 
groups (0.174 pre and 0.360 post RA, p ≤0.0001 and 0.104 pre and 0.247 post 
CRT, p<0.0001).  In addition, any difference documented between the samples 
taken during the different weeks of treatment for each technique is not statistically 
significant (p=0.333 and p=0.817 respectively). 
 
There was some variation in baseline foci numbers between patients and it is 
noteworthy that baseline levels in the group of patients treated with CRT tended to 
be lower than in the IMRT groups, although they are still generally similar to 
baseline foci levels in unirradiated cells reported in the literature 
[311,325,327,338,340,345,349,356].  Since these samples were collected and 
analysed in separate batches, this variation in baseline levels may reflect subtle 
changes in staining quality between experiments, but will not affect the main 
comparison in which foci change from baseline levels was analysed. 
 
To date, there are very few published data investigating the use of this assay in 
prospective studies to compare treatment techniques.  This study has confirmed 
that the -H2AX assay is sensitive enough to assess and quantify DNA-damage in 
patients receiving different radiotherapy delivery techniques.   
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There are a greater number of foci produced following irradiation with SF-IMRT 
compared to both RA and CRT.  Reproducible but smaller increases in -H2AX foci 
can be seen following RA and CRT (SF-IMRT 0.322 v RA 0.185 v CRT 0.142 foci 
per cell, p=0.005).  Extrapolating from the ex-vivo data from chapter 2, there is an 
increase in whole body exposure with SF-IMRT compared to both RA and CRT of 
1.7 and 2.3 fold respectively, which is broadly in line with changes in TLD 
measurements taken from regions some distance away from the tumour target 
volume. 
 
There are also differences observed in foci distributions following radiation using 
different treatment techniques, with a greater proportion of cells displaying lower foci 
numbers (between 1 to 5 foci per nucleus) compared to cells with greater foci 
numbers per cell.  This was associated with a greater change in the mean 
dispersion index following SF-IMRT compared to both RA and CRT; similar to 
results from ex vivo irradiation experiments to reflect the effect of partial body 
irradiation [325], but may also mirror the effects of DNA damage as a result of low 
dose radiation.  These findings are analogous to those of Zwicker et al. who, despite 
not managing to identify a statistically significant difference in -H2AX foci numbers 
between techniques, did demonstrate more delivery of doses below 20% of the total 
dose and less doses of between 30-90% with IMRT compared to conventional 3D 
conformal treatments in patients with prostate cancer [356].   
 
Given these findings, it is feasible that this difference results from the increased low 
dose radiation to non-target regions delivered by SF-IMRT.  This extra low-dose 
exposure is produced through various treatment delivery factors, including 
increased monitor units and ‘beam on time’, which are functions of the complexity of 
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static-field intensity-modulation, its delivery technique and collimator design [236].  
Scattered radiation can originate from internal scatter within the patient and is 
dependent on the dose delivered.  Importantly, the extra low dose is also a 
consequence of scatter from the linac head, multi-leaf collimators, and is generally 
dependent on the number of monitor units.  It has been shown previously that the 
number of radiotherapy fields has a direct effect on the amount of radiation 
delivered to distant sites, thereby increasing the scattered dose [255].  Beam 
modifiers can dramatically increase the amount of scattered radiation within the 
body and dynamic multileaf collimation fields require 2 to 14 times the number of 
monitor units than an open static field [252].  In vitro studies have demonstrated, 
using the -H2AX assay in human fibroblasts, a relative increase in linear energy 
transfer (LET) and DNA-DSB per unit dose in blocked beam configurations and in 
the penumbra of a 6MV photon beam [375] compared to levels seen with an open 
beam.  As a consequence, techniques, such as SF-IMRT, require a significant 
increase in monitor units and beam on time compared to conventional techniques 
[236,239].  This suggests that the high dose gradients produced by techniques, 
such as SF-IMRT, result in non-negligible extra dose to the surrounding normal 
tissues.  Early work has documented that an increase in the number of monitor units 
required for techniques, such as tomotherapy, in comparison to conventional 
techniques, results in a much higher whole body dose [236,241,244,246] and some 
have even suggested that dynamic leaf MLC IMRT is associated with higher monitor 
unit requirements compared to step and shoot IMRT [250-252].   
 
Conversely, as can be seen with data from this chapter, both RA and CRT require 
fewer monitor units and beam on time, although in terms of treatment planning and 
target definition, CRT often provides inferior target dose conformality than both SF-
IMRT and RA.  In fact, there have been various studies documenting the reduction 
 
 
136 
 
in beam on times and monitor units with RA in comparison to SF-IMRT [25,59-
61,63], with a reduction in monitor units in the range of 37-66% [60,61,376] and a 
similar reduction in treatment times [25], which is comparable to the findings in the 
work presented here.  This may in turn have benefits of a reduction in leakage 
radiation and therefore a reduction of integral radiation dose to the rest of the body 
[58,65,66]. 
 
Although it has been postulated that increased beam on time and monitor units 
(and also target volume) have an effect on the increased foci numbers and 
therefore whole body dose, the data from this study (and others [376]) has not 
been able to confirm that these confounding factors are directly implicated in the 
increased -H2AX foci levels.  This may, of course be limited by the small 
sample size within this patient cohort and further studies may be able to 
determine the true role of these factors.    
 
Nevertheless, this is the first study to demonstrate a significant difference in the 
level of DNA-damage in patient blood lymphocytes in a comparison between 
SF-IMRT and arc-based IMRT techniques.  One would predict a lower level of 
low-dose irradiation-induced DNA damage with CRT compared to both SF-IMRT 
and RA and these data demonstrate that the γ-H2AX assay was sensitive 
enough to detect differences in whole body exposure between SF-IMRT and 
CRT, which previous studies have not achieved [356].  No statistically significant 
difference was observed between foci numbers in patients treated with CRT and 
RA, although RA tended to produce slightly higher levels than CRT, as would be 
predicted.  Larger patient numbers would be necessary to estimate the size of 
this difference accurately.  
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Dose measurements using TLD and similar devices can give estimates of non-
target dose and the values presented here are in line with literature reports of 
peripheral, whole body dose assessments, which may suggest that this dose is 
as a result of scatter with doses of approximately 1% or less of the total dose 
recorded at distances approximately 20cm or more from the target edge 
[249,376,377].  From this, estimated scattered dose and organ equivalent doses 
appear to reduce as the distance from the target edge increases and some have 
compared these measurements between techniques as a rudimentary measure 
of scatter dose [376,377]. 
 
-H2AX within lymphocytes (which may reflect a combination of background 
irradiation, direct radiation as well as scattered irradiation) is useful to estimate dose 
delivered to the whole body, even in the presence of partial body irradiation due to 
lymphocyte redistribution [340,355].  However, it should be pointed out that 
modelling the dose delivered from external beam radiotherapy to a circulating 
population of lymphocytes is not straightforward for a number of reasons.  Irradiated 
lymphocytes may be mixed with those that are unirradiated and there is a 
continuous exchange of lymphocytes between blood and tissues as well as lethal 
damage to some lymphocytes, all of which need to be taken into consideration.  A 
recent publication has proposed a dynamic model, which predicts a significant dose 
to blood during transit through target volumes in brain (which others have also 
highlighted [340,347]), but does not include an estimate of the effect of scattered 
dose to the whole blood volume beyond the brain and does not account for repair or 
loss of damaged cells between doses, as the results from this data imply [378].  It is 
clear that, due to their circulation through the high and low-dose volumes, the dose 
received by any one peripheral lymphocyte may not bear a linear relationship to 
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delivered dose at the target or at any specific point as measured by TLD within a 
Rando-phantom.   
 
Nevertheless, this comparison with TLD measurements shows that the trend 
towards higher integral dose, estimated from foci counts, parallels an increase in 
measured peripheral doses, which would be expected.  Since the majority of 
lymphocytes at any one time will be outside the high-dose target volume, the 
majority of the foci may result from low-dose exposure. This could explain why this 
assay appears to be sensitive enough to pick up differences between treatment 
techniques. 
 
The effects of low-dose radiation on second malignancy risks have been widely 
discussed and estimated in the past.  There is evidence that the incidence of cancer 
increases steeply as a function of low radiation doses, then plateaus, but does not 
fall rapidly at high doses because of cell kill [266].  The exact dose plateau is difficult 
to determine, with varying reports in the literature.  Some have suggested a dose of 
10Gy, beyond which the risk of carcinogenesis exponentially declines [379].  
However, the accumulation of incomplete repair of sublethal damage, as suggested 
by some groups with IMRT [366], is a potential source of increased radiation 
exposure and, therefore, may be associated with an increased risk in secondary 
malignancies.  Attempts have been made to estimate the risk of radiation-induced 
malignancies following various modalities of treatment, with results pointing to as 
much as a doubling of the relative incidence rate after IMRT compared to 
conventional techniques [147,148], although some have estimated much lower 
levels when using lower energies [380].  The findings in the study presented in this 
chapter suggest that the level of low-dose DNA-damage experienced by circulating 
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lymphocytes was indeed significantly higher with SF-IMRT than CRT and RA, but 
that RA produced levels similar to those seen with CRT.  A linear no-threshold dose 
model predicts that even small increases in whole-body exposure, as described 
here would be associated with increased risk.  Modelling studies have proposed a 
non-linear response to dose, with tissues exposed to low dose irradiation at 
increased risk of second cancers [267-269].  In fact, recent large scale 
epidemiological studies examining the relationship between low radiation doses and 
risk of childhood malignancy [381,382] are consistent with this linear no threshold 
cancer risk model. 
 
As oncological treatments become more effective, there are a growing number of 
patients alive many years after treatment.  Therefore, damage to normal tissues that 
manifests itself over the longer term becomes an important consideration in the 
choice of treatment plans and modalities.  Dose-response relationships for tumours 
and therefore dosimetry for treatments has been fairly well documented.  However, 
dosimetry for late effects is performed on a relatively ad hoc manner.  Through our 
direct measurements of DNA damage, these results point to increased low dose 
irradiation-induced damage from SF-IMRT compared to RA and CRT for brain 
tumours, which may have implications in the choice of radiotherapy delivery 
techniques, especially in children and young adults with good prognosis disease.  
The results demonstrated here are generated on a small cohort of patients and, 
therefore, experiments with a larger group of participants may demonstrate further 
conclusive evidence of the increased DNA damage from SF-IMRT in comparison to 
other techniques and may also demonstrated a statistical difference between RA 
and 3D- CRT.  Further mathematical modelling of the data may allow a more 
accurate assessment and correlation of the DNA damage and scatter dose. 
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As developments in radiotherapy techniques move forward, it is important to be 
wary of the potential effects not just to the tumour, but also to normal tissue and the 
resulting long term consequences.  Techniques, such as proton therapy are now 
coming to the fore and one would expect a lower whole body dose, as many groups 
are beginning to investigate [383-388], although it is associated with secondary 
neutrons and therefore warrants further investigation.   
 
 
3.6 Conclusion 
 
The data presented in this chapter has demonstrated that, using the sensitive -
H2AX assay as a marker of double stranded DNA damage, a difference can be 
observed following irradiation using different radiotherapy delivery techniques, with 
a statistically significant difference between SF-IMRT and RA or CRT.  However, no 
statistically significant difference was seen between RA and CRT and further 
studies with larger sample sizes may be required to demonstrate this clearly.  There 
are greater numbers of lymphocytes observed with low foci numbers following SF-
IMRT compared to other techniques, which may reflect a greater low dose radiation 
to areas outside the target volume.  This low dose may, in turn, have an effect on 
the long term carcinogenic risks associated with various radiation techniques and 
may ultimately influence choice of technique in certain patient populations. 
 
There has been growing interest in the use of proton therapy; harnessing its distinct 
‘Bragg-peak’ properties to allow dose escalation, whilst further minimizing dose to 
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normal structures.  Extending this -H2AX comparison to proton therapy would be 
valuable to allow quantification of DNA damage (and whole body dose) to areas 
outside the target volume and provide assessment of the potential long term 
complications of this delivery technique. 
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Table 3.1: Patient characteristics and beam parameters for all treatment 
groups. 
Abbreviation: SF-IMRT=Static-field IMRT; RA=RapidArcTM; CRT=3D-conformal 
radiotherapy; PTV = planning target volume 
  
Parameter SF-IMRT RA CRT 
 Median Range Median Range Median Range 
Number of patients 15  5  4  
Age 52.5 38-65 54 40-68 60 29-68 
Dose (Gy) 
50.4  50.4 50.4-
54.9 
50.4  
Dose/# (Gy) 1.8  1.8 1.8-1.85 1.8  
       
Monitor Units (MU) 518 393-1014 323 284-470 256 240-339 
Dose rate (MU/min) 400  600  600  
Beam on time 
(seconds) 
124 98-254 98 96-188 57.75 51.5-72 
Number of fields or 
arcs 
5 4-7 1 1-2 3  
PTV (cm3) 
88 23.1-288 94 16.9-
506.9 
39 29.5-160 
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Fig. 3.1: Mean -H2AX foci per nucleus measurements at weekly time points 
during and after a six week course of RA. 
 
Error bars represent standard deviation; *=p<0.05. 
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 Mean -H2AX foci per nucleus (SD) 
Week during 
treatment 
Cumulative dose 
at point of 
sampling 
1 
1.8Gy 
2 
10.8Gy 
3 
19.8Gy 
4 
28.8Gy 
5 
37.8Gy 
6 
46.8Gy 
Pre RA (SD)  
0.202 
(0.058) 
0.140 
(0.027) 
0.220 
(0.085) 
0.155 
(0.074) 
0.169 
(0.076) 
0.165 
(0.063) 
Post RA (SD) 
0.337 
(0.087) 
0.381 
(0.092) 
0.423 
(0.168) 
0.356 
(0.060) 
0.343 
(0.101) 
0.321 
(0.088) 
Difference (SD) 
0.135 
(0.051) 
0.241 
(0.102) 
0.203 
(0.128) 
0.201 
(0.075) 
0.173 
(0.036) 
0.156 
(0.052) 
P values 0.004 0.006 0.024 0.004 <0.0001 <0.003 
 
Table 3.2: Mean -H2AX foci per nucleus levels pre and post RA for each week 
during treatment.   
Abbreviations: SD=standard deviation 
 
There is a statistically significant difference in foci numbers in samples taken weekly 
pre and post-treatment and calculated at the same time during each week of 
treatment.  The difference observed is independent of treatment week. 
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 Mean -H2AX foci per nucleus (SD) 
Week during 
treatment 
Cumulative dose at 
point of sampling 
1 
 
1.8Gy 
2 
 
10.8Gy 
3 
 
19.8Gy 
4 
 
28.8Gy 
5 
 
37.8Gy 
6 
 
46.8Gy 
Difference (SD) 
0.135 
(0.051) 
0.241 
(0.102) 
0.203 
(0.128) 
0.201 
(0.075) 
0.173 
(0.036) 
0.156 
(0.052) 
 
Fig.3.2:  Observed difference in pre and post RA mean -H2AX levels taken 
weekly during treatment. 
 
There is no statistically significant difference in the change in mean -H2AX levels 
from one week to another during a course of RA. 
Error bars represent standard deviation. 
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Fig. 3.3: Mean -H2AX foci per nucleus measurements pre and post irradiation 
over a six week course of RA. 
 
There is an increase of 0.185 ± 0.081 (p<0.0001) mean -H2AX foci seen within 
lymphocyte nuclei following RA over a whole 6 week course of treatment. 
Error bars represent standard deviation   
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Fig. 3.4:  Mean -H2AX foci per nucleus measurements at weekly time points 
during and after a six week course of CRT. 
 
Error bars represent standard deviation; *=p<0.05 
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 Mean -H2AX foci per nucleus (SD) 
Week during 
treatment 
Cumulative dose 
at point of 
sampling 
1 
1.8Gy 
2 
10.8Gy 
3 
19.8Gy 
4 
28.8Gy 
5 
37.8Gy 
6 
46.8Gy 
Pre CRT (SD)  
0.074 
(0.015) 
0.056 
(0.011) 
0.092 
(0.081) 
0.112 
(0.099) 
0.185 
(0.167) 
0.108 
(0.069) 
Post CRT (SD) 
0.222 
(0.105) 
0.196 
(0.053) 
0.214 
(0.100) 
0.260 
(0.199) 
0.347 
(0.169) 
0.246 
(0.095) 
Difference (SD) 
0.148 
(0.098) 
0.140 
(0.045) 
0.121 
(0.037) 
0.148 
(0.104) 
0.161 
(0.059) 
0.137 
(0.041) 
P values 0.057 0.009 0.008 0.006 0.012 0.007 
 
Table 3.3: Mean -H2AX foci per nucleus levels pre and post CRT for each 
week during treatment.   
Abbreviations: CRT=3D conformal radiotherapy; SD=standard deviation 
 
There is a statistically significant difference in foci numbers in samples taken weekly 
pre and post-treatment and calculated at the same time during each week of 
treatment.  The difference observed is independent of treatment week. 
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Fig.3.5: Mean -H2AX foci per nucleus measurements pre and post irradiation 
over a six week course of CRT. 
 
There is an increase of 0.142 ± 0.041 (p<0.0001) mean -H2AX foci seen within 
lymphocyte nuclei following CRT over a whole 6 week course of treatment. 
0.104 ± 0.090 mean -H2AX foci pre-treatment and 0.247 ± 0.125 post CRT with a 
mean difference of 0.142 ± 0.041 (p<0.0001).  
Error bars represent standard deviation.  
0
0.1
0.2
0.3
0.4
0.5
0.6
Pre Post
M
e
an
 f
o
ci
 n
u
m
b
e
r 
p
e
r 
n
u
cl
e
u
s 
 
 
150 
 
 
 Mean -H2AX foci per nucleus (SD) 
Week during 
treatment 
Cumulative dose at 
point of sampling 
1 
1.8Gy 
2 
10.8Gy 
3 
19.8Gy 
4 
28.8Gy 
5 
37.8Gy 
6 
46.8Gy 
Difference (SD) 
0.148 
(0.098) 
0.140 
(0.045) 
0.121 
(0.037) 
0.148 
(0.104) 
0.161 
(0.059) 
0.137 
(0.041) 
 
Fig.3.6: Observed difference in pre and post CRT mean -H2AX levels taken 
weekly during treatment. 
 
There is no statistically significant difference in the change in mean -H2AX levels 
from one week to another during a course of CRT. 
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Fig.3.7:  Mean -H2AX foci per nucleus measurements at weekly time points 
during and after a six week course of SF-IMRT, RA and 3D CRT respectively.    
 
Images demonstrate typical PTV volumes and isodose colour wash levels for each 
radiotherapy technique.  
Error bars represent standard deviation; *=p<0.05. 
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Table 3.4: Overall mean -H2AX foci per nucleus measurements before and 
after irradiation with mean change in -H2AX foci levels seen with different 
radiotherapy technique.    
 
 
  
Radiotherapy 
technique 
Mean -H2AX foci per nucleus (SD) 
Pre RT Post RT Difference 
SF-IMRT 
 
0.170 0.493 0.322 
RA 
 
0.175 0.360 0.185 
CRT 0.104 0.247 0.142 
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Fig. 3.8a:  Pre and post radiotherapy -H2AX foci values for all three radiation 
techniques 
Error bars represent standard deviation. 
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Fig. 3.8b: Overall change in mean -H2AX foci per nucleus following treatment 
with all radiotherapy techniques, calculated as the difference between pre and 
post-treatment samples over a course of radiotherapy.   
 
There is a greater increased change in mean -H2AX foci levels with SF-IMRT 
compared to RA and CRT (p=0.044 and p=0.013 respectively).  
Error bars represent standard deviation; *=p<0.05. 
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Fig. 3.9:  A Rando-phantom used to demonstrate dose to areas outside target 
volume with typical SF-IMRT, RA and CRT plans.   
 
TLD-100H (LiF) chips (Bicon-Harshow) were placed at a depth of 10cm from 
phantom surface and in specific areas: right and left shoulders (25 cm from the axis 
of the beam, 10 cm lateral to the centre), mid pelvis region (at midline and 60cm 
from the central axis of the beam).  Radiation was delivered to the Rando-phantom 
using a typical plan for each of the study techniques and dose recorded from the 
TLDs.  
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Table 3.5:  TLD readout values 
 
Four TLD chips were irradiated with 100MU at 5cm deep in solid water to provide a 
TLD reading to Gy factor (conversion factor) of 12.97 TLD reading per Gy. 
 
TLD= thermoluminescent dosimeter; SD=standard deviation; COV=coefficient of 
variation 
 
TLD number 
Reference 
reading 
1 1216.122 
2 1313.973 
3 1204.079 
4 1452.088 
Mean 1296.566 
SD (COV) 114.768 (9%) 
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Table 3.6:  TLD readings taken at different positions in a Rando phantom following irradiation after 4 fractions of 1.8Gy per fraction 
using one typical radiotherapy plan from each radiation technique.  
Abbreviation: SF-IMRT=Static-field IMRT; RA=RapidArcTM; CRT=3Dconformal radiotherapy; TLD=thermoluminescent dosimeter. 
Dose was calculated after the 4 fractions of radiotherapy using the TLD conversion factor.  Dose was then calculated for each fraction of 
radiotherapy, providing a mean dose per fraction. 
  SF-IMRT RA CRT 
TLD 
Position 
TLD 
Number 
TLD 
reading 
after 4 
fractions 
Dose 
after 4 
fractions 
(cGy) 
Dose 
after 1 
fraction 
(cGy) 
Mean 
dose 
(cGy) 
TLD 
Reading 
after 4 
fractions 
Dose 
after 4 
fractions 
(cGy) 
Dose 
after 1 
fraction 
(cGy) 
Mean 
dose 
(cGy) 
TLD 
reading 
after 4 
fractions 
Dose 
after 4 
fractions 
(cGy) 
Dose 
after 1 
fraction 
(cGy) 
Mean 
dose 
(cGy) 
Left 
Shoulder 
1 15.309 1.181 0.295 
0.280 
8.978 0.692 0.173 
0.172 
7.115 0.549 0.137 
0.139 
2 13.699 1.057 0.264 8.838 0.682 0.170 7.258 0.560 0.140 
Right 
Shoulder 
1 12.769 0.985 0.246 
0.257 
11.302 0.872 0.218 
0.221 
8.586 0.662 0.166 
0.154 
2 13.895 1.072 0.268 11.632 0.897 0.224 7.352 0.567 0.142 
Mid 
pelvis 
1 2.737 0.211 0.053 
0.051 
2.035 0.157 0.039 
0.039 
1.806 0.139 0.035 
0.056 
2 2.513 0.194 0.048 2.023 0.156 0.039 3.983 0.307 0.077 
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Table 3.7: Comparison of dose in Rando-phantom with different radiotherapy 
techniques as measured with TLDs at non-target sites.   
Abbreviation: SF-IMRT=Static-field IMRT; RA=RapidArcTM; CRT=3Dconformal 
radiotherapy; SD=standard deviation 
 
Dose delivered to the Rando-phantom was the equivalent of one individual fraction 
(1.8Gy). 
 
 
 
 
 
 
  
 Mean Dose in cGy (SD) 
 SF-IMRT RA CRT 
Left Shoulder 0.280 (0.022) 0.172 (0.002) 0.139 (0.002) 
Right Shoulder 0.257 (0.015) 0.221 (0.004) 0.154 (0.017) 
Mid Pelvis 0.051 (0.003) 0.039 (0.0001) 0.056 (0.030) 
Mean dose to 
area outside 
target volume 
0.196 (0.126) 0.144 (0.094) 0.116 (0.053) 
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Table 3.8: Mean increase in -H2AX foci numbers, TLD measurements at non-
target sites and estimated whole body exposure following three radiotherapy 
techniques. 
 
 
  
Radiotherapy 
Technique 
Mean increase in -
H2AX foci number 
per nucleus 
 
Mean TLD 
measurements 
(cGy) 
Estimated whole 
body exposure 
(Gy) 
SF-IMRT 0.322 0.196 0.104 
RA       0.185 0.144 0.060 
CRT 0.142 0.116 0.046 
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Fig. 3.10: Comparison of mean percentage increase in cells with specified 
numbers of -H2AX foci following a course of radiotherapy with SF-IMRT, RA 
and CRT. 
There is a greater increase in the number of cells with 1-2 and 3-5 foci following SF-
IMRT compared with RA and CRT and fewer cells with no foci.   
Error bars represent standard deviation; *=p<0.001.  
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Number of foci 
SF-IMRT
RA
CRT* 
* 
* 
* 
* 
* 
* 
Foci 
groups 
% increase in cells with foci 
groupings 
P value for comparison 
 SF-IMRT RA CRT 
SF-IMRT v 
RA 
SF-IMRT v 
CRT 
RA v CRT 
0 -11.76 -6.65 -5.96 0.001 0.001 1.000 
1-2 7.19 3.73 4.07 0.005 0.019 1.000 
3-5 2.85 1.75 1.61 0.015 0.011 1.000 
6-10 1.51 1.15 0.28 0.857 0.008 0.153 
11-15 0.16 0.008 0 0.339 0.373 1.000 
16-20 0.03 0 0 0.629 0.741 1.000 
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Table 3.9: Pre, post and change in mean dispersion indices (MDI) for all 
techniques. 
 
There is a greater change in MDI with SF-IMRT compared to RA and CRT. 
  
Radiotherapy 
Technique 
Mean Dispersion Index 
Pre RT Post RT Difference 
(Post-Pre) 
 
 
 
SF-IMRT 2.50 4.11 1.61 
RA       2.04 3.13 1.10 
CRT 1.79 2.60 0.81 
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Chapter 4 
 
IMRT for Meningioma 
Preliminary results from a phase I/II study of intensity 
modulated radiotherapy in the treatment of 
meningioma 
 
 
4.1 Aims 
 
 To prospectively assess the feasibility and efficacy of delivering intensity 
modulated radiotherapy (IMRT) to patients for the treatment of meningioma.  
 To evaluate the potential of IMRT to reduce dose to the neurological dose 
limiting structures. 
 To prospectively assess and document toxicity and outcome data. 
 To assess progression free survival and the incidence of repeat intervention. 
 To measure quality of life as measured by the EORTC QLQ-C30 and QLQ-
BN20 questionnaire. 
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4.2 Introduction 
 
Intensity modulated radiotherapy (IMRT) offers a significant benefit for the treatment 
of brain tumours, in particular meningioma.  It provides excellent dose conformality 
to irregularly shaped tumour volumes, and with steep dose gradients, has the ability 
to spare critical structures; an essential factor when treating patients with good 
prognosis tumours, such as meningioma, where long term survival is expected.  
Retrospective series suggest a role for radiotherapy in the treatment of 
meningiomas, [174,178,179,184,185,188,211], although 3D conformal radiotherapy 
techniques were found to be limited in areas close to critical structures [210].  
 
For this reason, IMRT has been found to be valuable for tumours of the skull base, 
although studies examining this have been largely retrospective 
[201,213,215,220,226].  Few groups have demonstrated outcomes in a prospective 
manner [217], where valuable information can be gained regarding long term toxicity 
and tolerability of treatment.   
 
A prospective phase I/II study was designed by Professor Short and Dr Guerrero 
Urbano to examine the use and feasibility of IMRT in biopsy proven meningioma 
and to assess the long term toxicity, quality of life and outcomes of patients over a 
period of prolonged follow-up. 
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4.3 Methods and Materials 
 
4.3.1 Patient Selection 
Patients at University College London Hospital (UCLH) with histologically confirmed 
meningioma deemed to require fractionated radiotherapy were recruited 
prospectively and treated with static field IMRT using a dose of 50.4Gy in 28 daily 
fractions.    
 
All enrolled patients were recruited as part of the study entitled “A phase I/II study of 
intensity modulated radiotherapy in meningiomas”.  Inclusion criteria encompassed 
all patients with histologically confirmed meningioma.  These could comprise 
atypical or malignant histology (WHO grades II or III), completely or partially 
resected as assessed on an MRI scan 3-4 months after surgery; benign 
meningioma (grade I) partially resected as assessed on MRI 3-4 months after 
surgery and considered to require post-operative radiotherapy, those with evidence 
of brain and/or bone/dural invasion.  All included patients were over 18 years of age, 
with a performance status of 0-2 and included those patients who were suitable to 
attend regular follow up and undergo visual assessment if appropriate.  Exclusion 
criteria comprised patients who had received previous radiotherapy to the meninges 
or brain interfering with the protocol treatment plan, previous malignancy except 
non-melanoma skin cancer, those with a previous or concurrent illness which was 
felt to interfere with either completion of treatment or follow-up.  The study protocol 
(designed and set up by Professor Short and Dr Gurerro Urbano) was approved by 
the local ethics committee (ref: 06/Q051/97).  I was involved in the study from the 
time of patient recruitment. Written informed consent was obtained from all patients.  
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All patients were treated with radiotherapy according to the indications set out by 
the treating clinician.  Patients were given encouragement to adhere to the protocol 
treatment and follow-up, although they had the right to withdraw consent for 
participation in any aspect of the study.  Reasons for patient withdrawal were 
classified as: 
a) Patient withdraws consent from protocol treatment and/or follow up 
b) Intercurrent illness preventing further treatment 
c) Any change in patient’s condition which justified withdrawal from study or 
discontinuation from treatment in the opinion of the treating clinician. 
 
4.3.2 Trial Interventions 
4.3.2.1 General 
All patients were required to undergo at least a biopsy to confirm the histological 
diagnosis.  Surgical resection before irradiation (if appropriate) was performed 
following local guidelines and was as radical as was safe and at the discretion of the 
operating surgeon.  Indications for radiotherapy were established in a consultant-led 
multidisciplinary meeting (MDT) and were in line with the inclusion criteria as above. 
 
4.3.2.2 IMRT procedure 
4.3.2.2.1 Planning and immobilisation  
All patients were immobilised in a custom made thermoplastic shell.  A planning CT 
scan was carried out in the treatment position (supine) and with the immobilisation 
shell in place.  Scans were acquired at 2.5mm intervals through the whole brain, 
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from vertex to the bottom of the C2 vertebrae and transferred to a contouring 
workstation for tumour and normal structure delineation. 
 
4.3.2.2.2 Target volume definition 
Image fusion of the planning CT scan with diagnostic and/or post-operative MRI 
scans was performed to aid volume definition.  Target volume definition was 
performed according to ICRU 50and 62 guidelines [106,107].  GTV was defined as 
the gross visible residual tumour, seen as the region of enhancement on the post-
operative MRI, areas of thickened dura and involved bone and/or brain on both the 
MRI and planning CT scan.  The GTV was delineated taking into consideration the 
maximum information available from both CT and MRI.  If no residual tumour was 
seen on the post-operative MRI or planning CT scan, then a ‘GTV equivalent’ was 
created using the pre-operative MRI to define the extent of tumour (respecting 
anatomical boundaries so that this did not result in a larger GTV than if the tumour 
was not resected) and any associated dural or bone thickening.   
 
A 1cm margin was added to the GTV or GTV equivalent in the plane of the dura to 
create the CTV (clinical target volume), accounting for subclinical spread of disease.  
This was not routinely extended into the normal brain or bony structures, unless 
there was evidence of brain involvement or abnormal /hyperostotic bone.  A margin 
of 3mm was added to the CTV symmetrically to create the PTV (planning target 
volume), reflecting the geometric accuracy of the immobilisation system. 
 
Organs at risk, such as optic chiasm, right and left optic nerves, right and left ocular 
globes, right and left lenses, right and left lacrimal glands, pituitary gland, right and 
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left inner ear, whole brain, right and left temporal lobes, right and left hippocampus, 
hypothalamic region, brain stem and spinal cord were delineated in all patients.  The 
exact anatomical locations of these organs were drawn in accordance with radiation 
anatomy available and with the assistance of a neuroradiologist (in particular for the 
location of the hippocampi).  A 3mm margin was added to the OARs to produce a 
planning organ at risk volume (PRV). 
 
4.3.2.2.3 IMRT planning 
A 5 - 9 field technique was used to create an IMRT plan using EclipseTM treatment 
planning system (TPS), with optimisations to allow adequate dose coverage of the 
PTV, whilst respecting dose objectives and constraints of organs at risk.  Details of 
dose objectives for the PTV and organs at risk can be found in tables 4.1a and 4.1b.  
Radiotherapy planning was undertaken by me in conjunction with dosimetrists and 
physicists in UCLH radiotherapy physics department, allowing me to gain valuable 
experience of the IMRT planning process.   
 
A total dose of 50.4.Gy in 28 daily fractions over 5.5 weeks using MV photons was 
prescribed to the mean target dose (the mean dose point on the dose volume 
histogram, such that the prescription dose is received by 50% of the PTV).  Dose 
distributions were corrected for bone and soft tissue inhomogeneities and 
normalised to the mean target dose.  The minimum and maximum doses to the PTV 
were kept within 90-107% of the prescription dose, such that the D98% received no 
less than 90% of the dose, D95% no less than 95%, D50% no less than 50%, D5% no 
more than 105% and the D2% no more than 107% of the prescribed dose as 
specified by ICRU 83 [110]. 
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Dose objectives for radiosensitive structures and organs at risk were set according 
to reports on normal tissue complication probability models [124,125] and assessed 
from dose volume histograms created by the TPS.  Some organs at risk were set as 
dose constraints and prioritised accordingly against coverage of the PTV (usually 
optic chiasm, brain stem, optic nerves and globes).  However for other organs at 
risk, a lower priority was given, and for others, such as hippocampi, whole brain, 
temporal lobes, hypothalamus, inner ear, dose was recorded without setting a 
specific dose constraint.  Table 4.1b gives the details of organs at risk and dose 
objectives set.   
 
4.3.3 Treatment planning assessment and delivery 
Assessment of treatment planning was undertaken as per ICRU 83 [110], with the 
following parameters derived and recorded: D2%, D50%, D98%, volume of 95% 
isodose, volume of PTV and standard deviation (SD) of mean dose to PTV.   
 
Homogeneity index (HI) was derived using the formula: 𝐻𝐼 =
(𝐷2%−𝐷98%)
𝐷50%
.  Conformity 
index (CI) was derived using 𝐶𝐼 = (
𝑇𝑉 𝑃𝐼2
𝑇𝑉 𝑥 𝑃𝐼𝑉
)  𝑥 100% [126], where TVPI = volume of 
target covered by the prescription isodose and PIV=volume of prescription isodose.  
However, CI using guidance from ICRU 62, calculated as  𝐶𝐼 =
𝑇𝑉95%
𝑃𝑇𝑉
  [107]  (where 
TV95% = Treated volume covered by 95% isodose) was also used as a comparison.   
 
Patients were treated daily (Monday to Friday) for 28 fractions.  Imaging for patient 
set up purposes was performed using daily kV imaging for the first 3 fractions of 
treatment and weekly thereafter.  Cone beam CT imaging was performed weekly 
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during treatment to ensure accuracy of set up and dose coverage of PTV and 
critical structures.  Patients were moved on set to correct for any systematic shifts in 
accordance with the treatment imaging. 
 
4.3.4 Clinical evaluation and follow up 
Patients were assessed at set time points with a relevant clinical history, full 
examination, CTCAE version 3.0 toxicity scores [389], mini mental test 
examinations, pituitary function tests, visual assessments, and self-completed 
quality of life questionnaires (EORTC QLQ-C30 and QLQ-BN20) [390] (see 
appendix B and C).  Assessments were carried out at baseline and at 3 months, 6 
months and yearly following IMRT, with the aim of collecting data for the life span of 
each patient and for a minimum of a 10 year period following IMRT.  Acute toxicities 
were assessed and recorded during IMRT: at weeks 1-2, weeks 3-4, weeks 5-6 and 
also soon after completing IMRT during weeks 9-10.  MRI scans were performed 
(with added diffusion and perfusion weighted sequences) at 3 months, 1 year and 
yearly intervals thereafter following IMRT.  Recurrence was defined as in-field, 
marginal or out of field.   Definitions of recurrence vary in the literature and some 
groups have described in-field recurrence for glioblastomas as ≥95% of recurrence 
within the high dose volume; marginal as > 95% of recurrence outside the high dose 
volume and distant (or out of field recurrence) as outside the radiation field (<20% 
isodose line) [391]. Others have defined central or in-field recurrence as a 
recurrence within the region that has received ≥90% of the prescribed dose and 
marginal or out of field as a recurrence within the region that received <90% of the 
prescribed dose [392].  However, those used by Press et al. to assess meningioma 
recurrence following IMRT have been employed in this study:   in-field if ≥90% of the 
enhancing recurrence is within the prescription isodose volume; distant if recurrence 
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is completely outside of the prescribed isodose volume; out of field (marginal) if 
recurrence volumes are not distant and > 90% of the recurrence is situated outside 
the prescription isodose volume, and as both if neither fully in field nor marginal 
[393].  A schematic diagram of the study is demonstrated in fig. 4.1. 
 
Assessment of quality of life data was carried out in accordance with the EORTC 
QLQ-C30 scoring manual [394].  Data from the 30 questions from QLQ-C30 were 
divided into 3 separate scales according to the issue addressed by particular 
questions: global health status/QoL scale, functional scale and symptom scale.  The 
functional scale was subdivided into a further five subscales (physical functioning, 
role functioning, emotional functioning, cognitive functioning and social functioning) 
and the symptom scale was subdivided into 9 categories.  The average of the items 
contributing to each scale was calculated to produce a raw score:   
𝑅𝑎𝑤𝑆𝑐𝑜𝑟𝑒 =  𝑅𝑆 =  (𝐼1 +  𝐼2 +. . . + 𝐼𝑛 )  ÷ 𝑛, 
where I1, I2 etc. indicate the score from a particular question answered. 
 
In accordance with the scoring manual [394], when data was missing but more than 
50% of the subscale (subgroups) questions were answered, raw scores were 
calculated for only those items answered.  Conversely, if more than 50% of a 
subscale was not answered, then the whole subscale could not be assessed and 
was therefore considered missing. 
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In order to standardise the scores, a linear transformation was carried out so that 
scores ranging from 0 to 100 were produced.  The following equations were used 
for the various scale groups to create these scores: 
𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑠𝑐𝑎𝑙𝑒 = (1 −
(𝑅𝑆 − 1)
𝑟𝑎𝑛𝑔𝑒
)  𝑥 100 
𝐺𝑙𝑜𝑏𝑎𝑙 𝐻𝑒𝑎𝑙𝑡ℎ 𝑠𝑡𝑎𝑡𝑢𝑠 𝑄𝑜𝐿 𝑠𝑐𝑎𝑙𝑒 = (
(𝑅𝑆 − 1)
𝑟𝑎𝑛𝑔𝑒
)  𝑥 100 
𝑆𝑦𝑚𝑝𝑡𝑜𝑚 𝑠𝑐𝑎𝑙𝑒 = (
(𝑅𝑆−1)
𝑟𝑎𝑛𝑔𝑒
)  𝑥 100    ,  
where RS is the raw score and range is the difference between the maximum and 
minimum possible scores in that particular category.  For example the functional 
and symptom items are scored between 1 and 4, so the range is 3.  However the 
global health status/QoL items are scored between 1 and 7, so the range is 6. 
 
The 20 questions from QLQ-BN20 were assessed in a similar way, so that the 
answers to questions were grouped into 11 groups: 1 functional scale and 10 
symptom scales.  Raw scores were produced and a linear transformation score 
generated in the same way as QLQ-C30 [395,396]. 
 
Data analysis and statistical tests were performed using PASW version 18.0 
statistical package. One way analysis of variance (ANOVA) was applied to compare 
QLQ-C30 and QLQ-BN20 scores between different time points (baseline and during 
follow up).  Statistical significance was set at 5%. 
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4.4 Results 
 
4.4.1 Patient and tumour characteristics  
 
28 patients were recruited and consented to study entry, although 2 patients were 
deemed ineligible for study inclusion due to lack of histological diagnosis of 
meningioma.  The remaining 26 patient cohort had a median age of 49.5 years 
(range 38-76 years) with a slightly higher ratio of female patients compared to male 
patients (1.17:1).  A large proportion of patients (80.8%) were considered to have a 
WHO performance status of 0 at the time of radiotherapy, with a small number 
assessed with a performance status of 1 (19.2%) and no patients with a 
performance status of over 1.  
 
All patients had biopsy proven meningioma as part of their eligibility into the study.  
16 (61.5%) patients were classified with WHO grade I tumours and 9 patients 
(34.6%) with a WHO grade II meningioma.  There were no patients classified with a 
WHO grade III meningioma.  However, in 1 patient, the tumour biopsy sample, 
although consistent with meningioma, was felt too small to grade and the risk of re-
biopsy too great in terms of further visual impairment.  57.7% of tumours occurred in 
skull base locations, of which almost half (46.7%) occurred in the sphenoid wing.  
Detailed patient and tumour characteristics are summarized in table 4.2.   
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4.4.2 Radiotherapy delivery and plan assessment 
The timing of radiotherapy occurred at various points in a patient’s presentation. 
Most instances were at recurrence (42.3%), although a smaller percentage (23.1%) 
took place as primary treatment (usually because of the risks of surgery) or 
following surgery (34.6%).  All radiotherapy was delivered using a linear accelerator 
with 6MV photons at a dose of 50.4Gy in 28 fractions over 5 and a half weeks and 
using a median of 5 intensity modulated fields (range 5 to 7 fields) in order to 
achieve optimised treatment plans.  Optimal plans provided coverage of the PTV by 
the 95% isodose with sparing of the adjacent critical structures.  Figure 4.2 show 
typical plans with good conformality of complex shaped planning target volumes by 
the 95% isodose.  Figures 4.3 and 4.4 demonstrate typical plans from 2 patients to 
compare the coverage by the 95% isodose with that from the 10% isodose.  It also 
demonstrates the sharp fall in dose gradients to allow sparing of high dose to 
organs at risk so that dose objectives were met.     
 
The median tumour volume (planning target volume [PTV]) irradiated for all patients 
was 107.1cm3 (range 15.2 to 338.0cm3).  Table 4.3 details the significant treatment 
assessment parameters.  The median volume of the PTV covered by the 
prescription isodose (TVPI) was 101.05cm3 (range 14.8 to 310.3 cm3); equivalent to 
a median of 95.6% (range 91.8 to 99.0%) of the target volume covered by the 
treatment isodose (TVPI).  The median near minimum dose or dose received by at 
least 98% of the PTV (D98%) was 47.4Gy (range 45.7 to 48.9Gy), which equates to 
94.1% (range 90.6 to 96.9%) of the prescribed dose. The median near maximum 
dose or dose received by at least 2% of the PTV (D2%) was 52.8Gy (range 51.4 to 
53.7Gy), equivalent to a median of 104.7% (range 102.0 to 107.0%) of the 
prescribed dose.  The maximum dose received by at least 50% of the PTV (D50%) 
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was 50.5Gy (range 50.3 to 50.8Gy), equating to a median of 100.17% (range 99.7 
to 100.6%) of the prescribed dose. 
 
The median homogeneity index (HI) for this cohort of patients was 0.10 (range 0.05 
to 0.16) and a conformity index (CI) of 77.54% (range 64.62 to 87.66%).  However, 
when using the CI suggested from ICRU 62 [107], the CI was slightly higher at 0.96 
(range 0.92 to 0.99).  The patient with the highest CI did not have the highest HI 
and vice versa.   
 
The organ at risk PRV doses are detailed in table 4.4.  In most cases, dose 
objectives and organ dose tolerances were adhered to.  However, there were cases 
where doses above the dose objective or organ tolerance were accepted.  This 
occurred in organs such as lenses and pituitary gland, where the balance of tumour 
dose coverage to treat the meningioma outweighed the potential long term toxicities 
of cataracts or pituitary dysfunction.  PRV doses above set dose constraints were 
also accepted in two other cases.  In one patient with a suprasellar meningioma, the 
mean dose to the PRV optic chiasm was 51.2Gy with a maximum dose of 51.6Gy.  
In another patient with a right optic nerve and sphenoid wing tumour, the median 
dose to the right optic nerve was 50.8Gy with a maximum dose point of 54.6Gy.  
However, the mean dose to the left optic nerve was below the dose constraint at 
28.2Gy, with a maximum point dose of 47.6Gy.  These PRV doses were accepted 
above the specified dose constraint as the aim of treatment was to spare vision to 
the contralateral eye in patients with an ipsilateral blind eye.   
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8 patients were treated with doses to the pituitary over the recognised dose limits (at 
a mean dose of 49.2Gy, [range 48.8 to 51.7Gy]), although the pituitary gland was 
not set as a dose constraint in many cases.  Similarly 7 patients received doses 
above the tolerance of the lenses, although these were also not set as a dose 
objective during IMRT planning. 
 
4.4.3 Toxicity 
4.4.3.1 Acute toxicity 
On the whole treatment with IMRT was tolerated well, although 25 (96.2%) patients 
suffered some form of acute toxicity.  23 of these 25 patients experienced grade 1 
toxicity (of which the most common were fatigue, alopecia and radiation dermatitis), 
whilst only 2 patients experienced a toxicity of grade 3 or more (1 patient with grade 
3 fatigue and 1 patient with grade 3 retinal detachment).  No patients suffered with 
grade 2 acute toxicity.  The observed acute toxicities during and just following IMRT 
(during weeks 9-10) are outlined in table 4.5.  
 
Fatigue occurred in 23 (88.5%) patients at a median onset at 3-4 weeks (range1-2 
weeks to month 3) from the start of IMRT.  However, this resolved at a median of 6 
months (range 9-10 weeks to 24 months) following treatment.  22 out of the 23 
patient experienced grade 1 fatigue.  1 patient suffered grade 3 fatigue which 
peaked at week 9-10, although had resolved by month 6 following IMRT.   
 
Expected grade 1 alopecia within the IMRT treatment fields occurred in 19 patients 
at a median of 3-4 weeks (range 3-4 weeks to 9-10 weeks) into IMRT with hair 
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regrowth by month 12 following treatment, although 1 patient had persistent 
alopecia until month 36 following radiation.  Grade 1 skin toxicity occurred in 10 
(36%) patients within the treatment area at a median onset of 3-4 weeks (range 3-4 
to 5-6 weeks) and with resolution of symptoms by a median of 9-10 weeks (range 9-
10 to 6 months following radiation).  Grade 1 mouth dryness was reported in 5 
patients, all with a spontaneous resolution and short duration of symptoms (for 
example onset at 5-6 weeks and resolution at 9-10 weeks, onset at 1-2weeks and 
resolution at month 3, onset at 6 months and resolution at 12 months). 
 
Seizure occurred in 1 patient at week 9-10 following IMRT and resolved without any 
intervention.  1 patient also noted a reduction in their short term memory (grade 1) 
at week 9-10, although this had resolved by month 3 following treatment. 
 
5 patients developed a self-limiting grade 1 keratitis or ocular surface irritation at a 
median of 5-6 weeks (range 1-2 to 9-10 weeks) from the start of treatment, which 
had resolved in all cases by month 3.  2 patients observed grade 1 diplopia at 3-4 
weeks and 5-6 weeks respectively, which resolved by month 3.  I patient developed 
a grade 3 right inferior retinal detachment, requiring surgical repair, one day 
following completion of his IMRT.  However, this was not felt to be as a direct 
consequence of his tumour or treatment. 
 
4.4.3.2 Late toxicity 
Of the 26 patients enrolled in the study, 2 patients have been lost to follow up at 
local hospitals; 1 at month 24 and the other patient shortly after completing IMRT.  
At a median follow-up of 29 months (range 9 to 58 months), 24 (92.3%) patients 
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have developed a late toxicity.  Most patients developed a grade 1 toxicity; however 
a grade 2 toxicity occurred on 7 occasions (6 different patients, 23.1%) and a grade 
3 toxicity in 3 patients (11.5%).  Details of late toxicity are outlined in table 4.6. 
 
The commonest late toxicity was a change in mood or personality following 
treatment in 12 patients.  This typically occurred at a median onset of 6months 
(range week 5-6 to month 24) following IMRT and most experienced grade 1 mood 
changes, with 1 person experiencing grade 2 changes.  Symptoms, such as 
irritation and anger were commonly cited.  Mood alterations appeared to be 
persistent for most, although these symptoms resolved in 3 patients. 
 
Late onset reduction in short term memory was highlighted in 11 (42.3%) patients 
and occurred at a median onset of 6 months (range weeks 5-6 to month 24) 
following IMRT.  This was consistently classed as a reduction in short term, rather 
than long term memory, with 2 patients experiencing grade 2 memory loss (self-
reported by patients and assessed formally with mini mental state examinations).  
Temporal lobe, and particularly hippocampi, have a role in learning, consolidation 
and memory and there are studies demonstrating that radiation dose to these areas 
may alter memory formation and neurocognition [397,398].  The median mean dose 
and Dmax to the temporal lobes for the 2 patients with grade 2 memory loss was 
25.2Gy (range 23.0 to 27.1Gy) and 52.3Gy (range 51.8 to 52.8Gy), with slightly 
higher doses received by the left temporal lobe (median mean dose: left = 26.8Gy 
[range 20.9 to 32.8Gy], right = 23.5Gy [range 21.6 to 25.3Gy]; Dmax: left = 52.5Gy 
[range 52.4 to 52.7Gy] and right = 52.1Gy [range 51.3 to 52.8Gy]). These particular 
patients were treated for tumours situated in the left sphenoid wing.  The median 
mean dose and Dmax to hippocampi was 25.7Gy (range 25.3 to 26.1Gy) and 40.1Gy 
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(range 39.6 to 40.6Gy) respectively, and as expected higher doses were seen in the 
left hippocampus compared to the right (mean dose: left = 27.6Gy [range 22.9 to 
32.3Gy], right = 23.7Gy [range 19.9 to 27.6Gy]; Dmax: left = 47.8Gy [range 44.45 to 
51.1Gy], right = 32.4Gy [range 28.1 to 36.7Gy]).  The median mean dose and Dmax 
to the temporal lobes for all patients experiencing memory issues was 19.6Gy 
(range 0.3Gy to 27.2Gy) and 50.7Gy (range 0.6Gy to 52.2Gy) with higher doses 
received by the left temporal lobe (mean dose: left = 20.8Gy [range 0.3 to 23.6], 
right = 16.0Gy [range 0.3 to 25.3Gy]; Dmax: left = 51.7Gy [range 0.6 to 55.3Gy], right 
= 49.7Gy [range 0.6 to 55.5Gy]).  The median mean dose and Dmax to hippocampi 
was 19.7Gy (range 0.7Gy to 37.4Gy) and 37.4Gy (range 1.3Gy to 50.7Gy) 
respectively and similarly higher doses were seen in the left hippocampus (mean 
dose: left = 20.5Gy [range 0.7 to 32.2Gy], right = 17.7Gy [range 0.7 to 27.6Gy]; 
Dmax: left = 43.0Gy [range 1.2 to 51.1Gy] and right = 31.5Gy [range 1.3 to 52.0Gy]).  
At the time of follow up, 3 patients described an improvement in memory symptoms 
that had developed following radiotherapy.  However, the remaining 12 patients had 
persistent symptoms.  
 
Late radiation dermatitis (grade 1) occurred in 1 patient at 4 years and late radiation 
related pain over the site of the surgical scar was recorded by clinicians in 2 patients 
(one at grade 2 and the other grade 3), both at 24 months following radiation. 
 
Grade 1 somnolence or fatigue was noted as a late toxicity in 10 patients at a 
median onset of 6 months following radiation (range month 3 to month 24).  5 
patients reported an improvement in their symptoms.  However, symptoms have 
persisted in the remaining patients.  The exact cause of somnolence and fatigue is 
likely to be multifactorial, but has been linked to cranial irradiation [399]; the median 
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mean brain dose was 16.9Gy (range 10.5Gy to 20.1Gy) and a median Dmax brain 
dose of 54.4Gy (range 53.2Gy-55.2Gy).  Grade 1 headaches were reported in 7 
patients, while 1 patient suffered grade 2 headache, with a median time of onset at 
month 3 (range month 3 to month 24).  Seizures occurred in 5 patients; 3 at grade1, 
1 with grade 2 and another patient with grade 3 symptoms, with a median onset at 
month 6 (range month 3 to month 24).  Seizures included auras and some were 
occipital in nature.  1 patient’s seizure was due to non-compliance with their 
medication.  1 patient developed a self-limiting anomic aphasia.  
 
3 patients developed cataracts, 2 with grade 1 (at month 12 and month 36) and 1 
patient with grade 2 (at month 6).  The 2 patients with grade 1 cataracts were aged 
76 and 65 years, with tumours in the left frontal brain and left sphenoid wing 
respectively at the time of IMRT.  The mean lens doses were 1.6Gy (Dmax 2.4Gy) 
and 5.2Gy (Dmax 6.0Gy) respectively. The patient with a grade 2 cataract was 51 
years of age at the time of radiation and received a mean lens dose of 3.3Gy with a 
Dmax of 5.2Gy for a meningioma in the olfactory grove and extending to the floor of 
the anterior cranial fossa.  9 patients developed a grade 1 dry eye at a median of 6 
months (range month 3 to month 48) and received a median mean lacrimal gland 
dose of 26.9Gy (range 8.1Gy to 33.4Gy) and a median Dmax of 33.2Gy (range 
10.9Gy to 48.8Gy).  5 of these patients had tumours located either in the cavernous 
sinus, sphenoid wing or orbit.  1 patient with a left sphenoid wing tumour extending 
through the orbit developed grade 3 dry eye at month 12 requiring further treatment 
after receiving a mean lacrimal gland dose of 26.9Gy (Dmax of 33.2Gy) . 
Interestingly, the patient with grade 3 toxicity did not receive the largest dose to the 
lacrimal gland.  In fact, 4 patients with mean and Dmax lacrimal doses over 26Gy and 
33Gy respectively have not developed symptoms or signs of dry eye.  The same 
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patient developed grade 1 keratitis at month 3 (with mean globe dose of 24.8Gy and 
Dmax of 41.2Gy) and was managed with lubricants and anti-inflammatory eye drops.   
 
An increase in prolactin levels (to levels outside the normal range) were also noted 
in 2 patients between years 1 and 2 following IMRT.  They have not experienced 
any associated symptoms, but have been referred to local endocrinologist for further 
follow up and investigations.  Other pituitary parameters and MRI scans of the 
pituitary have been unremarkable.  These patients have not required any treatment 
for the hyperprolactinaemia to date and in 1 patient, the levels have fallen to near 
normal levels. 
 
4.4.4 Clinical outcomes 
17 out of 26 (65.45%) patients had an improvement in at least one baseline tumour 
related symptom.  Table 4.7 and figure 4.5 demonstrate the change in symptoms 
following IMRT.  Most symptoms either remained stable or improved following 
treatment.   
 
6 out of 13 patients noticed a relief in their baseline headache at a median of 12 
months following IMRT (range month 3 to month 24), whilst 5 patients had stable 
symptoms.  2 patients described a slight deterioration in their headaches from grade 
1 to grade 2 at month 6 and month 12 following IMRT respectively.  In addition 3 out 
of 4 patients noticed an improvement in their motor function at a median of 12 
months following IMRT and all patients noticed an improvement in sensory 
symptoms at month 3 (3 patients with complete resolution).  2 patients noted an 
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improvement in their speech at month 3 and month 6 following IMRT respectively.  1 
patient with baseline tumour related nasal stuffiness had a complete resolution of 
their symptoms during weeks 5-6 of treatment and this improvement has persisted 
to date. 
 
5 patients experienced an improvement in visual symptoms (mainly visual field 
defects), whilst those with complete or almost complete visual loss tended to 
demonstrate stable disease, rather than improvement.  Proptosis was notably 
improved in 3 of the 4 patients at a median of 12 months following IMRT (range 
week 5-6 to month12).  Improvements in cranial nerve function were also seen.  3 
out of 4 patients had a resolution of their baseline ptosis at a median of 6 months 
following treatment and all patients developed a complete resolution of numbness 
over the area supplied by the ophthalmic division of the trigeminal nerve by month 6 
following IMRT.  Resolution of CN VII neurology was also seen early after IMRT 
(week 5-6 and month 3). 
 
Clinical status, as assessed by performance score, remained stable in 18 patients 
and improved in 1 patient at month 24.  However 3 patients reported a reduction in 
their performance status by I point at 12 months, 24 months and 48 months 
respectively. 
 
Patient reported outcomes using the EORTC QLQ-C30 and QLQ-BN20 are 
summarised in table 4.8 and fig. 4.6.  Higher scores indicate better functioning and 
quality of life for the Global health status/QoL and functioning scales.  However 
higher scores indicate worse symptomatology for all symptom scales.  Overall 20 
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patients had returned a completed quality of life questionnaire.  However, 15 
patients completed this for months 3, 6, and 12 following IMRT and 6 patients had 
completed a form for month 24. 
 
There is a higher patient self-reported incidence of symptoms such as fatigue, pain 
and insomnia overall following IMRT.  Interestingly, there is also a high level of 
financial difficulty experienced by this patient group.  Conversely, there appears to 
be good functioning in all subscales (physical, role, emotional, cognitive, social and 
future) and a reasonable level of global health/quality of life.   
 
Figure 4.7 demonstrates the change in all subscales over the course of follow-up 
and documents the level of each scale at each time point: baseline, months 3, 6, 12 
and 24.  It can be seen that there appears to be an increase in many of the 
functioning scales with time (physical, role, emotional and social), although there 
appears to be a trend for a reduction in cognitive functioning over time.  However 
variations in the scale with each time point was not statistically significant for most 
items (p>0.05), with the exception of appetite loss, which appears to improve over 
time.  The observed difference of appetite loss from baseline to any other time point 
(month 3,6,12 or 24) is statistically significant at all time points (baseline to month 3: 
change in score of 22.22; baseline to month 6: 26.67; baseline to month12: 28.89; 
baseline to month 24: 33.33, F(4,65): 6.0740, p < 0.0003).   
 
Radiological assessment using MRI has demonstrated an overall local control rate 
of 84.6% (22/26 patients) after a median follow up of 29 months (range 9-58 
months).  22 patients had stable disease based on MRI findings and there were no 
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tumour volume reductions as assessed by the Response Evaluation Criteria in Solid 
Tumours (RECIST).  4 patients showed tumour progression on MRI scanning at a 
median of 24 months following IMRT (range 12 to 26 months).  These have been 
identified as in-field (1 patient), marginal (2 patients) and out of field relapses (1 
patient) as defined in the ‘methods and materials’ section.  All have developed 
following treatment of a grade II meningioma.  Fig 4.5 summarises the findings on 
MRI follow up and change in baseline symptoms.  This demonstrates that most 
patients had either an improvement or stability in their baseline clinical symptoms 
(with a slightly higher proportion showing stable symptoms), while follow up MRI 
images failed to confirm any improvement in tumour volume, but did demonstrate 
stable appearances. 
 
The first patient to develop recurrence was initially treated with radiotherapy 
following a Simpson’s grade 2 surgical resection of a grade II atypical left posterior 
parietal meningioma with a focally high Ki67 ratio and a mitotic count of >4/10 hpf 
(high power field).  The patient had residual symptoms from his initial treatment, 
including right sided motor and sensory reduction.  However, he did report some 
change in personality from month 6 following his IMRT and following this 
experienced worsening of motor symptoms within the right arm.  A relapse was 
identified on MRI scanning within the inferior portion of the original tumour (in the 
posterior parietal region).  Further surgery confirmed a grade II recurrence with focal 
mitotic activity of 10/10 hpf, but <20/10 hpf and with no anaplastic or malignant 
progression.  At the current time, this patient is alive and now recurrence free, but 
has residual symptoms from his surgery including motor weakness and dysphasia. 
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A further patient developed relapse at 24 months following IMRT.  He initially 
underwent  surgery, achieving a Simpson’s grade 1 resection of a grade II chordoid 
left sphenoid wing meningioma with focally increased Ki67 and mitotic activity 
reaching 4/10 hpf, but less than 20/10 hpf. There was also evidence of brain and 
bone invasion in the initial meningioma.  A surveillance MRI scan demonstrated an 
area of recurrence just at the edge of the surgical and radiation field in the floor of 
the anterior cranial fossa.  Surgical excision was an option, but the patient declined 
further treatment. 
 
The third patient initially underwent surgery for a parafalcine meningioma, although 
surgical resection was noted to be incomplete with a small amount of disease left 
surrounding the sagittal sinus (Simpson’s grade 4).  Histology revealed a grade II 
chordoid meningioma with a high mitotic rate, recorded at 6/10 hpf with brain 
invasion. Increase in the size of this known residual disease was noted on imaging 
and he therefore received radiotherapy for this recurrent parafalcine meningioma.  
He subsequently suffered with intermittent recurrence of his original seizures and 
subsequent MRI scanning demonstrated a recurrence of his tumour just lateral to 
the original parafalcine meningioma.  He underwent surgical resection of his tumour, 
the histology of which confirmed a meningothelial meningioma with high mitotic 
activity (10/10 hpf) and with evidence of dural and brain invasion. 
 
The fourth patient was treated with IMRT for a grade II recurrent left anterior cranial 
fossa meningioma with chordoid features and moderate mitotic activity of less than 
4/10 hpf and a low Ki67.  This was initially surgically resected and required 2 further 
surgical resections due to recurrences.  The patient also had a history of a grade I 
parasagittal meningioma, previously resected.  Although, complete surgical 
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resection had been stated in operative notes, it has been difficult to accurately 
allocate a Simpson’s grade for these resections, although it probably falls into the 
Simpson’s grade 1-3 group.  Nevertheless, in view of the frequent recurrences of 
the anterior cranial fossa meningioma, this patient went on to receive post-operative 
IMRT.  Despite this, the patient developed new onset seizures at 3 months prior to a 
surveillance MRI scan at month 12 following IMRT.  This identified a recurrence in 
the right parietal region and was amenable to surgical resection.  However, the 
patient died before surgery due to unrelated cardiac causes.  There have been no 
further deaths within this cohort of patients at this time of follow up. 
 
At the current median follow up of 29 months, the progression free survival is 84.6% 
with the incidence of repeat surgery of 15.4% and with an overall survival of 96.2%.  
However, it is acknowledged that the recurrence rate is 44.4% in those patients with 
grade II meningioma, although progression free survival within grade I patients 
remains at 100%.   
 
 
4.5 Discussion 
 
This prospective study has demonstrated the use of IMRT in the treatment of 
meningioma.  Radiotherapy to treat meningioma, either in the primary or adjuvant 
setting, has been well documented [172-174,193,195,400] and in this group of 
patients, just under half (42.3%) received radiotherapy at the time of recurrence, 
with smaller numbers receiving radiotherapy as an adjunct to surgery (34.6%), or as 
primary treatment (23.1%).  Over half of the 26 patients in this cohort had tumours 
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within the skull base region; an area notoriously difficult to treat with conventional 
radiation techniques (or radiosurgery) due to dose limiting adjacent critical 
structures [210], where IMRT can conform to the shape of the tumour and avoid the 
use of high dose per fraction as seen with radiosurgical techniques.  The use of 
IGRT (in the form of cone beam CT and portal kV imaging) within this study has 
allowed accurate and safe delivery of IMRT. 
 
Acceptable coverage and conformality of the tumour volume, as demonstrated by 
the treatment plan parameters, has been documented with this IMRT technique.  
The median D50% (100.2% in this group) is believed to be a good measure of 
absorbed dose in homogenously irradiated tumours [110].  However, the 
homogeneity index (HI) is a more accurate measure of homogeneity of tumour dose 
coverage using IMRT, and in this cohort, has been shown to produce high levels of 
homogeneity with a value close to 0 (median HI 0.10).   
 
Similarly, the conformity index (CI) is a measure of how accurately the volume of 
dose distribution conforms to the size and shape of a target volume (with values of 1 
or 100% providing excellent conformality.  Using the ICRU 62 definition of CI [107], 
a value of 0.96 was achieved.  However, it has been recognised that this formula 
can give false optimism as it assumes that the centre of the treatment volume is 
always at the centre of the target volume.  However, this is not always the case and 
may result in a good CI value whether the prescribed isodose volume has covered 
the target volume completely or whether it was missed altogether.  The formulae 
created by Paddick et al. has circumvented this by evaluating, not only the ratio of 
independent volumes, but the volume of target covered by the prescription isodose 
and incorporates any over (radiation spill outside the PTV) or under coverage of the 
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target volume by the prescription isodose [126].  Using this formulae the CI was 
slightly lower at 0.78, (77.54%) in comparison to the ICRU 62 CI value of 0.96, 
although it is perhaps a more realistic estimate and valuable tool in assessing 
conformality.  In fact, others have demonstrated slightly lower levels of conformality 
(CI of 0.47 ± 0.12) when delivering IMRT to benign intracranial tumours, including 
meningioma, acoustic neuromas and pituitary adenomas [213]. 
 
In practice, there is often a trade-off between homogeneity and conformality.  If the 
priority is conformality, then an increase in inhomogeneity may be accepted, 
whereas if the priority is homogeneity, a slightly reduced conformity may be 
accepted and this is often closely related to coverage of the tumour or target 
volume, while also aiming to respect the dose tolerances of adjacent normal 
structures. 
 
Dose reductions to organs at risk situated beside the target volume using IMRT for 
meningiomas have been described in the literature [213,220,224] and this is 
consistent in most cases seen in this study where dose limits for critical structures 
have been adhered to.  Of course, there have been circumstances where, due to 
the anatomical nature of the tumour, dose tolerances for a particular organ have 
been exceeded, but careful thought has gone into the benefit of treating the tumour 
whilst increasing the potential for late organ radiation damage, against the risks of 
inadequate treatment but the ability to keep within normal tissue tolerance.  More 
often than not, the choice to treat the tumour whilst exceeding the tolerance of a 
particular organ was made in situations where the aim was to preserve the 
contralateral eye in a patient with an already blind ipsilateral eye. 
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The prospective collection of toxicity data demonstrates patient tolerance of this 
particular radiation technique, with acceptable levels of acute toxicity resolving at a 
median of 6 months following treatment and is largely in line with other reports 
[191,201,217,220,400-403].  At a relatively short median follow up of 29 months, the 
late toxicity in this cohort of patients was well tolerated and reports in the literature 
have similarly demonstrated low rates of toxicity following IMRT [217]. 
 
As more than half of the patients in this study had tumours located in the skull base, 
dose and toxicity becomes of paramount importance and it has been demonstrated 
here that significant late ocular toxicity is not common.  There were no reports of 
any deterioration in vision at this stage in ongoing follow-up.  Nevertheless, grade 1 
dry eye was noted in 9 of the 26 patients and grade 3 in 1 patient.  There have been 
suggestions that dose to the lacrimal gland is associated with an increase in dry 
eye, with some reports concluding that a dose of over 30-34Gy can lead to a 5% 
incidence of dry eye and is dependent on the total dose and dose per fraction 
[404,405].  The incidence appears to remain static at 6% for doses between 35 to 
39Gy, although rises sharply with higher doses.  Reports of a 50% incidence with 
45-49Gy and 90% incidence with dose of 60-65Gy have been documented following 
radiotherapy to the head and neck in a cohort of 78 patients [405].  However, more 
recently studies have suggested that maximum dose to the lacrimal gland is a more 
useful predictor of acute and late toxicities compared to mean dose and, in 
particular, the V20 a useful predictor of late toxicity, with suggestions of a Dmax and 
mean dose of 30Gy and 25Gy threshold for acute toxicity [406].  The small numbers 
in our cohort make any statistical evaluation difficult.  Nevertheless, the median Dmax 
and mean dose in those patients with symptoms of a dry eye were 33Gy and 26Gy 
respectively (in those with grade 1 and grade 3 toxicity).  There were of course 
patients who received much lower doses to the lacrimal gland, but still 
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demonstrated symptoms of a dry eye and it is worth mentioning that causes of a dry 
eye may be multifactorial and also related to damage of other ocular structures. 
 
Changes in short term memory were also recognised by many patients as a late 
toxicity in this group of patients.  The temporal lobes have, for a long time, thought 
to be involved in the process of memory formation.  Groups treating nasopharyngeal 
tumours with IMRT have noted more neurocognitive impairment in patients who 
received a mean dose over 36Gy to the temporal lobes [407]; impairment increasing 
with doses over 53-60Gy and with V60 over 10% [407,408].  This compares to Dmax 
of 50.7Gy and 52.3Gy in the 2 patients who experienced grade 1 and 2 short term 
memory problems.   
 
However, recent attention has focused on the hippocampi, situated within the 
temporal lobes, and a vital part of the limbic system, involved in the formation of 
new memories.  They are a source of multipotent stem cells and therefore sensitive 
to radiation, with animal studies reporting a decline in neurogenesis and cognitive 
function with 10Gy and perhaps with a threshold value of 5Gy [409-411].  
Consequently some clinical studies have demonstrated a hippocampal dose 
threshold with a D40% of 7.3Gy and suggestions of an association with D100% over 
0.0Gy, above which prospectively assessed decline in neurocognition has been 
documented [177].  As a result of these findings and the potential for long term 
reduction in neurocognition, attempts are being made to employ hippocampal 
sparing when irradiating the brain [398] and some have attempted to constrain the 
hippocampal volumes receiving 10Gy or more to less than 50%, with maximum 
dose points of less than 16Gy [412], whilst others have constrained this to a mean 
dose of less than 30Gy to at least one hippocampus [413] and this continues to be 
 
 
190 
 
the subject of ongoing trials [412,414].  11 patients in this study group who 
developed issues with short term memory (and 2 patients with grade 2 short term 
memory reduction) received a median mean dose to the temporal lobes of 19.6Gy 
(median Dmax of 50Gy) and a median mean dose to the hippocampi of 19Gy 
(median Dmax of 37Gy).  The 2 patients who developed grade 2 memory problems 
had a median mean dose to the temporal lobes of 25.1Gy and median Dmax of 
52.8Gy with hippocampal doses of 25.7Gy and 40.1Gy respectively.  Although small 
in sample size, all patients receiving IMRT to the brain for meningioma do receive 
significant doses to the temporal lobes (in this cohort, a median mean dose of 
49.8Gy [range 0.6 to 55.0Gy] and Dmax 18.7Gy [range 0.3 to 55.9Gy]) and, in 
particular, to the hippocampi (overall median mean dose 18.6 [range 0.7 to 49.4Gy] 
and median Dmax 33.2Gy [range 0.7 to 52.0Gy]), which may in turn have long term 
consequences in respect of neurocognition.  Conversely, there have been reports 
from some groups suggesting that radiation does not necessarily play a role in the 
development of late neurocognitive decline [415,416].  Nevertheless, it would be 
useful to examine hippocampal sparing and neurocognitive sequelae prospectively 
in this group of good prognosis patients.  
  
10 patients developed a form of somnolence (including symptoms of drowsiness, 
lethargy or fatigue) following IMRT, 5 of which have continued at last follow up.  
Whilst recognised as a consequence of cranial radiation and thought to be as result 
of some form of transient demyelination [399], reports in the past have failed to 
demonstrate a radiation dose dependence for somnolence syndrome following 
radiotherapy [417].  Nevertheless, the cause of somnolence and fatigue can be 
multifactorial.  A recent phase III study comparing IMRT with 3D conformal 
radiotherapy for head and neck tumours unexpectedly found a greater incidence of 
fatigue within the IMRT group and postulated a relationship to higher doses within 
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the posterior fossa, and brainstem [116], with further reports of associations with 
mean dose to the cerebellum, basal ganglia and pituitary gland [418]. It is 
conceivable that, through IMRT and the inadvertent dose to non-target areas [216], 
patients receiving IMRT may experience more symptoms related to dose in these 
non target areas of the brain areas.  However, longer follow-up within prospective 
studies may be able to document these findings further. 
 
Within this prospective study, 65% of patients with meningioma had experienced an 
improvement in their baseline symptoms following IMRT.  Patients had 
meningiomas within several different regions of the skull and symptoms associated 
with optic nerve impairment or other cranial nerve impairment seemed as likely to 
respond as symptoms related to other areas of the brain.  However, due to the small 
sample size within this cohort, detailed statistical analysis to determine whether a 
particular deficit was more likely to respond was not performed.  Nevertheless, 
these findings have also been seen in the literature from other studies, largely 
looking at optic nerve sheath or skull base meningiomas treated with radiotherapy 
[201,215,217,400,419-422].  Milker-Zabel and colleagues demonstrated an 
improvement in pre-existing neurological deficit in 39.8% patients, including a 
reduction in diplopia, exophthalmos and trigeminal neuralgia.  Similarly, Minniti and 
colleagues documented an improvement in neurological deficits in 30% of patients, 
including vision and cranial nerve function[400].  Whereas Pirzkall and colleagues 
found a significant resolution in patients’ neurologic deficits 6 weeks following IMRT, 
and similar to the cohort presented in this chapter, they also noted particular 
improvements in headache, visual fields and acuity, trigeminal neuralgia and motor 
disturbance during longer follow-up [201].  Improvement in performance status was 
observed in half of the 20 study patients with stability in 8 patients.  Although within 
the cohort of patients described in this chapter, most were assessed as displaying 
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stability in their performance status (18 of the 26 patients) and an improvement in 
just 1 patient. 
 
It was interesting to note, (although expected), that in this study the radiological 
findings did not match the clinical improvement in symptoms seen, with stable 
disease rather than an improvement in tumour dimensions seen on the MRI.  This is 
largely in line with other studies, although some have demonstrated radiological 
improvement in a larger group of patients and over a longer follow up [201,215].  
However, follow-up in this study is still short and it may be that the radiological 
changes may be appreciated over a much longer period of time.   
 
A concern regarding radiotherapy for largely good prognosis tumours relates to long 
term toxicity and impairment in quality of life.  Patient reported outcomes are now 
being highlighted as an important measure of treatment success.  Quality of life 
assessments, using QLQ-C30 and QLQ-BN20, have been used in this study to 
formally assess patient reported outcome measures (PROM).  The findings from 
this generally match those findings seen where patients were assessed by clinicians 
at time points following IMRT.  However, financial worries were a concern for most 
following IMRT, but patient functioning and overall global health and quality of life 
did not deteriorate after IMRT.  Looking closer, there appears to be a trend for 
improvement in most of the functioning scales but possibly a decline in cognitive 
functioning, although these observations did not reach statistical significance.  In 
fact, only improvement in appetite following IMRT was found to be statistically 
significant.  However, the clinical significance of this is uncertain and one has to 
question if lack of statistical significance in this setting can be used as a surrogate 
for lack of clinical significance.  Prospective collection of data is imperative and this 
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is now being recognised when studies are being set up to assess new techniques.  
One of the few prospective studies for IMRT in the treatment of meningioma has 
shown improvement or stability of quality of life following IMRT over a follow-up of 
10 years and, reassuringly, only small numbers of patients developing new 
symptoms [217].  
 
Although the follow-up in this group of patients is limited to date, the overall 
progression free survival is slightly lower in comparison to other studies with a rate 
of 84.6% at a median of 29 months (although this was 100% in those patients with 
grade I tumours) and overall survival of 96.2% (1 disease unrelated death occurred 
in a patient with grade II meningioma).  Combs’ group have demonstrated local 
control of 98% at 1 year, 95% at 3 years and 94% at 5 years with higher control 
rates associated with more benign histology [217].  Others have also demonstrated 
favourable outcomes with recurrence free survival in grade 1 meningiomas of 97.5% 
at 3 years and 96.3% at 5 years and with overall survival rates of 98% and 97% at 1 
and 5 years following IMRT [215].   
 
However, it is important to note the low progression free survival rate (55.6%) in the 
cohort of patients with grade II histology within this prospective study. There have 
been documented reports in the literature regarding low tumour control rates 
associated with grade II or III tumours.  Milker-Zabel and colleagues have 
demonstrated lower recurrence free survival rates for grade 2 tumours compared to 
grade I tumours (89% v 97.5% and 77.8% v 96.7% at 3 and 5 years respectively) 
[215].  Similar to this study group, they also noted radiological progression at a 
median of 22.3 months and 3 non tumour related deaths [215].  Others have also 
found similar local control and overall survival rates, although with longer follow-up 
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times [201,220,225].  However, it is well recognised that there is an association with 
grade II/III tumours and poorer local tumour control rates and survival [186,198].   
Some reports suggest that factors, such as gross total resection and maximal 
mitotic rate ≥ 4/10 per hpf are powerful prognostic parameters [203].  In fact, 3 of 
the 4 patients who developed post radiotherapy recurrence in this cohort had 
histological specimens displaying over 4/10 mitosis per hpf.   
 
Reports also correlate the degree of surgical resection with overall survival rates 
[198], suggesting a complete resection leads to a significantly greater 5 year local 
control rate compared to subtotal resections (39% v 0% respectively) [200] and 
some authors have correlated recurrence and survival rates to Simpson’s grade of 
resection [200,423].  Reports in the literature document much higher recurrence 
with high grade tumours following subtotal excision compared to compete resection 
(93% v 63% at 5 years [169], and 71% v 57 [200]), with significantly worse local 
control rates (17% v 87%) [423].  Additionally recurrence risk ratios of 2.71have 
been calculated  following Simpson’s grade 1-3 resections compared to Simpson’s 
grade 4 or 5 resections [200]. However, only one patient in the prospective study 
documented in this thesis had a grade 4 or more Simpson’s resection, whilst the 
others underwent a Simpson’s grade 1-3 resection. It was also interesting, but not 
completely unexpected, to note that 3 out of the 4 patients did develop recurrent 
symptoms before progressive disease was identified on imaging.   
 
Whilst there are undoubtedly histological features from the tumour itself and the 
extent of surgical resection which can have prognostic implications, there is 
evidence to suggest that additional radiotherapy in this particular group of patients is 
not yet optimal.  A study examining 59 patients with grade II or III meningioma and 
 
 
195 
 
treated with radiotherapy reported a 66% disease progression rate, 28% 5 year 
overall survival rate, of which over 90% died of meningioma [193].  Interestingly, 
they also noted that a radiation dose of 50Gy or more was independently 
associated with a better 5 year cause specific survival (42% v 0%).  Similar results 
were replicated in other centres, with 5 year survival rates of 40 to 58% [204,424].  
Other studies have also commented on the dose used in these higher grade 
meningiomas.  Coke and colleagues examined 17 patients with higher grade 
meningiomas, delivering a median dose of 61Gy.  They noted that 3 of the 5 
patients who died of recurrent disease were treated with doses of less than 54Gy 
[425].  Others have used mean doses over 60Gy for grade II and III meningiomas 
with demonstrable increases in 5yr progression free survival (0% with <60Gy and 
90-100% with ≥60Gy) [192].  These studies have all been retrospective studies, and 
it is difficult to determine the exact dose required for higher grade tumours without 
robust prospective data detailing outcomes and potential associated toxicity.  
However, there is an ongoing EORTC 22042-26042 trial aiming to prospectively 
evaluate the efficacy and toxicity of higher doses of radiation for grade II and II 
tumours, delivering 60Gy in cases with a Simpson’s grade 1 to 3 resections and 
60Gy with a 10Gy boost in those with a Simpson’s grade 4 and 5 resection.  
Additionally, there is a ROAM/EORTC 1308 trial examining whether patients with 
atypical meningioma should receive early or late radiotherapy following complete 
surgical resection (Simpson’s grade 1-3). 
 
In addition to the potential benefit of higher doses in this group of meningioma 
patients, some groups have promoted different planning target volumes, with an 
increase in the CTV margin.  Adeberg has recommended a margin of 1-2cm from 
the GTV for grade II meningiomas and a larger margin of 2-3cm for grade III 
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tumours [426].  However, a consensus regarding exact margins has yet to be 
reached. 
 
The poor tumour control rates seen with the grade II tumours in this study may 
therefore be related to the dose of radiation used, as well as tumour volume 
irradiated, although this was a small cohort of patients and the results of the larger 
prospective EORTC trial will be useful.  As 2 of the recurrences occurred at the 
edge of the radiotherapy field, it may be tempting to look at the accuracy of target 
delineation in greater detail, utilising other imaging modalities, such as functional 
MRI or molecular PET in the planning process to improve target definition and 
therefore radiotherapy outcome.  Some groups have altered target volumes using 
high specificity PET tracers [427,428], although clear correlation with clinical 
outcome is not yet available.  However, recent studies have suggested that it is the 
pathological features that worsen outcome from radiotherapy, rather than just a 
reduction in target volume margin size with IMRT [393]. 
 
As more emphasis is placed on the long term outcomes of patients undergoing 
therapy, especially for patients with good prognosis tumours, it is important to 
prospectively document the outcome, tolerability and long term consequences of 
such treatments.  Local control and toxicity profiles appear to be well tolerated in the 
group of patients with grade I meningioma undergoing IMRT.  Conversely, there is 
poor tumour control with doses of 50.4Gy and ‘standard’ clinical target volumes for 
the small group of patients grade II tumours and larger radiation doses and/or 
alterations to tumour volumes may be warranted.  However, longer follow-up is 
necessary to fully and accurately document these findings.   
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4.6 Conclusion 
 
The data presented in this chapter demonstrates that IMRT is an effective and safe 
treatment modality for long term control and toxicity in patients with grade I 
meningiomas.  IMRT offers the possibility of highly conformal irradiation, especially 
for complex shaped, and otherwise difficult to treat meningiomas in the skull base, 
with the ability to spare adjacent critical structures.   
 
Treatment in this cohort is well-tolerated with acceptable levels of acute toxicity, is 
not associated with deterioration in quality of life and produces an early 
improvement in neurology in a significant proportion of cases.  Progression-free 
survival appears equivalent to those documented in retrospective and prospective 
series. 
 
However, IMRT with doses of 50.4Gy has led to a much lower progression free 
survival rate in patients with grade II tumours, although this is within a small cohort 
of patients.  Nevertheless, it is important to consider whether patients with grade II 
or III meningiomas warrant higher doses and larger tumour volumes than those with 
grade I tumours as some studies suggest [192,425], especially as this may also 
increase toxicity levels and this is the subject of ongoing EORTC trials. 
 
Highly conformal plans may come at the expense of significant dose to non-
delineated extra target organs and, therefore, prospectively collected data is vital to 
document toxicity and patient reported outcome measures.  However, longer follow-
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up is essential to fully document the outcomes in this group of patients.  Late toxicity 
from treatment, especially regarding decline in neurocognition, continues to be a 
concern in these patients and prospective neurocognitive testing before, during and 
after IMRT would provide further valuable information. 
 
Dose to non-target areas of the brain may always be of concern from photon based 
conformal radiotherapy.  The application of protons for this indication is an area of 
active research, since a reduction in integral dose with protons can be achieved due 
to properties of its beam.  The depth of the Bragg peak is energy dependent and 
can lead to equally highly conformal dose distribution as photon IMRT, but with 
greater reduction in the entry and exit doses [429].  Protons may, therefore, be a 
promising approach to further sparing of critical organs and perhaps, more 
importantly, low dose to other areas of the brain, which may in turn reduce the long 
term effects from radiation. 
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Dose volume index Objective dose (% of 
prescription dose) 
D98% 90% 
D95% 95% 
D5% 105% 
D2% 107% 
 
Table 4.1a: Dose objectives for planning target volume (PTV) 
Abbreviations: D95% = dose received by 95% of the PTV, D5% = dose received by 5% 
of PTV, D98% = dose received by 98% of PTV (near minimum dose), D2% = dose 
received by 2% of PTV (near maximum dose). 
 
Organ at risk Dose objectives (Gy) 
Brain Stem 55  
Spinal cord 48 
Optic nerves 50 
Optic chiasm 50 
Globe 45 
Lenses 6 
Pituitary gland 45 
Cochlea Mean dose 44 
 
Table 4.1b:  Dose objectives for organs at risk 
All dose objectives are point max values unless specified. 
Dose was minimised to temporal lobes (below 40Gy), where possible.  Dose was 
recorded for other organs at risk outlined (such as hippocampi, whole brain, and 
hypothalamus).  
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Baseline*
IMRT 50.4Gy/28#
Acute toxicity scores
(CTCAE version 3.0)
1 3 6 12 Month
Year
1 32 4 5 6 7 8 109
QLQ-C30 and QLQ-BN20 Quality of Life 
Questionnaires
Time following IMRT
Acute toxicity score
Late toxicity score
Baseline information
Radiotherapy fraction
MRI
 
Fig.4.1: Schematic overview of IMRT study methods 
 
Baseline information included toxicity scoring, mini neurological examination, mental 
test examination, visual assessment and pituitary function tests. 
Acute and late toxicities were assessed using CTCAE version 3.0 toxicity scoring. 
Late toxicity (including mini neurological examination, mental test examination, 
visual assessment and pituitary function tests) was assessed at the time points 
shown. 
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Table 4.2: Baseline patient and tumour characteristics 
Unknown = sample too small to characterise grade  
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Fig 4.2: Typical IMRT plans displaying coverage of the planning target volume 
by the 95% isodose  
 
Dose conformity to irregularly shaped PTVs by the 95% isodose is shown in dose 
colour wash, with concave dose distributions to spare organs at risk, such as optic 
nerve, retina and brain stem.
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a) 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
c) 
 
 
 
 
 
 
 
 
Fig 4.3: Typical plan from one patient demonstrating dose coverage 
(displayed as dose colour wash) by the a) 95% isodose b) 50%  isodose c) 
10% isodose d) 45Gy or more e) 50Gy or more 
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d) 
 
 
 
 
 
 
e) 
 
 
 
 
 
 
 
These plans are taken from the same patient and demonstrate the use of 5 
modulated radiation fields to achieve tight conformality of the 95 % isodose to the 
planning target volume (shown as the outer red line).  However figures 4.3b and 
4.3c also demonstrate the dose received from the 50% isodose, in addition to the 
lower dose bath wash to the rest of the brain (receiving 10% or more of the dose).  
Almost all of the brain receives some dose of radiation from this technique, although 
there is less volume receiving high doses of radiation. 
Figures 4.3d and 4.3e show areas of that brain that receive at least 45Gy and at 
least 50Gy (respectively), demonstrating the steep dose gradients close to organs 
at risk (and therefore respecting dose constraints of the ipsilateral and contralateral 
globe and optic nerves respectively).  
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  a) 
 
 
 
 
 
  b) 
 
 
 
 
  c) 
 
 
 
 
 
  d) 
 
 
 
 
 
Fig 4.4 Typical plan from one patient demonstrating coverage (shown in dose 
colour wash) by a) 95% isodose b) 10% isodose, c) 45Gy or more d) 50Gy or 
more 
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Fig 4.4 (previous page) 
These plans demonstrate tight conformality of the PTV by the 95% isodose and the 
lower dose bath effect by areas receiving at least 10% of the dose.  Figures 4.4c 
and 4.4d show colour wash dose coverage to those areas receiving at least 45Gy 
and those receiving at least 50Gy demonstrating the steep dose gradients adjacent 
to organs at risk (globe and optic nerve, outlined in pink with optic nerve PRVs 
outlines in blue and green).  Also outlined are other organs at risk: temporal lobes 
[blue line], hippocampi [green], brainstem [light pink], brainstem PRV (planning risk 
volume) [yellow], pituitary gland [pink].
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Table 4.3:  IMRT plan assessment parameters 
 
 
208 
 
Table 4.3 (previous page) 
Abbreviations: 
PTV: planning target volume 
D2%: near maximum dose; D98%: near minimum dose; D50%: median dose 
TVPI (cm3) = volume of target covered by the prescription isodose; derived from eclipse treatment planning system by assessing the D100% 
and PTV overlap. 
PIV: volume of prescription isodose; 
SD across target vol (measure of homogeneity)(%) standard deviation of the mean dose across the target volume; 
HI: homogeneity index; calculated as (D2% - D98%)/D50% 
CI: conformity index; derived using the formula ((volume of target covered by 95% isodose)2/(volume of target x volume of 95% 
isodose))x100% 
CI ICRU 62: conformity index as stipulated from ICRU62 for 3D conformal planning; derived from treated volume/PTV 
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Table 4.4 Organ at risk doses 
Abbreviations: R= Right; L= Left; NS = not set; N/A = not applicable 
All are PRV doses, except where dose constraints were not set for that organ.
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Toxicity Frequency 
Number of 
patients 
% 
Fatigue 23 88.5 
Alopecia 19 73.1 
Skin toxicity 10 36 
Mouth dryness 5 19.2 
Pain (radiation related) 1 3.8 
Keratitis/ocular surface irritation 5 11.5 
Diplopia 2 7.7 
Retinal detachment 1 3.8 
Seizure 1 3.8 
Short term memory impairment 1 3.8 
 
Table 4.5:  Frequency of acute toxicities 
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Toxicity Frequency 
Number of 
patients 
% 
Fatigue  10  38.5 
Radiation dermatitis  1   
Radiation related pain  2  7.7 
   Grade 2  1  
 Grade 3  1  
Salivary gland changes  1  3.8 
Headaches  8  30.8 
 Grade 2  1  
Seizure  5  19.2 
 Grade 2  1  
 Grade 3  1  
Motor symptoms  1  3.8 
Sensory symptoms      
Speech impairment  3  11.5 
Memory  11  42.3 
 Grade 2  2  
Mood/personality changes  12  46.2 
 Grade 2  1  
Cataracts  3  11.5 
 Grade 2  1  
Dry eye  10  38.5 
 Grade 3  1  
Eyelid dysfunction  1  3.8 
Glaucoma  1  3.8 
Keratitis  1   
Optic disc oedema  1   
 
Table 4.6: Frequency of late toxicities 
All toxicity classified as grade 1, unless stated.  
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Baseline Symptom/sign 
Number of 
patients with 
baseline 
deficit 
Outcome following IMRT at 
follow up 
  Improved Stable Worse 
Headache 13 6 5 2 
Seizure 2 1 1 0 
Mood/personality 5 3 0 2 
Memory 9 3 6 0 
PS 22 1 18 3 
Motor deficit 4 3 1 0 
Sensory deficit 4 4 0 0 
Expressive dysphasia 4 2 2 0 
Reduced sense of smell 3 1 2 0 
Nasal stuffiness 1 1 0 0 
Ocular surface disease 1 1 0 0 
Proptosis 4 3 1 0 
Vision 14 5 7 2 
CNIII 4 3 1 0 
CNV 2 2 0 0 
CNVII 2 2 0 0 
CNVIII 2 1 1 0 
 
Table 4.7: Outcome of baseline symptoms 
 
Abbreviations: IMRT: Intensity modulated radiotherapy, PS =performance status  
 
 
213 
 
 
 
Fig. 4.5: Change in baseline symptoms and radiological assessment following 
IMRT 
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Table 4.8: EORTC QLQ-C30 and QLQ-BN20 Quality of Life Scores  
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Table 4.8 (previous page) 
Abbreviations: QoL= Quality of life; SD = standard deviation 
Mean scores with standard deviation shown for each scale in the QLQ-C30 and QLQ-BN20.   
QLQ-C30 is subdivided into 3 scales: global health status /QoL, functional and symptom. 
QLQ-BN20 is subdivided into 2 scales: functional and symptom. 
p value shown for difference in each scores compared at different time points.  The difference in appetite loss scores between baseline and 
various time points during was found to be statistically significant.  
  
 
 
216 
 
 
 
Fig 4.6: EORTC QLQ-C30 and QLQ-BN20 overall mean scores over the duration of IMRT and follow up 
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Fig 4.7: EORTC QLQ-C30 and QLQ-BN20 mean scores at baseline and at time points following IMRT 
Abbreviations: M=month 
Higher scores indicate better functioning/ quality of life for the Global health status/QoL and functioning scales.  However higher scores indicate 
worse symptomatology for all symptom scales. 
There is a statistical significance for change in appetite loss between baseline and all other time points following IMRT, p=0.0003.  
 
 
218 
 
Chapter 5 
 
Concluding Discussion 
 
Intensity modulated radiotherapy (IMRT) has brought an exciting dimension to 
radiation therapy.  This sophisticated radiation technique is now being used in many 
clinical settings to enable improved target conformality, dose escalation and 
reductions in high radiation dose to organs at risks.  Whilst there has been much 
attention paid to the advantages of this type of radiotherapy technique, there has 
also been recognition of the low dose radiation bath to non-target areas of the body.  
There have been suggestions that this potential low dose bath produced by IMRT is 
associated with increased whole body dose and a possible increased risk of second 
cancers [147,235,239,241,268,270]. 
 
The low dose bath or ‘out of target dose’ has been associated with increased 
leakage and scatter radiation from the delivery of intensity modulated techniques in 
comparison to 3D-conformal radiotherapy.  Attempts have been made to explore 
this low dose bath further and whole body dose has been estimated using indirect 
measures [239,241,244-246,430].  However, a more direct measure, through 
assessment of the phosphorylation of histone H2AX (-H2AX), has been utilised to 
demonstrate DNA damage from ionising radiation, even at low doses [279] and 
therefore may be useful in determining low dose radiation exposure from 
techniques, such as IMRT. 
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The laboratory work in this thesis has investigated the use of -H2AX within 
peripheral blood lymphocytes of patients undergoing static field intensity modulated 
radiotherapy (SF-IMRT) and other radiotherapy techniques.  The feasibility of using 
the -H2AX assay to identify radiation induced DNA damage within lymphocytes 
following in vivo irradiation has been demonstrated in chapter 2.  This data has 
confirmed a consistent increase in -H2AX foci levels following irradiation; an effect 
that is seen after each daily fraction of SF-IMRT.   
 
Having demonstrated the reproducibility and consistent increase in foci levels 
following irradiation, and the lack of any statistically significant difference in foci 
levels between daily doses, has allowed weekly rather than daily sampling of 
patients’ blood.  The results from chapter 2 also reveal no significant difference 
between the weekly -H2AX increase following a fraction of SF-IMRT, and this 
provides evidence to suggest that sampling of blood from patients for -H2AX 
before and after radiotherapy may only need to be done at one time point during a 
course of radiotherapy in future studies.  This will have an impact, not only on 
reducing invasive procedures for patients, but also reducing the time for sample 
processing and analysis of DNA damage within peripheral blood lymphocytes.  
 
The mean increase of 0.323 -H2AX foci per nucleus following a course of cranial 
SF-IMRT within this study (approximately 2-3 times that of baseline levels), is 
broadly comparable to foci levels found by other groups investigating DNA damage 
following IMRT to different areas of the body, such as the prostate [356,366,431].  
Despite the lack of -H2AX foci accumulation in this particular subset of cells at 2 
and 6 weeks following IMRT, others have reported a persistence of -H2AX foci 
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within other cell populations, consistent with ongoing DNA damage and lack of 
efficient repair [279,337,366].  The persistence of DNA damage following treatment 
may produce stochastic changes and could potentially have implications in long 
term toxicity. 
 
The work in chapter 3 extended the findings from chapter 2 and established the 
feasibility and reproducibility of using -H2AX within lymphocytes of patients 
undergoing other types of radiation delivery techniques, such as volumetric 
modulated arc therapy (RapidArcTM [RA]) and 3D-conformal radiotherapy (CRT).  
Similarly to SF-IMRT, these experiments have confirmed a consistent increase in 
DNA damage, through quantification of -H2AX foci levels, following treatment with 
other radiation techniques.  However, a statistically significant greater rise in -
H2AX foci levels was demonstrated with SF-IMRT (0.323 -H2AX foci per nucleus) 
in comparison to both RA (0.185 -H2AX foci per nucleus) and CRT (0.142 foci per 
nucleus), confirming that the -H2AX assay has sufficient sensitivity to identify and 
quantify differing levels of DNA damage in patients undergoing various radiation 
techniques.  However, although there was a reproducible but smaller increase in -
H2AX following RA in comparison to CRT, this difference did not reach statistical 
significance.  
 
The results demonstrating different increases in -H2AX foci levels with the various 
techniques, together with the dose response data established from the ex vivo 
experiment in chapter 2, may point towards an increase in whole body exposure 
following SF-IMRT (of 1.7 and 2.3 times that after RA and CRT), although it is 
difficult to confirm that this is as a result of scatter radiation alone.  In a similar way, 
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the TLD measurements (reported in chapter 3), taken at set distances outside the 
target volume, have documented a higher mean ‘out of target dose’ following 
treatment with SF-IMRT (0.196cGy) compared to both RA and CRT (0.144cGy and 
0.116cGy respectively).  As the increase in -H2AX foci levels (and out of target 
dose) is to some extent thought to be as a result of the low dose bath from SF-
IMRT, foci distribution within cell nuclei was examined further in chapter 3.  A 
greater proportion of cells displaying lower foci numbers (between 1-5 foci per 
nucleus), compared to cells with higher foci levels, was found following all radiation 
techniques examined.  However, this increase in cells with lower numbers of foci 
was greatest in those patients undergoing SF-IMRT in comparison to those 
undergoing RA or CRT, which, in turn, may be compatible with a model in which 
there is more DNA damage, partly as a result of low dose exposure from radiation 
with SF-IMRT compared to the other techniques examined. However, it is 
acknowledged that the process of estimating low dose irradiation is not simple and 
there are clearly other causes of radiation induced DNA damage than from low dose 
scatter radiation alone. 
 
The low dose bath effect, recognised as a result of IMRT, is caused by a complex 
interaction of several factors including scatter from the treatment head and 
collimators of the linear accelerator, as well as from internal scatter.  Due to the 
complexity of the modulated fields and the inefficiencies of the photon beam, there 
is a requirement for increased beam on time and monitor units. The low dose bath 
is thought to be dependent on these factors as well as from dose delivered to the 
target volume and the beam energy used [236,239-241].  It was surprising, 
therefore, not to be able to demonstrate a direct correlation between increased -
H2AX foci levels and factors such as beam on time, number of monitor units or 
tumour volume.  Small sample size may, of course, be a reason for the lack of 
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correlation.  The small sample size may also be a factor in the lack of statistical 
significance for higher -H2AX levels seen in patients undergoing RA compared to 
those treated with CRT.  Nevertheless, despite the small sample size, the -H2AX 
assay was sensitive enough to detect a significant difference between SF-IMRT and 
other radiation techniques. 
 
Attempting to postulate that the difference in -H2AX levels between the different 
radiation techniques is a result of scatter radiation is not easy.  Distributions of -
H2AX foci within in vitro irradiated cells show a good correlation with Poisson 
distributions [327], however this does not appear to be the case within in-vivo 
irradiated cells.  The lymphocyte population within blood samples taken at any one 
time may represent those that have been directly irradiated, those that have 
received indirect radiation through scatter and those which have background levels 
of radiation.  Trying to distinguish between these scenarios is difficult to do due to 
lymphocyte circulation, migrations and adhesion to vessel walls [340].  By 
measuring the distribution of -H2AX foci in lymphocytes following in vivo radiation 
and with knowledge of the in vitro dose response relationship of -H2AX formation, 
may provide information regarding recirculation and redistribution in the blood pool 
of in vivo irradiated lymphocytes.  In the future, further mathematical modelling 
could provide a way forward to determine the fraction of lymphocytes that are 
directly irradiated and the fraction that receive radiation dose purely from indirect 
means.  Models should utilise the knowledge of circulating blood volume, the total 
blood volume as well as the speed of blood circulation in order to estimate DNA 
damage to lymphocytes that circulate through the treatment field and those that 
endure damage through out of field radiation dose.  However, it is likely that 
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lymphocytes can pass through a beam more than once and this will also need to be 
taken into account in any model. 
 
Whilst there is still much debate regarding the significance of the increased low 
dose bath and whole body dose, there is no doubt that IMRT can be useful in the 
treatment of complex shaped tumours, where techniques such as 3D CRT have 
struggled to achieve an optimal therapeutic ratio.  The data from chapter 4 details 
the feasibility, efficacy and tolerability of SF-IMRT for the treatment of meningioma, 
in particular within patients with a grade I meningioma.  This prospective study has 
demonstrated that SF-IMRT can achieve good levels of homogeneity and 
conformality (through assessment of the homogeneity and conformality indices [HI 
and CI]), whilst also limiting dose to nearby critical structures; a particular problem 
in tumours located in the region of the skull base.  While other groups have 
demonstrated similar findings, these have principally been through retrospective 
studies [201,213,215,220] and there is growing recognition of the value that 
prospective studies can bring. 
 
Through collection of prospective data, this study has been able to demonstrate and 
detail the type, onset and duration of acute toxicities, as well as late toxicities.  It 
has revealed a low level of high grade late toxicity and a high local control rate for 
patients with grade I meningioma (100%% at a median follow up of 29 months), 
which is comparable to other published reports in the literature [201,215,217].  
However, in contrast to this, there was a low local tumour control rate in those 
patients treated for a grade II meningioma (55.6% at a median follow-up of 29 
months) and although lower than expected, has been reported in the literature.  
Several factors may play a part in this poor outcome, including extent of surgical 
 
 
224 
 
resection and adverse histological features [186,198,200,203,423].  However, 
inadequate dose may be an issue here, with evidence emerging in the literature to 
suggest that grade II and III tumours may require higher doses in comparison to 
grade I tumours [192,204,424,425].  Furthermore, treatment planning volumes may 
need to be increased to counteract the poorer outcomes of such tumours [426].  
This may be aided by utilising informative imaging during the planning process and 
there have been groups that have examined the use of particular high specificity 
PET tracers (such as 68-Gallium-Dotatoc), as well as PET/MRI, offering better soft 
tissue definition and therefore better tumour definition [428,432,433].  Further trials 
are required to formally assess the use of higher doses in higher grade tumours, as 
well as focusing attention to tumour definition and delineation in these higher grade 
meningiomas.  However, due to the relative rarity of these tumours, recruitment to 
national or international trials is warranted in order to gain valuable and robust 
results. 
 
In addition to local control and progression free survival, long term toxicity and 
effects on quality of life have been investigated as important measures of treatment 
outcome.  At a relatively short median follow up of 29 months, the clinical IMRT 
study described in chapter 4 has prospectively documented these outcomes.  There 
was an improvement in baseline symptoms in over 65% patients, ranging from an 
improvement in visual symptoms to improvements in other cranial nerve deficits.  
Quality of life measures generally remained stable over time, although an 
improvement in appetite was shown to reach statistical significance.  This is broadly 
in line with Combs’ group, who have reported on a prospective study examining 
IMRT and stereotactic fractionated radiotherapy in 507 patients (131 patients 
treated with IMRT) over a median follow up period of 107 months, demonstrating 
stable and even some improvements in quality of life measures [217].  However, it 
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is interesting to note from the results in chapter 4, that there is a trend towards a 
slight reduction in cognitive functioning, although this did not reach statistical 
significance.  A prospective study with formal neurocognitive testing, perhaps 
through the use of EEG assessment during defined computer tasks and used as a 
surrogate for processing deficits associated with cognitive decline, could be 
invaluable to document this potential toxicity further.  Radiation dose to the 
hippocampi has been linked to the development of neurocognitive decline [177,414] 
and it would also be interesting to build upon the results in chapter 4 and explore 
this relationship within this patient population where long term survival is expected.  
The clinical study described in chapter 4, does of course, require longer follow up to 
fully determine the outcomes of IMRT and, in particular, the potential for longer term 
toxicity, which may only manifest over many years. 
 
The results from this thesis have demonstrated that IMRT enables delivery of highly 
conformal radiotherapy for meningioma and is associated with acceptable levels of 
acute and late toxicity and without a significant decline in quality of life at this stage 
in follow up.  However, local control within the cohort of patients with grade II 
tumours was suboptimal; perhaps due to inadequate dose and tumour volume 
delineation.  Nevertheless, longer follow up and prospectively collected longer term 
toxicity will be invaluable to fully assess the outcomes in these patients treated with 
IMRT.  The clinical impact of the increased DNA damage and potential increased 
whole body dose from IMRT is still relatively unknown.  Calculations have predicted 
an approximate doubling of radiation induced second malignancies in people living 
beyond 10 years [147,148], which is pertinent to the group of patients studied in this 
thesis. 
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In the future, this work could be extended by exploring the correlations of IMRT 
dose distributions with functional MRI assessment of irradiated normal tissues in the 
brain and this could also potentially be used to correlate with long term toxicity data 
from this population of patients.  This may provide valuable information regarding 
dose response data for non-target areas of the brain.  In a similar way, -H2AX may 
be used to prospectively correlate foci levels with long term toxicity, including 
second malignancies.   
 
Highly conformal plans, using photon therapy, may always come at the expense of 
significant dose to some extra target organs, which could have implications 
regarding increased long term toxicity.  The use of protons has gained increasing 
interest over the last few years, as there is the potential to improve the therapeutic 
ratio through the properties of its beam.  Further work is warranted to prospectively 
document the feasibility and tolerance of using proton therapy in this patient 
population, whilst utilising -H2AX to establish dose response data and determine 
the potential reduction in whole body dose.  
 
In summary, through the translational and clinical research described in this thesis, 
the biological and clinical implications of intensity modulated radiotherapy in the 
treatment of brain tumours have been explored.  This work has encompassed 
translational work using -H2AX to document the feasibility and reproducibility of 
assessing DNA damage in patients undergoing different conformal external beam 
photon radiotherapy techniques as a means of exploring whole body dose.  It has 
documented higher levels of -H2AX foci following SF-IMRT compared to other 
techniques studied and is the first study to document higher -H2AX levels following 
SF-IMRT in comparison to RA.  The feasibility and tolerance of IMRT in a 
 
 
227 
 
prospective phase I/II study have been described, with documentation of the 
toxicities as well as both clinical and patient reported outcomes.  However, data 
collection and analysis on longer term outcomes, both for the tumour and more 
importantly, normal tissue, will be ongoing.  The results from this thesis add to the 
body of work defining the use, outcomes and associated radiation induced DNA 
damage from IMRT, whilst providing further information to guide future studies in 
this field, highlighting the role of -H2AX and the value of prospective clinical studies 
in such work. 
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Appendix A 
Proforma for Static field IMRT (SF-IMRT) study patients 
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Proforma for static field IMRT (SF-IMRT) study patients 
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Proforma for RapidArcTM (RA) study patients  
 
 
 
 
 
 
 
 
 
 
 
 
231 
 
Proforma for RapidArcTM (RA) study patients 
 
  
 
 
232 
 
Proforma for 3D-Conformal Radiotherapy (CRT) study patients 
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Proforma for 3D-Conformal Radiotherapy (CRT) study patients 
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Appendix B 
 
 
Acute toxicity follow-up forms 
Late toxicity follow-up forms 
Neurological evaluation forms 
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ACUTE TOXICITY FOLLOW-UP FORM 
 
Trial number:   Patient’s initials:      
Hospital no.: __________________________ 
 
Please complete the corresponding grades for each visit according to the CTCAE version 3.0 acute toxicity follow 
up legend. Please fill in each line. If the patient has no toxicity for a particular site please fill in 0. NCI website: 
http://ctep.cancer.gov/reporting/ctc.htlm. 
D
a
te
 
(d
d
/
m
m
/
y
y
y
y
) 
 
        
During Radiotherapy Post-Radiotherapy 
 
Before 
RT 
Week 
1-2 
Week 
3-4 
Wee
k 
5-6 
 
Week 
9-10 
 
Week 
18 
 
OCULAR/VISUAL 
Cataract          
Dry eye syndrome          
Eyelid dysfunction          
Glaucoma          
Keratitis           
Night blindness          
Nystagmus          
Ocular surface 
disease 
         
Diplopia          
Optic disc oedema          
Proptosis/ 
enophthalmos 
         
Retinal detachment          
Retinopathy          
DERMATOLOGY / SKIN 
radiation dermatitis          
alopecia          
FATIGUE 
fatigue radiation 
related 
         
WHO PS 
score          
MUCOSITIS 
mucositis radiation 
related 
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ACUTE TOXICITY FOLLOW-UP FORM 
 
Trial number:   Patient’s initials:      
Hospital no.: __________________________ 
 
Please complete the corresponding grades for each visit according to the CTCAE version 3.0 acute toxicity follow 
up legend. Please fill in each line. If the patient has no toxicity for a particular site please fill in 0.  
D
a
te
 
(d
d
/
m
m
/
y
y
y
y
) 
 
        
During Radiotherapy Post-Radiotherapy 
 
Before 
RT 
Week 
1-2 
Week 
3-4 
Week 
5-6 
 
Week 
9-10 
 
Week 
18 
 
PAIN 
pain due to radiation          
SALIVARY GLAND 
mouth dryness          
salivary gland 
changes 
         
NEUROLOGY 
CSF leak          
Leukoencephalopathy          
Memory impairment          
Mental status          
Mood alteration           
Cranial neuropathy:           
I (smell)          
II (vision)          
III (Pupil/ upper 
eyelid/ extraocular 
movements) 
         
IV (downward/ 
inward eye 
movement) 
         
V (motor-jaw 
muscles; sensory-
facial) 
         
VI (lateral eye 
deviation) 
         
VII (motor-face; 
sensory-taste) 
         
VIII (hearing and 
balance) 
         
IX (motor-pharynx; 
sensory-ear, pharynx, 
tongue) 
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ACUTE TOXICITY FOLLOW-UP FORM 
 
Trial number:   Patient’s initials:      
Hospital no.: __________________________ 
 
Please complete the corresponding grades for each visit according to the CTCAE version 3.0 acute toxicity follow 
up legend. Please fill in each line. If the patient has no toxicity for a particular site please fill in 0.  
D
a
te
 
(d
d
/
m
m
/
y
y
y
y
) 
 
        
During 
Radiotherapy 
Post-Radiotherapy 
 
Before 
RT 
Week 
1-2 
Week 
3-4 
Week 
5-6 
 
Week 
9-10 
 
Week 
18 
 
NEUROLOGY 
X (motor-palate, 
pharynx, larynx) 
         
XI (motor SCM/ 
trapezius) 
         
XII (motor-tongue)          
Neuropathy: motor          
Neuropathy: 
sensory 
         
Personality          
Phrenic nerve 
dysfunction 
         
Psychosis          
Pyramidal tract 
dysfunction 
         
Seizure          
Somnolence          
Speech impairment          
Syncope          
Tremor          
Neurology-Other: 
Specify_________
_______________
________ 
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LATE TOXICITY FOLLOW-UP FORM 
 
Trial number:   Patient’s initials:      
Hospital no.: __________________________ 
 
Please complete the corresponding grades for each visit according to the CTCAE version 3.0 acute toxicity follow 
up legend. Please fill in each line. If the patient has no toxicity for a particular site please fill in 0.  
DATE           
OCULAR           
Cataract           
Dry eye syndrome           
Eyelid dysfunction           
Glaucoma           
Keratitis           
Night blindness           
Nystagmus           
Ocular surface disease           
Diplopia           
Optic disc oedema           
Proptosis/ 
enophthalmos 
          
Retinal detachment           
Retinopathy           
SKIN           
radiation dermatitis           
alopecia           
FATIGUE           
fatigue radiation related           
WHO PS           
score           
MUCOSITIS           
mucositis radiation 
related 
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LATE TOXICITY FOLLOW-UP FORM 
 
Trial number:   Patient’s initials:      
Hospital no.: __________________________ 
 
Please complete the corresponding grades for each visit according to the CTCAE version 3.0 acute toxicity follow 
up legend. Please fill in each line. If the patient has no toxicity for a particular site please fill in 0.  
DATE           
PAIN           
pain due to radiation           
SALIVARY GLAND           
mouth dryness           
salivary gland changes           
NEUROLOGY           
CSF leak           
Leukoencephalopathy           
Memory impairment           
Mental status           
Mood alteration            
Cranial neuropathy:           
I (smell)           
II (vision)           
III (Pupil/ upper 
eyelid/ extraocular 
movements)  
          
IV (downward/ inward 
eye movement) 
          
V (motor-jaw muscles; 
sensory-facial) 
          
VI (lateral eye 
deviation) 
          
VII (motor-face; 
sensory-taste) 
          
VIII (hearing and 
balance) 
          
IX (motor-pharynx; 
sensory-ear, pharynx, 
tongue) 
          
X (motor-palate, 
pharynx, larynx) 
          
XI (motor SCM/ 
trapezius) 
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LATE TOXICITY FOLLOW-UP FORM 
 
Trial number:   Patient’s initials:      
Hospital no.: __________________________ 
 
Please complete the corresponding grades for each visit according to the CTCAE version 3.0 acute toxicity follow 
up legend. Please fill in each line. If the patient has no toxicity for a particular site please fill in 0.  
DATE           
NEUROLOGY           
XII (motor-tongue)           
Neuropathy: motor           
Neuropathy: sensory           
Personality           
Phrenic nerve 
dysfunction 
          
Psychosis           
Pyramidal tract 
dysfunction 
          
Seizure           
Somnolence           
Speech impairment           
Syncope           
Tremor           
Neurology-Other: 
Specify_____________
__________________
_ 
          
           
           
           
 
  
 
 
241 
 
NEUROLOGIC EVALUATION FORM-1 
 
Study number:              Patient’s initials:   
 
Date of assessment:   Hospital no.: __________ 
  dd       mm         yyyy 
 
 
NEUROLOGIC SYMPTOMS 
 
Headache      
 
0 = None, 1 = Minor/ intermittent, 2 = Requires non-narcotic analgesics, 3 = Requires 
narcotic preparation, 4 = Incapacitating, 9 = Unknown  
 
Visual Disturbance  
 
0 = None, 1 = Acuity decreased, 2 = Field defect, 3 = Diplopia, 4 = Blind/unilaterally, 5 = 
Blind/bilaterally, 9 = Unknown  
 
Speech Impairment 
 
0 = None, 1 = Minor/ intermittent, 2 = Moderate, 3 =Severe, 9 = Unknown  
 
Sensory Symptoms  
 
0 = None, 1 = Minor/ intermittent, 2 = Moderate, 3 = Severe, 9 = Unknown  
 
Motor Symptoms 
 
0 = None, 1 = Minor/ intermittent, 2 = Moderate, 3 = Severe, 9 = Unknown  
 
Memory Symptoms 
 
0 = None, 1 = Recent event, 2 = Remote event, 3 = Both, 9 = Unknown  
 
Personality changes 
 
0 = None, 1 = Minor/ intermittent, 2 = Moderate, 3 = Severe, 9 = Unknown  
 
Seizures  
 
0 = None, 1 = Occasional (<1/week, without anticonvulsants), 2 = Occasional with 
anticonvulsants, 3 = Frequent (>1/week, with anticonvulsants), 4 = uncontrollable, 9 = 
Unknown  
 
Other Neurological symptoms 
 
0 = None, 1 = Minimal, 2 = Moderate, 3 = Severe, 9 = Unknown  
 
Specify: .............................................................................................................................. 
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NEUROLOGIC EVALUATION FORM-2 
 
Study number:              Patient’s initials:   
 
Date of assessment:   Hospital no.: __________  
  dd       mm         yyyy 
 
 
NEUROLOGIC EXAM  
 
Mental Status 
 
0 = Normal, 1 = Minor Mental confusion, 2 =Gross confusion but awake, 9 =Unknown  
 
Somnolence  
 
0 = None, 1 = Lethargy, 2 = Rousable with difficulty, 3 = coma, 9 = Unknown  
 
Papilloedema  
 
0 = None, 1 = Suggestive, 2 = Definite or exudate, 3 = Definite haemorrhage, atrophy,  
4 = post papilledema, 9 = Unknown  
 
Motor Deficit function  
 
0 = Normal, 1 = symptomatic weakness only, 2 = <50% decrease in function,  
3 = >50% decrease in function, 5 = complete paralysis, 9 = Unknown  
If paralysis, specify area: ..........................................................................................  
 
Cranial Nerve Deficit  
 
0 = None, 1 =Minor/ intermittent, 2 =Moderate, 3 =Severe, 9 = Unknown  
Specify: ..............................................................................................................................  
 
Sensory Deficit 
 
0 = None, 1 = Minor/ intermittent, 2 = Moderate, 3 = Severe, 9 = Unknown  
 
Visual test 
 
0 = Intact, 1 = Deficit sight, 2 = Deficit visual field  
Specify: ..............................................................................................................................  
 
Cerebral Deficit 
 
0 = None, 1 = Minor/ intermittent, 2 = Moderate, 3 = Severe, 9 = Unknown  
Specify: ..............................................................................................................................  
 
Reflex function 
 
0 = Normal, 1 = Abnormal  
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Appendix C 
 
 
EORTC QLQ-C30 
EORTC QLQ-BN20 
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Appendix D 
 
List of Abstracts and Publications 
 
Maclean J, Fersht N, Bremner F, Stacey C, Sivabalasingham S, Short, S 
Meningioma causing visual impairment: Outcomes and toxicity following Intensity 
modulated radiotherapy 
Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):e179-86. 
 
S Sivabalasingham, M Worku, P Bassett, N Lalli, A Abulimiti, N Fersht, T Guerrero-
Urbano, S C Short. Gamma H2AX: a sensitive biomarker for comparison of whole 
body dose from IMRT, RapidArcTM or 3D-conformal radiotherapy.   
Radiotherapy and Oncology, Vol 103, Suppl 1, May 2012, S144-S145. ESTRO May 
2012. Selected for oral presentation in Young Scientist Poster Session. 
 
J Maclean, S Sivabalasingham, F Bremner, D D’Souza, N Fersht, S Short 
Meningioma causing visual impairment: Toxicity and outcome with IMRT. 
Radiotherapy and Oncology Vol 103 suppl 1, May 2012, S406-S407) ESTRO May 
2012. 
 
S Sivabalasingham, M Worku, S C Short 
Gamma-H2AX as a biomarker of radiation-induced DNA damage in patients 
receiving brain radiotherapy: a comparison of volumetric modulated arc therapy 
(RapidArcTM) with static field intensity modulated radiotherapy (IMRT) 
National Cancer Research Institute (NCRI) Cancer Conference 2011; Nov 2011; 
Liverpool UK. Abstract B58. NCRI; Nov 2011.  
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D Woolf, R Bakhshi, S Fawcitt, M Worku, D Ghosh, S Sivabalasingham, N Williams, 
S Short, K Pigott, M Keshtgar. An observational study using γ-H2AX foci to 
investigate cardiac doses of radiation following adjuvant radiotherapy for breast 
cancer: Standard external beam radiotherapy to the breast versus intraoperative 
radiotherapy. J Clin Oncol 29: 2011 (suppl; abstr TPS 129). ASCO June 2011. 
 
S Sivabalasingham, M Worku, SC Short. Whole body dose, using gamma h2ax 
measurement, following radiotherapy: a comparison of volumetric modulated arc 
therapy (RapidArcTM) with static field intensity modulated radiotherapy (IMRT).  
Radiotherapy and Oncology, Vol 99, Suppl 1, May 2011, S490. ESTRO, May 2011. 
 
S Sivabalasingham, N Fersht, D D’Souza, I Rosenberg, C Stacey, P Davies, T 
Guerrero-Urbano, SC Short. Preliminary results from a phase I/II study of intensity 
modulated radiotherapy in the treatment of meningiomas.  
Clin Oncol 2011; 23(3):S53. UKRO, April 2011. 
 
S Sivabalasingham, M Worku, P Bassett, N Lalli, A Abulimiti, N Fersht, T Guerrero-
Urbano, S C Short. Gamma H2AX: a sensitive biomarker for comparison of whole 
body dose from IMRT, RapidArcTM or 3D-conformal radiotherapy. Radiotherapy and 
Oncology, Vol 103, Suppl 1, May 2012, S144-S145. ESTRO May 2012. Selected for 
oral presentation in Young Scientist Poster Session. 
 
S Sivabalasingham, M Worku, G Marks, T Guerrero-Urbano, SC Short. γ-H2Ax 
quantification of low dose irradiation-induced DNA damage in patients receiving 
intensity modulated radiotherapy (IMRT). Cancéropôle Grand-Ouest ‘Biology of 
ionizing radiation’ workshop, France 2011. Selected for oral presentation. 
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S Sivabalasingham, M Worku, G Marks, T Guerrero-Urbano, SC Short. Gamma 
H2AX as a biomarker of low dose irradiation-induced DNA damage in patients 
receiving intensity modulated radiotherapy for brain tumours. Radiotherapy & 
Oncology, Vol 96 Suppl. 1 (2010), Abstract number 411. ESTRO, Barcelona, 2010. 
Selected for oral presentation. 
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